Cardiology

Part 1: Basic Cardiac Anatomy and Physiology

1. Normal Cardiac Anatomy and Blood Flow

• Anatomy Overview: The heart comprises four chambers (Right Atrium [RA], Right Ventricle [RV], Left Atrium [LA], Left Ventricle [LV]) separated by the interatrial and interventricular septa, and the associated great vessels.
• Radiographic Appearance: A normal chest X-ray (CXR) visual identifies the right heart border as the RA and the left border as the LV and LA appendage. The pulmonary trunk and aortic arch sit superiorly.
• Normal Hemodynamic Pathway: A detailed flowchart visual illustrates normal blood circulation:
  • Systemic Return: Systemic veins → Superior/Inferior Vena Cavae → RA.
  • Right Heart/Pulmonary: RA → Tricuspid Valve (Right AV valve) → RV → Pulmonary Semilunar Valve → Pulmonary Trunk → Pulmonary Arteries → Lungs (gas exchange).
  • Left Heart/Systemic: Pulmonary Veins → LA → Mitral Valve (Left AV valve) → LV → Aortic Semilunar Valve → Aorta → Peripheral Tissues.

2. The Cardiac Cycle

• Wiggers Diagram & Cardiac Phases: Visual diagrams demonstrating the synchrony of the cardiac cycle show:
  • Ventricular Systole (Contraction): Ventricular contraction increases pressure, pushing blood against the AV valves, causing them to close (1st heart sound). Papillary muscles and chordae tendineae prevent everting into the atria. Semilunar valves are forced open, ejecting blood into the pulmonary trunk and aorta.
  • Ventricular Diastole (Relaxation): Ventricles relax. Backflow of blood in the aorta and pulmonary trunk forces the semilunar valves to close (2nd heart sound). AV valves open, allowing ventricles to fill passively, followed by active filling via atrial contraction.

3. Cardiac Function and Output

• Cardiac Output (CO): Measured in liters/minute, it is the volume of blood pumped to the systemic circulation to meet tissue oxygen demand.
  • Formula: CO = Heart Rate (HR) x Stroke Volume (SV)
• Heart Rate: Regulated by the autonomic nervous system. Sympathetic stimulation (↑) increases HR; parasympathetic stimulation (↓) decreases HR.
• Stroke Volume: The volume of blood ejected into the systemic circulation in one beat.
  • Formula: SV = End Diastolic Volume (LVEDV) - End Systolic Volume (LVESV).
  • Visual Example: A ventricular diagram shows an LVEDV (preload) of 80 units. After contraction, 20 units remain (LVESV). Therefore, SV = 80 - 20 = 60 units.
  • Determinants of SV:
    1. Preload: Volume of blood in the LV at end-diastole (venous return).
    2. Afterload: Resistance against which the LV is pumping.
    3. Contractility: Degree of muscle shortening when it contracts (muscle strength).

Part 2: Pediatric Heart Failure

1. Definition and Pathophysiology

• Simply stated, heart failure in children is the failure of the heart to produce a cardiac output that meets metabolic demands.
• Compensatory Mechanisms: When supply becomes less than demand, the body attempts to compensate:

2. Clinical Presentations (Signs & Symptoms)

Pediatric presentation differs significantly from adults. It is categorized by the underlying physiological derangement:

3. Etiologies of Pediatric Heart Failure

Etiology depends on the pathophysiologic defect. It includes signs specific to the etiology itself:

4. Diagnosis and Management of Heart Failure

• Diagnosis: Mainly depends on clinical features.
  • ECG: Suspected arrhythmogenic cause, secondary rhythm disturbance, or structural disease.
  • CXR: Assesses cardiomegaly (not specific for etiology) and degree of pulmonary edema.
  • Echocardiography: Highly effective for definitively determining the structural etiology.
• Clinical Management Guide:
  • Nutritional Support: Increase caloric intake using fortified formulas, more frequent feeds, or NG (nasogastric) tube feeding if needed to combat failure to thrive.
  • Medications:
    • Diuretics (e.g., Furosemide, Spironolactone): Decrease congestion, improve respiratory distress.
    • Afterload Reduction (e.g., ACE inhibitors, ARBs): Improve tissue perfusion; may manipulate shunts in CHD.
    • Inotropic Support: Sympathomimetics, phosphodiesterase inhibitors, Digoxin.
    • Beta-blockers: Primarily for long-term use.
  • Treating the Etiology: Surgical repair of CHD, rhythm control/pacemakers for arrhythmias, or specialized devices/transplantation for refractory cases.

Part 3: Presentation of Congenital Heart Disease (CHD) in the Neonate

CHD occurs in roughly 9 per 1,000 liveborn children (local data suggests 13-15 per 1,000). Half will need intervention (catheterization or surgery), and 25-30% will require congenital heart surgery.

1. General Presentations of CHD

• Asymptomatic Newborn with a Murmur:
  • Transitional physiology: Murmur of a closing PDA, PFO, or Peripheral Pulmonary Artery Stenosis (PPPS). The protocol is to wait 6 hours and re-evaluate.
  • Immediate structural causes: Small muscular VSD, regurgitant murmurs (TR, MR), stenotic murmurs (AS, PS with clicks), or Pink TOF (cyanosis develops later).
  • Delayed presentation: VSD, AVSD, and large PDAs often present at 4-8 weeks of life as pulmonary vascular resistance naturally drops, allowing volume overload to occur.
• Progressive Heart Failure (Infants): Common in VSD, AVSD, PDA. Symptoms include difficulty in breathing (DIB), sweating on feeds, and failure to thrive. Signs include a gallop rhythm, murmur, and hepatomegaly.

2. Catastrophic Heart Failure and Shock (Ductal-Dependent Lesions)

• Pathophysiology: In specific left-sided obstructive lesions, systemic blood flow is completely compromised. It relies on the RV ejecting blood retrogradely through the PDA into the systemic circulation.
• The Crisis: Catastrophic heart failure occurs abruptly when the PDA closes.
• Consequences of PDA Closure:
  • Systemic blood flow decreases significantly.
  • Leads to oliguria, profound severe metabolic acidosis (pH < 7.0), pulmonary edema, and overt heart failure.
  • Myocardial Ischemia: As cardiac output drops, retrograde flow into the coronary arteries decreases, causing ischemia, ventricular dysfunction, and death.
• Etiologies: Critical Aortic Stenosis (AS), Critical Aortic Coarctation, Interrupted Aortic Arch, Hypoplastic Left Heart Syndrome (HLHS).
  • Visuals: A diagram highlights the difference between Coarctation of the Aorta (severe localized narrowing) and Interrupted Aortic Arch (complete separation between the ascending and descending aorta).
• Clinical Picture: Mimics severe sepsis or septic shock. Characterized by tachypnea, tachycardia, mottled skin, decreased central and peripheral pulses, and decreased perfusion (prolonged capillary refill).
• Acute Management of Neonatal Shock:
  • ABCs and respiratory support.
  • Fluid resuscitation: Give 10-20 cc/kg boluses up to three times; meticulously monitor the clinical response by assessing heart rate and hepatomegaly.
  • Obtain blood labs and initiate antibiotics (must rule out/treat mimicking sepsis).
  • Inotropes.
  • Initiate PGE1 (Prostaglandin E1) immediately to reopen/maintain the ductus arteriosus.
  • Call pediatric cardiology urgently.

Part 4: Cyanotic Congenital Heart Disease (The "5 T's")Year 6

1. Definition and Diagnostic Approach

• Cyanosis: The presence of at least 4 g/dL of deoxygenated blood in the systemic circulation, equating to a pulse oximetry reading of 80% or below.
• Approach to the Cyanotic Child:
  • Accurate prenatal and natal history.
  • Vital signs, specifically including Upper Limb (UL) and Lower Limb (LL) pulse oximetry.
  • Hyperoxia Test: Administer 100% oxygen for at least 10 minutes. A lack of response (failure to hyperoxygenate) strongly indicates a cardiac etiologic origin rather than pulmonary, mandating further cardiac workup.
  • Chest X-ray and Echocardiography.
• Pulse Oximetry Screening Algorithm (Visual Flowchart): Implemented for well-infants at 24-48 hours of age.
  • Fail (Positive Screen): <90% in Right Hand (RH) or Foot (F).
  • Repeat: 90-95% in RH and F, OR >3% difference between RH and F. Repeat the screen in 1 hour.
  • Pass (Negative Screen): ≥95% in RH or F, AND ≤3% difference between RH and F.

2. Differential Diagnosis by Cyanosis Severity

3. Pathophysiologic Models of Cyanotic CHD (The 5 T's)

There are two main models based on the anatomical connections of the heart chambers and vessels.

A. Normal Cardiac Connections with a Shunt and Right-Sided Obstruction

The atria receive their respective veins, ventricles connect to corresponding inlet valves, and outflow tracts emerge from respective ventricles. Deoxygenated blood is shunted due to downstream obstruction.

• 1. Tetralogy of Fallot (TOF): The most common cyanotic CHD (5% of all CHD).
  • Pathophysiology: The primary defect is the anterior malalignment of the interventricular septum (noted as the "Monology of Fallot" by cardiologists). This single deviation causes: 1) A Ventricular Septal Defect (VSD), 2) Overriding aorta, 3) Pulmonary outflow tract obstruction (sub-pulmonary/infundibular stenosis), leading to 4) RV Hypertrophy.
  • Visual Comparison: Diagrams heavily contrast the normal heart with TOF, illustrating the thickened RV, the narrowed pulmonary valve, and the aorta straddling the VSD to receive mixed blood. The spectrum of disease ranges from "Pink TOF" to the most severe form, Pulmonary Atresia with VSD.
  • Clinical Presentation: Harsh ejection systolic murmur over the pulmonic area (indicating PS), single S2. Higher saturations indicate less RV outflow obstruction.
  • CXR Visual: Shows the classic "Boot-Shaped Heart" (coeur en sabot) due to RV hypertrophy and a concave main pulmonary artery segment.
  • Tet Spells (Hypercyanotic Spells): Acute episodes of profound cyanosis.
  • Management of Tet Spells: 1) Calm the patient. 2) Knee-to-chest position (increases systemic vascular resistance [SVR]). 3) Oxygen via non-noxious route. 4) IV fluid bolus. 5) IV metoprolol (slows heart rate). 6) Phenylephrine (increases SVR). 7) May require anesthesia.
  • Surgical Timing: Determined by the degree of RV outflow obstruction. Children with SpO2 < 80% or those experiencing Tet spells are scheduled for surgery.
• 2. Pulmonary Atresia with Intact Ventricular Septum: Visual diagrams demonstrate an impermeable pulmonary valve, an underdeveloped (atretic) RV, and a mandatory Atrial Septal Defect (ASD) to allow blood to escape the right heart.
• 3. Tricuspid Atresia: Diagrams illustrate an absent tricuspid valve. Blood cannot enter the RV from the RA, forcing an obligatory Right-to-Left shunt across an ASD. An associated VSD is required to get blood from the LV back to the pulmonary artery.
• 4. Ebstein's Anomaly: Diagrams show severe downward displacement of the tricuspid valve into the RV, resulting in "atrialization" of the right ventricle. The provided CXR demonstrates massive, wall-to-wall cardiomegaly driven by massive right atrial enlargement.

B. Abnormal Cardiac Connections

Deoxygenated blood enters the systemic circulation directly due to abnormal plumbing.

• 5. Transposition of the Great Arteries (D-TGA): Second most common cyanotic CHD (~2%), but the most common cyanotic CHD presenting at birth/first week.
  • Pathophysiology: Ventriculoarterial discordance. The aorta arises abnormally from the RV (anterior to the PA), and the pulmonary artery arises from the LV. This creates two completely parallel circulations (systemic venous blood goes right back to the body; pulmonary venous blood goes right back to the lungs). Survival relies entirely on mixing via a PFO/ASD, PDA, or VSD (present in 35-40% of cases).
  • Presentation: Severe cyanosis within 12 hours of life; unresponsive to O2. Usually, there is no murmur and a single loud S2 (aortic component is anterior).
  • CXR Visual: Demonstrates the classic "Egg on a String" appearance. The mediastinal silhouette is narrow due to the anterior-posterior orientation of the great vessels and thymic regression.
  • Management: Initiate PGE1 to keep PDA open. May require balloon atrial septostomy to enlarge the ASD. Definitive treatment is the Arterial Switch procedure.
  • Long-term Complications Post-Arterial Switch (First performed in 1975): Requires lifelong follow-up. 5-30% of patients require reintervention at 25 years. Common reasons include neoaortic valve regurgitation (>75%), supravalvar pulmonary stenosis (>75%), and coronary artery disease (5-8%).
• 6. Truncus Arteriosus: Diagram visual shows a single massive arterial trunk arising from both ventricles (over a VSD) that supplies the systemic, pulmonary, and coronary circulations.
• 7. Total Anomalous Pulmonary Venous Return (TAPVR): The pulmonary veins do not connect to the LA.
  • Pathology: Divided into Supracardiac, Cardiac, and Infracardiac. A visual of Supracardiac TAPVR shows pulmonary veins converging into a vertical vein that drains into the innominate vein and then the Superior Vena Cava (SVC).
  • CXR Visual: Demonstrates the classic "Snowman" or "Figure 8" appearance, where the dilated vertical vein, innominate vein, and SVC form the upper "head" of the snowman.

4. General Acute Management of Cyanotic Heart Disease

• If the infant presents with Severe Cyanosis + Acidosis + A suspected PDA-dependent lesion:
  • Start PGE1 immediately (with or without bicarbonate).
  • All lesions will improve with PGE1 except infracardiac obstructive TAPVR.
  • If cardiology is unavailable, initiate PGE1, monitor airway closely (due to risk of PGE1-induced apnea), and transport promptly.
• If the infant presents with Mild to Moderate Cyanosis + No acidosis:
  • Wait for an echocardiogram for definitive diagnosis.

Part 5: Overview of Pediatric Arrhythmias and ECGYear 6

1. Pediatric vs. Adult ECG Principles

• Age Variations: A pediatric ECG changes dramatically with age. A completely normal ECG for one age bracket may be abnormal if the age is incorrect. Interpretation absolutely requires tables of normal age-adjusted values.
• Indications: Ischemic heart disease is extremely rare in children. Primary indications for a pediatric ECG include: episodes of loss of consciousness (LOC), palpitations, suspected congenital/structural heart disease, incidental irregular/abnormal rhythm, or chest pain.

2. ECG Interpretation Algorithm

Interpretation must be systematic, mapping the electrical vectors to the anatomy (SA Node → AV Node → His Bundle → Bundle Branches).

• Leads: Inferior (aVF, II, III), Left Precordial (V5, V6), Right Precordial (V1, V3R), Septal (V3, V4).
• Rate: Determine the rate of ventricular depolarization (QRS rate). If the rhythm is regular, measure the R-R duration in seconds and divide 60 by the R-R interval. (Rate = 60 / R-R).
• Rhythm: Determine if regular or irregular.
  • Sinus Arrhythmia: Normal variation of HR between inspiration and expiration.
  • Premature Contractions (PACs/PVCs): "Missed beats" on auscultation; benign in most cases.
  • Atrial Fibrillation: Irregularly irregular rhythm, usually fast in children.
• P Wave: Represents atrial depolarization. Assess presence, relationship to QRS, axis (is it sinus or ectopic? Normal sinus P wave should be upright in I and aVF), and morphology (Leads II and V1 assess for Right or Left Atrial Enlargement).
• PR Interval: Time from beginning of P to beginning of QRS. Normal is generally < 0.16 seconds in children (up to 0.20 sec in adults).
  • Long PR: First-degree AV block.
  • Elongating PR until dropped beat: Second-degree AV block (Mobitz Type 1).
  • Variable PR: Suspect AV dissociation.
  • Short PR: Wolff-Parkinson-White (WPW) syndrome.
• QRS Complex: Represents ventricular depolarization. Analyze axis, duration, and morphology (all change with age).
  • Q Waves: Normal in inferior leads (occasionally >3mm). Deep Q waves in I, aVL strongly suggest ALCAPA (Anomalous Left Coronary Artery from the Pulmonary Artery). Deep Q in left precordial leads suggests LVH/septal hypertrophy.
  • Ventricular Hypertrophy Criteria:

• ST Segment:
  • Elevated: Pericarditis (diffuse), ischemia. Note: Early repolarization is a benign finding that may look like ST elevation but is continuous with the T wave.
  • Depressed: Ischemia.
• T Wave: Normal direction in V1 changes with age: Upright in newborns (first few days), inverted in infants through adolescents, and upright again in adults. High amplitude is defined as T wave > 2/3rd of the QRS amplitude.
• U Wave: Repolarization of the Purkinje system. Significant U waves suggest hypokalemia. If the U wave amplitude is > 1/2 of the T wave amplitude, it must be counted in the QT interval calculation.
• QT Interval: Must be corrected for heart rate.
  • Formula: QTc = QT / √(R-R)
  • Normal: Up to 450 msec.
  • Note: Irrelevant in the presence of Bundle Branch Block (BBB) or a ventricular rhythm.

3. Specific Rhythm Disturbances and Clinical Examples

• Bradycardia & Heart Blocks:
  • Can be sinus bradycardia (usually non-cardiac causes) or sinus node dysfunction (common after congenital heart surgeries like SV ASD or Fontan operations).
  • Heart Block: Ranges from 2nd degree (regularly irregular) to Complete Heart Block. An ECG visual of a 3-year-old with LOC demonstrates Complete Heart Block, showing complete AV dissociation where P waves march through independently of the QRS complexes.
• Long QT Syndrome: An ECG visual of an 11-year-old with LOC upon waking shows a significantly prolonged QTc of 580 msec, predisposing to lethal arrhythmias.
• Tachyarrhythmias: Ventricular Tachycardia (VT):
  • Always presents with a wide complex QRS. Rate is variable, usually 20% faster than normal sinus rhythm.
  • Diagnostic Clues: Occasional normal sinus beats captured between wide complex QRSs, or the presence of normal P waves marching independently (Ventriculo-Atrial dissociation).
• Tachyarrhythmias: Supraventricular Tachycardia (SVT):
  • Usually a narrow complex QRS (can be wide with aberrancy). Rate is outside the limits of sinus tachycardia. Presentation ranges from incidental to palpitations to heart failure.
  • Age distribution (Visual graph): AVRT (WPW) is most common prenatally and in infancy. AVNRT probability increases with age. Atrial Tachycardia (AT) remains consistently low.
  • Wolff-Parkinson-White (WPW) Syndrome: An ECG of a 14-year-old with palpitations shows the classic triad: Short PR interval, wide QRS, and a Delta wave (slurred upstroke of the QRS).
  • Mechanisms of SVT: Divided broadly into Re-entry and Non-reentry (Automatic).
    • Re-entry: AV Node Reentry (AVNRT), Accessory Pathway (WPW, Concealed AP, PJRT), Non-AP mediated (Atrial Flutter, AFib, IART).
    • Non-reentry: Atrial Ectopic Tachycardia (AET), Junctional Ectopic Tachycardia (JET), Chaotic Atrial Tachycardia.
  • AVNRT Pathways: The AV node has an alpha (fast conduction, long refractory period/RP) and beta (slow conduction, short refractory period/RP) pathway.
    • Typical AVNRT (Slow-Fast): Results in a Short RP interval.
    • Atypical AVNRT (Fast-Slow): Results in a Long RP interval.
  • Differentiating Narrow Complex SVT by RP Interval:
    • Short RP: Typical AVNRT, WPW, Concealed accessory pathway.
    • Long RP: Atrial Ectopic Tachycardia (AET), PJRT, Atypical AVNRT. Visual ECGs confirm Long RP by showing P waves distinctly separated (e.g., 0.16s/0.14s) from the preceding QRS.

4. Clinical Management Approach to Tachycardia (Algorithm)

1. Assess Clinical Status:
   • If Unstable (signs of shock): Immediate attempt at synchronized cardioversion.
   • If Stable: Obtain a 12-lead ECG.
2. Analyze ECG (QRS Width):
   • Wide Complex: Look for P waves. If 1:1 conduction → SVT with aberrancy or Antidromic WPW. If < 1:1 or independent sinus beats seen → VT.
   • Narrow Complex: SVT. Look for P waves to measure RP interval. If >1:1 conduction, suspect Atrial Flutter.
3. Acute Medical Management (Based on Diagnosis):
   • Re-entry involving AV node: Administer Adenosine to stop SVT.
   • Re-entry not involving AV node: Elective cardioversion OR Medical cardioversion.
   • Automatic mechanisms: Medical cardioversion.
4. Maintenance Therapy: Depending on the specific arrhythmia, use Propranolol (PO), Procainamide (IV), Amiodarone (IV), Digoxin, or Flecainide.

Endocrinology

Part I: Normal Growth and Short Stature

1. Principles of Normal Growth

• Biological Significance: Growth in childhood is one of the most fascinating, dynamic, and tightly regulated biological processes. It serves as a primary index of public health and economic well-being, particularly in developing countries and countries in transition.
• Growth Parameters: Normalcy is evaluated by plotting specific parameters on standardized percentiles:
  • Weight for age
  • Height (length) for age
  • Weight for length
  • Head circumference for age
  • Body Mass Index (BMI) for age
• Visual Element - CDC Growth Charts: The lecture utilizes several visual examples of CDC growth charts (e.g., Stature-for-age and Weight-for-age percentiles for Boys 2-20 years; Length-for-age and Weight-for-age for Girls birth-24 months; Head circumference for Boys birth-24 months). A specific highlight on the BMI chart demonstrates standard weight classifications: Overweight is defined as a BMI between the 85th and 95th percentiles, while Obese is defined as a BMI >95th percentile.

2. The ICP Concept of Growth

The ICP model (Karlberg J.) is a mathematical model that breaks down linear growth from birth to adulthood into three distinct, overlapping components reflecting different hormonal phases:

• Visual Element - ICP Concept Graph: A plotted line graph depicts these three phases. It shows a steep infantile curve that quickly decelerates, intersected by a steady, linear childhood curve, which is finally intersected by a steep pubertal curve. The summation of these overlapping curves dictates final adult stature.
• Infantile Phase (I):
  • A rapid period of growth from 0 to 2 years.
  • Represents a continuation of the rapid but decelerating intra-uterine growth phase.
  • Growth during this phase depends heavily on nutrition, insulin, and insulin-like growth factors (IGFs). It is largely independent of Growth Hormone (GH).
  • Birth size primarily reflects the intra-uterine environment (e.g., maternal nutrition) and therefore has a relatively poor correlation with final adult height.
  • From birth to age 2, the infant "tracks" onto their genetic centile, related to their parents' heights (based on the Aberdeen growth study).
• Childhood Phase (C):
  • A long phase spanning from roughly age 2 to 12 years (the onset of puberty).
  • Characterized by a slower, slightly decelerating growth curve.
  • Dependent on Growth Hormone (GH) and Thyroxine.
  • A healthy child will stay on their childhood (genetic) centile until puberty.
• Pubertal Phase (P):
  • Begins around age 12 and continues to final height.
  • A variable phase in terms of age of onset, duration, and intensity.
  • Dependent on the sex steroid estrogen (aromatized from testosterone), which causes a significant increase in GH secretion.
  • The resulting growth acceleration is ultimately limited and terminated by the fusion of the epiphyses (driven by estrogen in both sexes).

3. Height Velocity and Pubertal Staging

• Visual Element - Height Velocity Graph: A graph plotting height gain (cm/year) against age (years) compares boys (solid line) and girls (dotted line). It demonstrates that girls experience an earlier peak in height velocity (around age 12), whereas boys experience a later, higher-amplitude peak (around age 14).
• Visual Element - Tanner Staging: Clinical reference diagrams illustrate the progression of puberty. In girls, breast development progresses from Stage I (prepubertal) to Stage V (mature, with projection of the papilla). In boys, genital development progresses from Stage I to Stage V, tracking the enlargement of the scrotum, testes, and penis length/breadth. An accompanying photo shows an orchidometer, a string of sized beads used to measure testicular volume clinically.

Table 1: Pubertal Stages vs. Height Velocity

4. Growth Assessment and Evaluation

Essentials for Assessment:

• Reliable, accurate measuring equipment.
• Visual Elements - Measurement Techniques: Photographs show a clinician measuring a child's standing height using a wall-mounted stadiometer ensuring the head is in the Frankfurt plane (horizontal alignment), and another photo shows an infant being measured supine on a rigid length board by two practitioners.
• Accurate measurement of the child and parents.
• Calculation of decimal age and height velocity.
• Measurement of sitting height in selected cases (to evaluate for disproportion).
• Calculation of Mid-Parental Height (MPH) and Target Range:
  • Girls MPH: (Father's height - 13 cm + Mother's height) / 2
  • Boys MPH: (Father's height + Mother's height + 13 cm) / 2
  • Target Range: MPH ± 8.5 cm. (95% of normal individuals will attain final heights within 2 SD of MPH).
• Pubertal staging and Bone Age assessment.
  • Visual Element - Bone Age X-Ray: A standard anterior-posterior radiograph of a left hand and wrist is shown, which is compared against standardized atlases (Greulich & Pyle or Tanner Whitehouse) to determine skeletal maturity and predict adult height.

Defining Short Stature & Growth Failure:

• Evaluation Questions: How short is the child? Is Height Velocity (HV) impaired? What is the likely adult height? Is the child on an appropriate centile for genetic target height?
• Short Stature: Defined as a height below 2 Standard Deviations (SD) from the mean (i.e., the 3rd centile).
  • Visual Element - Gaussian Distribution: A bell curve graph correlates percentiles with standard deviations, illustrating that the 3rd percentile aligns closely with -2 SD.
• Growth Failure (Impaired HV): Failure to maintain a HV appropriate for age and maturity. HV must be calculated in cm/year using accurate measurements separated by at least six months. Growth failure is likely if:
  • The height-for-age curve deviates downwards across two major height percentile curves.
  • Age 2-4 years: HV < 5.5 cm/year.
  • Age 4-6 years: HV < 5.0 cm/year.
  • Age 6 to puberty: HV < 4.0 cm/year (boys) or < 4.5 cm/year (girls).
• Failure to Thrive (Weight Faltering): A term usually applied to infants and preschool children denoting failure to gain weight at an appropriate rate.

5. Etiologies of Short Stature

• Normal / Idiopathic Variants:
  • Familial (Genetic) Short Stature: Child is short and normal; parents are short; bone age is not delayed. The child is destined to become a short adult. Visual Element: A growth chart shows a child growing parallel to, but just below, the 3rd percentile, matching their low target familial range.
  • Constitutional Delay of Growth and Puberty (CDGP): Child is short but looks younger than chronological age. Parents are not short but may have a history of being "late bloomers." Bone age is delayed. Puberty is late, followed by catch-up growth. Final height is usually in the lower half of the target range. Visual Element: A comparative growth chart shows a CDGP curve temporarily dropping below the 3rd percentile before catching up, contrasted against a familial short stature curve that remains low.
  • Idiopathic Short Stature (ISS): Significant short stature (< -2.5 SD) not attributable to familial genetics, constitutional delay, or pathology. It is a heterogeneous condition that may include partial GH resistance or mild skeletal dysplasias.
• Intrauterine Growth Retardation (IUGR) / Small for Gestational Age (SGA):
  • Asymmetric (Head Circumference > Length > Weight): Due to 3rd-trimester malnutrition. Catch-up growth occurs during infancy, resulting in normal childhood growth and final height.
  • Symmetric (HC = Length = Weight): Due to prolonged intrauterine malnutrition. Catch-up growth is partial or absent. Results in short stature in childhood despite a normal growth rate, leading to a short adult.
  • Prognosis: Most SGA infants experience catch-up by age 2. ~10% (particularly severe SGA) do not.
• Dysmorphic Syndromes: Include Turner, Noonan, Silver-Russell, Williams, and Prader-Willi syndromes. Visual Elements: Photographs show characteristic facies of affected children, and a specific photo of a girl highlights features of Turner syndrome (cubitus valgus [outwardly angled forearm] and webbed neck).
• Skeletal Dysplasias: Frank skeletal abnormalities affecting epiphyses, metaphyses, or the spine (e.g., spondylo-epiphyseal dysplasia). Bone age tends to be advanced. Adult height SDS is worse than Childhood height SDS. Visual Elements: A diagram shows normal body proportions divided into quarters from newborn to adult. A clinical photo shows a 2.7-year-old boy with Achondroplasia, demonstrating severe rhizomelic (proximal) limb shortening, macrocephaly, and frontal bossing.
• Chronic Systemic Disease: Any chronic condition (GI, cardiac, respiratory, renal, metabolic, CNS, joint) can cause slow growth. Note that chronic renal disease and GI disorders (like celiac disease) can be clinically silent except for the presentation of short stature.
• Psychosocial Deprivation: Severe short stature and growth failure resulting from emotional abuse or neglect. (Children from poor communities also generally tend to be shorter than those from affluent areas).
• Endocrine Disorders: Hypothyroidism, Cortisol excess, Precocious puberty, and Growth Hormone deficiency.

6. Investigation and Treatment of Short Stature

• Screening & Investigation:
  • History: Growth pattern, parent heights/puberty, birth/postnatal history, health, psychosocial situation.
  • Auxology: Accurate plotting, sibling measurements, sitting height/leg length.
  • Screening Labs: Low threshold for karyotype in girls. FBC, blood film, ESR, TTG antibodies (celiac), LFTs, blood gas, TFTs, IGF-1, IGFBP3, prolactin, cortisol, creatinine, electrolytes, Ca, PO4, urinalysis/culture.
  • Further Workup: Endocrine stimulation testing (ITT, arginine, clonidine, glucagon), Pituitary imaging, Genetics, Skeletal survey.
• Growth Hormone Physiology:
  • Anterior pituitary protein secreted by somatotrophs. Pulsatile secretion, stimulated by sleep and exercise, inhibited by free fatty acids.
  • Antagonizes insulin action, promotes lipolysis in fat, and augments protein synthesis.
  • Visual Element - GH/IGF Axis Diagram: Shows Hypothalamus driving Pituitary GH release. GH targets the liver to produce IGF-1 and IGFBP/ALS. IGF-1 provides negative feedback and acts via endocrine, autocrine, and paracrine pathways on target tissues.
• Growth Hormone Deficiency (GHD):
  • Classification: Congenital vs. Acquired; Permanent vs. Temporary; Complete vs. Partial; Isolated vs. Multiple pituitary deficiency.
  • Congenital Causes: Idiopathic, Genetic defects (isolated AR/AD/X-linked, or multiple AP defects like PROP-1), Prader-Willi, Midline defects (septo-optic dysplasia).
  • Acquired Causes: Tumors (craniopharyngioma, optic glioma), Surgery, Cranial radiotherapy (e.g., for medulloblastoma), Granulomatous disease (Langerhans cell histiocytosis).
  • Visual Element - MRI: A sagittal MRI scan of the brain (by L.J. Abernethy) highlights the normal pituitary, stalk, and optic chiasm architecture.
• Growth Hormone Treatment:
  • Treat the underlying cause first.
  • Recombinant Human Growth Hormone (RHGH): Given as daily bedtime subcutaneous injections of aqueous biosynthetic solutions.
  • Indications: GHD, Turner/Noonan/SHOX syndromes, Prader-Willi, SGA with no catch-up by age 4, Chronic renal insufficiency, ISS (debatable).
  • Visual Element - Insulin/GH Pens: Images display "Norditropin" pens. Dosing is titrated by "clicks" which translate to mg, differing based on the specific treatment indication.
  • Side Effects: Metabolic effects (hyperglycemia), GH antibodies, progression of pre-existing scoliosis, slipped capital femoral epiphysis (SCFE), pseudotumor cerebri, transient gynecomastia, increased growth/pigmentation of nevi, carpal tunnel syndrome, edema/arthralgia, hypothyroidism, second neoplasms (meningioma), pancreatitis.

Part II: Type 1 Diabetes Mellitus (T1DM)

1. Definition and Classification

• Definition: A metabolic disorder characterized by the presence of hyperglycemia due to defective insulin secretion, defective insulin action, or both.
• Classification:
  • Type 1: Autoimmune disease. Onset is typically 6 months or after (requires a developed immune system). Features two incidence peaks: age 4 (school age, where more infections trigger it) and age 13 (puberty).
  • Type 2.
  • Other Specific Types: Genetically defined forms (MODY, Monogenic), or secondary to other diseases/drug use.

2. Diagnosis

• Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (to convert to mmol/L, divide by 18).
• Random Plasma Glucose ≥ 200 mg/dL + symptoms of diabetes.
• 2-hour Plasma Glucose in a 75-g OGTT ≥ 200 mg/dL.
• Presentation in CKD Patients: A handwritten clinical note details that in patients with CKD on dialysis, newly diagnosed diabetes may present with tachypnea and shortness of breath due to risk of pulmonary edema or metabolic acidosis. Initial treatment step: Give Calcium (Ca2+), then Bicarbonate.

3. Pathophysiology and Genetics

• Genetics: Familial clustering is present. Monozygotic twins have 30-65% concordance; dizygotic twins 6-10%; siblings 6%; mother 2%; father 7%. Rare monogenic T1DM includes IPEX syndrome and Autoimmune Polyglandular Syndrome (APS).
• Environmental Factors: ~50% of monozygotic twins are discordant. Incidence varies between urban/rural areas of the same ethnic group, changes with migration, and has increased globally in recent decades.
• Pathogenesis of T1DM:
  • Visual Element - Pathogenesis Graph: A graph charts β-cell mass over time. A genetic predisposition combined with environmental triggers initiates immune dysregulation. Autoantibodies appear (IAA, GADA, ICA512A, ICA). Progressive loss of first-phase insulin response (IVGTT) and variable insulitis lead to glucose intolerance. "Overt diabetes" symptoms arise only when β-cell mass falls below 10%. Diabetic Ketoacidosis (DKA) occurs when β-cell mass is almost 0%.
• Insulin Physiology:
  • Visual Element - Insulin/Glucagon Loop: A diagram illustrates the pancreas releasing insulin in response to high glucose, which lowers glucose by storing it as glycogen (liver), fat (adipose), and protein (muscle).
  • Secreted by β-cells.
  • Inhibits: Glycogenolysis, gluconeogenesis, lipolysis, and proteinolysis.
  • Stimulates: Protein synthesis and lipogenesis.
  • Absence of Insulin leads to: Decreased lipogenesis/protein synthesis, and massively increased lipolysis, proteinolysis, glycogenolysis, and gluconeogenesis.

Table 2: Counter-regulatory Hormones vs. Insulin

4. Diabetic Ketoacidosis (DKA)

• Definition: The end result of the metabolic abnormalities resulting from severe insulin deficiency. It is 100% preventable.
• Triggers: Non-compliance to insulin therapy (including injection into lipohypertrophy sites or inappropriate insulin storage) OR intercurrent illnesses not managed according to sick day guidelines. Progression to DKA is accelerated by stress.
• Clinical Presentation:
  • History: Polyuria, polydipsia, weight loss, abdominal pain (due to peritoneum irritation from acidosis), vomiting, confusion, tiredness, difficulty breathing.
  • Signs: Kussmaul breathing, lethargy, dehydration, signs of infection.
• Diagnosis of DKA:
  • Glucose > 200 mg/dL.
  • pH < 7.3.
  • Serum Bicarbonate < 18 mmol/L. (A handwritten note emphasizes obtaining a VBG rather than an ABG because it is safer and avoids arterial thrombosis).
  • Ketonuria or ketonemia.
• Management with Vascular Decompensation:
  • ABCs.
  • Normal saline 10 mL/kg to expand vascular space.
  • Decrease fluids to 5-7 mL/kg/hr with Potassium Chloride (KCl).
  • Do not infuse NaHCO3 (Bicarbonate) except in specific, severe circumstances.
  • Continuous IV insulin infusion at 0.1 units/kg/hr.
  • When to add glucose: If acidosis is improving and Blood Glucose < 270 mg/dL (or drops by > 90-100 mg/dL in one hour), change IV to D5/Normal Saline with potassium and decrease the insulin infusion rate.
• Complications of DKA:
  • Arrhythmias/cardiac arrest (secondary to electrolyte abnormalities or long QTc).
  • Venous thrombosis (hypercoagulable state—hence avoiding ABGs).
  • Pulmonary edema/ARDS, Acute Renal Failure (ATN), Bowel ischemia (necrosis, stricture).
  • Cerebral Edema (CE): Pathophysiology is now believed to be predominantly vasogenic (activation of cell membrane ion transporters in the brain) rather than strictly osmotic.
    • Risk Factors for CE: Younger age (<5 years), new-onset diabetes, high initial serum urea, low initial pCO2, rapid administration of hypotonic fluids, IV bolus of insulin, early IV insulin infusion (within the first hour of fluids), and the use of bicarbonate.
• Sick Day Management:
  • Counter-regulatory hormones during stress blunt insulin action and raise glucose.
  • DO NOT OMIT INSULIN. Adjust doses based on frequent monitoring.
  • Goals: maintain hydration, control glucose, avoid DKA.
  • Check ketones early (whenever nausea/vomiting occurs). Use urine ketodiastix, or a Precision Xtra blood meter for earlier detection without needing urine. Visual Element: A photo of a Bayer Keto-Diastix color chart shows reading results at exactly 15 seconds (Negative to Large/160 mg/dL).

5. Insulin Therapy and Delivery

• Visual Element - Endogenous Profile: A graph shows the normal physiological insulin profile, maintaining a low basal level with sharp spikes directly correlating to breakfast, lunch, and dinner.
• Insulin Analogues: Synthetic modification alters absorption profiles.
  • Visual Element - Molecular Structure: A biochemical diagram shows the α and β chains of insulin. Fast-acting analogues (Lispro, Aspart) have amino acid substitutions at positions 28/29 of the β-chain. Long-acting analogues (Glargine, Detemir) have additions (like a C14-Fatty Acid chain or arginine attachments) that prolong absorption.
  • Visual Element - Time-Action Profiles: A graph shows Rapid-acting insulins (Aspart, Lispro, Glulisine) peaking sharply at 1-2 hours; Regular insulin peaking later; Intermediate (NPH) with a broad curve peaking at 6-8 hours; and Long-acting (Glargine, Detemir) maintaining a flat, continuous line over 24 hours.
• Delivery Mechanisms:
  • Insulin Pens: Visual Element: Close-up photo of a patient dialing a dose and injecting subcutaneously into the abdomen.
  • Continuous Subcutaneous Insulin Infusion (CSII/Pump): Visual Elements: Multiple photos show different insulin pumps (MiniMed, Accu-Chek Spirit), disposable insulin reservoirs, and the subcutaneous infusion set adhered to the abdomen. A corresponding graph shows how the pump delivers a continuous low "Basal Infusion" combined with immediate "Bolus" activations for meals.

6. Monitoring and Hypoglycemia

• Monitoring:
  • HbA1c: A reliable index of long-term control, measuring glucose nonenzymatically attached to hemoglobin over the preceding 2-3 months.
  • Continuous Glucose Monitoring (CGM): Visual Element: A photo of a Freestyle Libre sensor on a patient's arm being scanned by a reader. A note clarifies it is "sensing the glucose in the interstitial fluid."
  • Screening (ISPAD Guidelines): Retinopathy and Nephropathy screening begins annually from age 11 (if duration is 2 years) OR from age 9 (if duration is 5 years).
• Hypoglycemia:
  • Symptoms: Hunger, trembling, sweating, extreme mood changes, extreme tiredness, pale skin, dizziness, blurred vision, headaches. These autonomic symptoms always precede neuroglycopenia, except in patients with long-standing T1DM experiencing hypoglycemia unawareness.
  • Action: If blood sugar is < 72 mg/dL, treat with oral carbohydrates. (A clinical note adds: avoid chocolates or foods high in fat for rapid rescue, as fat prolongs the digestion process).
  • Severe Rescue: Family must have and know how to use Glucagon. Visual Elements: Photos show three rescue options: 1) The standard red-case GlucaGen kit (requires reconstitution). 2) Gvoke HypoPen (FDA approved Sep 2019), a ready-to-use auto-injector. 3) BAQSIMI (FDA approved July 2019), the first non-injectable, single-use nasal powder dispenser.

7. Other Forms: MODY & Wolfram Syndrome

• MODY (Maturity-Onset Diabetes of the Young): Heterogeneous disorders causing β-cell dysfunction (primary defect in insulin secretion). Rare (1-2%). Often misdiagnosed as T1 or T2. Onset is 9-25 years. Autosomal Dominant inheritance (must be in at least 3 consecutive generations, with diagnosis before age 25 in at least 1 subject).
• Wolfram Syndrome: Characterized by the DIDMOAD triad: Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness. Other features include neurogenic bladder (hydroureteronephrosis), neurodegenerative illness (ataxia), psychiatric problems, and hypogonadism.

Part III: Adrenal DisordersYear 6

1. Anatomy and Physiology of the Adrenal Gland

• Anatomy:
  • Visual Element - Adrenal Cross-Section: A diagram divides the adrenal cortex into three zones above the Medulla:
    1. Zona Glomerulosa: Produces Mineralocorticoids (5-10% of cortex).
    2. Zona Fasciculata: Produces Glucocorticoids (75% of cortex).
    3. Zona Reticularis: Produces Androgens.
• Steroid Biosynthesis:
  • Cholesterol (mostly obtained from circulating LDL) is the starting point for all steroid hormones. It is modified by a series of hydroxylation reactions requiring substrate movement between the mitochondria and endoplasmic reticulum.
  • Visual Element - Biosynthesis Flowchart: A detailed biochemical map shows the specific enzymatic pathways:
    • Cholesterol → Pregnenolone (via StAR, 20,22-desmolase).
    • Mineralocorticoid Path: Pregnenolone → Progesterone → DOC (via 21-hydroxylase) → Corticosterone (via 11β-hydroxylase) → 18-OH-Corticosterone → Aldosterone.
    • Glucocorticoid Path: 17-OH-Pregnenolone → 17-OH-Progesterone → 11-deoxycortisol (via 21-hydroxylase) → Cortisol (via 11β-hydroxylase).
    • Androgen Path: DHEA → Androstenedione → Testosterone (via 17βHSD). Aromatase converts androgens to estrogens (Estrone, Estradiol).
• Regulation of Steroidogenesis:
  • HPA Axis: Visual Element - Diagram: Hypothalamus (CRH) → Pituitary (ACTH) → Adrenal Cortex (Cortisol). Cortisol provides negative feedback. ACTH (derived from POMC) stimulates LDL receptors.
  • Diurnal Rhythm: CRH peaks around 4:00 AM; ACTH peaks 4:00-6:00 AM; Cortisol follows, peaking at 8:00 AM. Hormones are released in pulses every 30-120 minutes (established by age 3).
  • Aldosterone Regulation: Governed primarily by the Renin-Angiotensin system. Visual Element - RAAS Diagram: Kidney senses low BP → Renin → Angiotensin I/II → Adrenal releases Aldosterone → Salt/water retention raises BP. ACTH deficiency does not alter aldosterone production. Aldosterone is cleared rapidly but provides 80% of mineralocorticoid activity.
  • Androgen Regulation: Secretes DHEA/S and androstenedione (converted peripherally to testosterone). Peaks in newborn period, rests until adrenarche (7-8 years), peaks in young adulthood, and wanes.
• Catabolism: <1% of cortisol/aldosterone is excreted unchanged in urine. 99% is metabolized by the liver (adding OH, sulfate, or glucuronide to make them water-soluble). 24-hr urine MS analysis is a tough but diagnostic tool.

2. Primary Adrenal Insufficiency (Addison's Disease)

• Historical Context: Visual Element: Portrait of Dr. Thomas Addison (described the acquired disease in 1855). Usually autoimmune (~80% of acquired cases).
• Etiologies:
  • Primary Acquired: Autoimmune adrenalitis, Autoimmune Polyglandular Syndromes (APS I/II), TB/fungal infections, Sepsis, AIDS, Bilateral injury (hemorrhage, necrosis, metastasis).
  • Primary Congenital: CAH, Congenital adrenal hypoplasia, Adrenoleukodystrophy (ALD), Wolman disease, Allgrove syndrome (AAA), Kearns-Sayre.
  • Secondary Insufficiency: Glucocorticoid withdrawal, Hypopituitarism, Hypothalamic tumors, Radiation/surgery, POMC defects.
• Clinical Presentation:
  • Visual Element - Historical Patient Portrait: An illustration of a patient with Addison's disease emphasizes characteristic hyperpigmentation.
  • Symptoms: Fatigue, weakness, weight loss, poor appetite, neuropsychiatric (apathy, confusion), nausea/vomiting, abdominal pain, salt craving.
  • Signs: Hyperpigmentation, hypotension, orthostasis, weak pulses, shock, loss of axillary/pubic hair in women.
• Laboratory & Diagnostics:
  • Labs: Hyponatremia, Hyperkalemia, Hypoglycemia. CXR shows narrow cardiac silhouette; EKG shows low voltage.
  • Evaluation: 0800 cortisol, ACTH, Renin, Electrolytes, ACA/Anti-21-OH antibodies, Imaging, Genetic testing.
  • ACTH Stimulation Test: Low dose (1 mcg) is more physiological and useful in central AI. High dose (250 mcg) provides stronger stimulation.

3. Treatment of Adrenal Insufficiency & Crisis

• Adrenal Crisis: Life-threatening emergency.
  • Goals: Treat hypotension/dehydration, reverse electrolyte/glucose abnormalities, correct cortisol.
  • Fluids: IV bolus 10-20 mL/kg Normal Saline.
  • Hypoglycemia: 2-4 mg/kg of 10% Dextrose (or 2 mL/kg 10% dextrose bolus).
  • Hyperkalemia: Usually normalizes with fluids/steroids. If >6 mmol/L, use cardiac monitor. If >7 mmol/L, use Ca-gluconate or insulin/glucose IV.
• Stress Dosing:
  • Loading: 50-100 mg/m2 Hydrocortisone IV/IM (Infants 25mg, Small children 50mg, Teens 100mg).
  • Maintenance during illness: 50-100 mg/m2/day divided q6-8 hours. Mineralocorticoid is unnecessary during high-dose stress treatment.
• Long-Term Treatment:
  • Glucocorticoid: Hydrocortisone 10-15 mg/m2/day divided TID (can switch to prednisone in teens).
  • Mineralocorticoid: Fludrocortisone 0.05-0.2 mg daily.
  • Requires medical alert ID and emergency Solu-Cortef at home.

Table 3: Relative Steroid Potencies

4. Congenital Adrenal Hyperplasia (CAH)

• Pathophysiology: Defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol accounts for >95% of CAH cases, mediated by a 21-hydroxylase deficiency (mutations in CYP21A2 gene).
  • Visual Element - Pathophysiology Diagram: Illustrates how the adrenal gland cannot produce cortisol. The lack of cortisol removes negative feedback, causing the pituitary to oversecrete ACTH. This overstimulates the adrenal gland (hyperplasia), and the metabolic backlog is pushed into the androgen pathway, creating massive amounts of Testosterone.
• Classification:
  1. Classic - Salt Wasting: Complete deficiency. Results in a life-threatening crisis in infancy (severe hyponatremic dehydration, hyperkalemia, metabolic acidosis).
  2. Classic - Simple Virilizing: Significant but partial defect.
  3. Non-Classic: Mild deficiency with elevated enzyme levels presenting later.
• Clinical Findings:
  • Visual Element - Prader Scale: Diagrams illustrate progressive stages (I to V) of female virilization, from mild clitoromegaly to complete labial fusion creating a pseudo-scrotum with a phallic urethra. Clinical photos accompany this, showing severe ambiguous genitalia in female newborns.
  • Visual Element - Hyperpigmentation: Photos of children with CAH show distinct hyperpigmentation on the lips/gums and the knuckles of the hands and toes, driven by high ACTH/POMC levels.
• Treatment: It is vital to identify and manage CAH immediately, as Salt-Losing crisis causes death. Volume replacement is essential. Infants with classic 21-OH deficiency require lifelong glucocorticoid, mineralocorticoid, and salt supplementation.

5. Cushing Syndrome

• Pathology: Hypercortisolism.
  • Cushing Disease: Overproduction of ACTH due to a pituitary microadenoma (accounts for 80-85% of cases in children). ACTH is 10-100 times normal and is not suppressed by the dexamethasone test. Treatment is trans-sphenoidal surgery.
  • Ectopic ACTH: Oat cell carcinoma, carcinoid, pancreatic islet cell, thymoma (adults) or neuroblastoma (infants).
  • Adrenal Tumors: Adenomas (secrete cortisol) or Carcinomas/Nodular hyperplasia (secrete cortisol and androgens). More common in young children < 7 years. Carcinomas have a more fulminant course.
  • Iatrogenic: From exogenous steroid use.
• Clinical Findings:
  • Visual Element - Clinical Characteristics Diagram: An illustration maps the physical signs: thinning hair, moon face, acne, red cheeks, buffalo hump, supraclavicular fat pad, pendulous abdomen with purple striae, thin extremities due to muscle atrophy, and slow wound healing/easy bruising.
  • In children, generalized obesity coupled with growth arrest are the most important and alarming initial signs.
  • Other signs: Hirsutism, hypertension, bone undermineralization, puberty arrest, compulsive behavior, psychological disturbances.

6. Pheochromocytoma

• Definition: Catecholamine-secreting tumor of the adrenal medulla. Note: 50% are caused by an underlying diagnosable genetic anomaly.
• Suspect if:
  • Triad: Episodic headache, diaphoresis, tachycardia ± hypertension.
  • Family history or clinical features of MEN2, von Hippel-Lindau (VHL), or paraganglioma syndromes.
  • Hypertension is unexplained, poorly responsive to treatment, or surges during anesthesia/surgery.
• Diagnosis & Management: Measure metanephrines in urine/blood. Localize via CT, MRI, or 131/123I-MIBG scintigraphy. Manage with pre-operative/perioperative BP control followed by surgical removal. Carries a 12-47% risk for malignancy.

Part IV: Congenital Hypothyroidism

• Epidemiology: Prevalence of 1:3500 in white infants, varying significantly among ethnic groups. Female-to-Male ratio is 2:1.
• Importance: Detection and treatment of neonates is a pediatric emergency. If levothyroxine therapy is not begun soon after birth, irreversible developmental delay and mental retardation result within weeks to months. Neonatal screening is essential due to the difficulty of clinical diagnosis early on.
• Clinical Manifestations:
  • Most infants are asymptomatic at birth (protected by maternal thyroid hormone). Birth weight and length are normal, though head size may be slightly increased.
  • Earliest sign: Prolongation of physiological jaundice.
  • Progression (if undetected): Decreased activity, feeding difficulties, respiratory difficulties, constipation, subnormal temperature, slow pulse. By 3-6 months, full clinical picture develops: stunted growth, short extremities, widely opened anterior and posterior fontanelles, coarse features, protrusion of a large tongue (macroglossia), dry scaly skin, coarse/brittle/scanty hair, and hypotonic muscles.
• Actions of Thyroid Hormones: Increase oxidative metabolism (↑ oxygen consumption, ↑ BMR, ↑ glucose/fat metabolism). Promote growth and CNS development (essential for normal myelination). Augment cardiac and reproductive function.
• Etiologies:
  1. Permanent Primary Hypothyroidism (↓ T4, ↑ TSH):
     • Thyroid Dysgenesis (85% of permanent cases): Ectopy, agenesis, hypoplasia, hemiagenesis.
     • Thyroid Dyshormonogenesis: Goiter, TPO mutation (most common).
     • TSH resistance (rare).
  2. Permanent Central Hypothyroidism (↓ T4, ↓ or inappropriately normal TSH): Developmental pituitary/hypothalamic defects (may have midline defects), TRH receptor mutations, or TSH β subunit/transcription factor mutations.
  3. Transient Hypothyroidism: Severe iodine deficiency, acute iodine overload (antiseptics), maternal antithyroid drugs (clears in 3-4 days), maternal TSH-receptor blocking antibodies, or Hypothyroxinemia of prematurity (adaptation rather than true disease).

Part V: Precocious PubertyYear 6

• Definition: The appearance of secondary sexual development more than 2.5 standard deviations earlier than the mean age for that population.
• Physiological Milestones: Thelarche (breast development), Pubarche (pubic hair), Adrenarche (adrenal androgen onset), Menarche (first menses).
• Tanner Staging: (See Part I, Table 1 for details on Stages I-V and accompanying visual descriptions).
• Normal Hypothalamo-Pituitary-Gonadal (HPG) Axis Progression:
  • Active during fetal life (gonadotropins are high in mid-fetal life, low in cord blood due to high maternal estrogen).
  • Mini-Puberty: Inhibition discontinues with placental separation. The HPG axis activates briefly in infancy.
    • Boys: LH increases 10-fold following delivery, spiking testosterone. Lasts ~12 hours.
    • Girls: FSH increases and stays high until age 2-4. Female newborn ovaries are larger than in childhood (measured at 1 mL until age 1).
  • After mini-puberty, the axis becomes dormant (childhood phase) due to central inhibition by gamma-aminobutyric acid (GABA). The precise trigger releasing this inhibition to start true puberty is unknown.
• Genetics: The GPR54 gene (chromosome 19p13.3) codes for a G-protein coupled receptor. Its ligand, kisspeptin, modulates negative feedback on GnRH. Gain-of-function mutations cause central precocious puberty; loss-of-function mutations cause autosomal recessive idiopathic hypogonadotropic hypogonadism.
• Classification:
  1. Central (Gonadotropin-Dependent) Precocious Puberty - GDPP.
  2. Peripheral (Gonadotropin-Independent) Precocious Puberty - GIPP.
  3. Isosexual (phenotype matches genetic sex) vs. Contrasexual (virilization in girls / feminization in boys).

1. Gonadotropin-Dependent Precocious Puberty (GDPP)

• Causes: Idiopathic, CNS tumors (Hamartomas, Astrocytomas, Adenomas, Gliomas, Germinomas), CNS infections, Head trauma, Iatrogenic (Radiation, Chemo, Surgery), CNS Malformations (Arachnoid/suprasellar cysts, Septo-optic dysplasia, Hydrocephalus), or Genetic (GPR54).
• Evaluation: History (onset, CNS insults, neuro symptoms), Physical (growth, Tanner staging, neuro/thyroid exam), Investigations (Bone Age, TFT, LH/FSH, Estradiol/Testosterone, GnRH stimulation test, Pelvic US, Brain MRI).
• Treatment: Depends on etiology, pace of maturation, and psychosocial factors.
  • GnRH Agonists (Leuprolide acetate, Triptorelin, Histrelin). Continuous administration downregulates receptors, slowing accelerated puberty and improving final adult height. Given until the normal age of puberty.

2. Gonadotropin-Independent Precocious Puberty (GIPP)

• Causes: CAH, Testosterone/Estrogen-producing tumors (Adrenal carcinoma/adenoma, Granulosa/Theca/Leydig cell tumors), Ovarian cysts, hCG-producing tumors (Choriocarcinoma, Dysgerminoma, Hepatoblastoma, Teratoma), Exogenous steroid exposure, severe Hypothyroidism.
• McCune-Albright Syndrome: A rare disorder caused by a somatic mutation of the alpha subunit of the G3 protein (activating adenylate cyclase). Presents with a triad: Peripheral precocious puberty, café-au-lait skin pigmentation, and fibrous dysplasia of bone. Recurrent follicular cysts lead to cyclic menses/vaginal bleeding.
• Familial Male-Limited Precocious Puberty (Testotoxicosis): Rare, autosomal dominant disorder presenting at age 1-4 years. An activating mutation in the LH receptor gene causes premature Leydig cell maturation and testosterone secretion independent of GnRH.
• Treatment: Surgical removal of testis, adrenal, or ovarian tumors. hCG tumors may require surgery, radiation, and chemotherapy. Defects in adrenal steroidogenesis (CAH) are treated with glucocorticoids to suppress excess androgens.

Gastroenterology

Comprehensive Lecture Overview

This document provides an exhaustive medical summary of three distinct lecture slide decks focusing on pediatric gastroenterology and hepatology:

1. Acute Gastroenteritis: Covers GI physiology, the epidemiological burden of diarrhea, etiologies, dehydration assessment parameters, and detailed management protocols (including WHO ORS osmolarity).
2. Chronic Diarrhea: Details the pathophysiological mechanisms of chronic diarrhea, extensive differential diagnoses stratified by age, red flags, specific workup investigations, and profiles of key diseases (e.g., Celiac, Cystic Fibrosis, Toddler's Diarrhea, IBD).
3. Liver Diseases in Children: Provides a deep dive into hepatic anatomy and function, bile composition, and the clinical approach to neonatal jaundice, cholestasis, acute/chronic hepatitis, and acute liver failure, complete with six practical clinical case studies and a guide to interpreting Hepatitis B serologies.

PART 1: ACUTE GASTROENTERITIS (AGE)

1. GI Tract Job Description

The primary function of the GI tract is to perform the mechanical and chemical processes required for:

• Digestion of food.
• Absorption of nutrients.
• Elimination of waste.
• Visual Integration (Daily Water Exchanges): A diagram of the human digestive system illustrates the massive fluid balance required in the intestines.
  • Exogenous sources (2 liters): Derived from food and fluid intake.
  • Endogenous sources (7 liters): Derived from saliva, gastric juices, intestinal secretions, pancreatic juices, and biliary secretions.
  • Water Secretion/Excretion: Under normal conditions, water absorption is highly efficient, leaving very little water to be secreted in waste (<5ml/kg in children; <200 ml in adults). Disruption of this absorption/secretion balance results in diarrhea.

2. Definition and Classification of AGE

• Definition: Acute gastroenteritis is generally defined as a decrease in the consistency of stools and/or an increase in the frequency of evacuations (typically ≥ 3 in 24 hours), presenting with or without fever or vomiting.
• Clinical Nuance: A change in stool consistency versus the patient's previous stool consistency is a more indicative marker of diarrhea than stool number alone, particularly in the first months of life.
• Duration: Acute diarrhea typically lasts less than 7 days. If the condition extends beyond 14 days, it is reclassified as chronic diarrhea.

3. Epidemiology and Burden of Diarrhea

• Global Impact: Diarrhea is the second leading cause of death in children under five years old, causing 525,000 deaths each year. Globally, there are nearly 1.7 billion diarrheal episodes annually.
• Complications: It is a leading cause of malnutrition in children under five. It is both preventable and treatable.
• Peak Incidence: The highest incidence occurs between 6 and 11 months of age. This correlates with:
  • The age of complementary feeding.
  • Developmental age behaviors (mouthing of objects).
  • Declining protective maternal antibodies.
• Department of Statistics (Jordan 2017-2018 Survey):
  • 10% of children under age 5 had diarrhea in the 2 weeks preceding the survey.
  • Medical advice was sought in only 54% of children.
  • 28% of children with diarrhea were inappropriately given antibiotics.
  • Only 31% were given more fluids than usual (which is the recommended approach).
  • 44% of children were given fluids prepared from an Oral Rehydration Solution (ORS).
  • Visual Integration: The slide features the cover of the "Jordan Population and Family Health Survey 2017-18 Key Indicators" report, displaying a colorful bar chart map of the world.

4. Etiology of AGE in Children

The causes are heavily skewed toward viral pathogens.

• Visual Integration (Local Study): A screenshot of a research paper titled "Viral Gastroenteritis Among Young Children in Northern Jordan" is shown. The key takeaway highlighted in the presentation is that 39.6% of the tested cases had Rotavirus (detected by ELISA).

5. Complications of Diarrhea

• Dehydration leading to shock.
• Electrolytes imbalance.
• Metabolic acidosis.
• Convulsions (secondary to brain edema or electrolyte shifts).
• Malnutrition (if chronic or recurrent).
• Sepsis and DIC (Disseminated Intravascular Coagulation).

6. Assessment of Dehydration

Dehydration assessment must be carried out through a complete physical evaluation. Studies (e.g., Duggan C, et al. J Pediatr Gastroenterol Nutr 1996) correlating clinical signs with post-treatment weight gain indicate:

• First signs of dehydration might not be evident until a 5% fluid loss.
• More numerous clinical signs become evident at 5-9% fluid loss.
• Signs indicating severe dehydration and shock are not evident until fluid loss reaches 10%.

• Visual Integration (Physical Signs): An illustration of an infant being physically examined highlights the core physical signs of dehydration to look for:
  • Sinking fontanelle (in infants).
  • Sudden tearless eyes.
  • Dry mouth.
  • Fast, weak pulse.
  • Sudden weight loss.
  • Loss of elasticity or stretchiness of the skin (skin turgor).
  • Little or no urine; urine is dark yellow.

Classification of Degree of Dehydration:

• Mild dehydration: No clinical signs present.
• Moderate dehydration: 2 clinical signs present with stable circulation.
• Severe dehydration: 2 clinical signs present plus signs of shock.

7. Diagnostic Workup and Hospitalization

Most children with acute gastroenteritis do not require a diagnostic workup.

• Indications for Workup:
  • Very young children.
  • Patients with underlying chronic conditions (e.g., cancer, inflammatory bowel diseases, immune deficiency disorders, diabetes mellitus).
  • Very sick patients.
  • Patients with febrile invasive diarrhea or bloody diarrhea (with or without fever).
  • Patients with known travel to high-risk areas or during a disease outbreak.

• Indications for Hospital Admission:
  • Shock.
  • Moderate-to-severe dehydration in young children.
  • Neurological abnormalities (lethargy, seizures, etc.).
  • Intractable vomiting.
  • Failure of oral rehydration.
  • Suspected surgical conditions.
  • Electrolyte and/or acid/base imbalance.
  • Unmet conditions for safe follow-up and home management.

8. Treatment: Fluid and Nutritional Management

• Oral Rehydration Solution (ORS): Should be used as first-line therapy for children with mild or moderate dehydration. All other therapies are add-ons.
  • Dosage: 75 ml/kg given over 3-4 hours.
  • Maintenance: 100 ml given after each loose stool.
• Visual Integration (WHO ORS Osmolarity): A specific table breaks down the optimal composition of WHO-standard ORS.

• Nutritional Management:
  • Breastfeeding should continue all through the illness.
  • Early resumption of regular feeding after rehydration therapy is recommended.
  • Provide extra food and extra drink.
  • The use of lactose-free feeds is not recommended.
  • The use of diluted milk is not recommended.
• Additional Therapies (Add-ons to ORS if needed): Probiotics, Antibiotics, Anti-diarrheal drugs, Antispasmodics.

9. Prevention

• Wash hands thoroughly before and after eating, and when preparing meals.
• Ensure tools used for eating and preparing meals are clean.
• Cover food or store it in the fridge to prevent contamination.
• Administer Rotavirus vaccines.

PART 2: CHRONIC DIARRHEA

1. Definition and Pathogenesis

• Definition: A decrease in consistency and/or an increase in frequency and/or volume of stools lasting longer than two weeks. The change in stool consistency is more important diagnostically than stool frequency.
• Visual Integration (Normal Intestinal State): An illustration of the intestinal mucosal folds shows the normal physiological flow: The Villus Tip is responsible for downward flow/Absorption, while the Crypt is responsible for upward flow/Secretion. Chronic diarrhea represents a sustained breakdown of this mechanism.
• Pathogenesis Mechanisms:
  • Osmotic
  • Secretory
  • Inflammatory
  • Dysmotility
  • Factitial

2. Clinical Evaluation

• History: Age, Family history, Growth trajectory, Associated symptoms, Dietary history, Stool characteristics.
• General Clinical Features to note: Insidious onset, usually no fever.
• Localization based on stool:
  • Small bowel: Profuse, watery, offensive smell, no blood.
  • Colon: Small volume, containing blood or mucus (Dysentery).
• Specific Triggers to ask about:
  • Dietetic history: Formula, gluten, soy, eggs, etc.
  • Drugs: Antibiotics, laxatives, colchicine, propranolol, etc.
• Stool Characteristics to identify: Undigested food particles, Mucus, Blood, Steatorrhea, Offensive smell.
• Physical Examination:
  • Assess weight and height for age.
  • Check for abdominal distension and tenderness.
  • Examine the perianal area and check for oral lesions.
  • Look for other affected organs (e.g., skin, respiratory system).
  • Visual Integration (Symptom Context): A slide featuring the word "Urgency" shows a humorous image of a woman wearing a t-shirt stating "People say love is the best feeling but I think finding a toilet when having diarrhea is much better," overlaid with Arabic text affirming this sentiment. This highlights the severe impact of urgency on quality of life.
  • Visual Integration (Dermatological Findings): Three clinical photographs show extra-intestinal manifestations:
    1. Acrodermatitis: An infant with severe, erythematous, crusting lesions around the mouth and perianal area (indicative of zinc deficiency).
    2. Dermatitis Herpetiformis (DH): A close-up of a limb showing clusters of small, red, intensely itchy bumps (strongly associated with Celiac disease).

3. Red Flags in Chronic Diarrhea

If any of these are present, an aggressive workup is required:

• Poor weight gain, weight loss, or Failure to Thrive (FTT).
• Night stool (waking from sleep to defecate).
• Acid stools accompanied by a burning sensation and redness.
• Presence of blood and mucus.
• Associated symptoms of systemic disease (rash, fever, arthritis, etc.).

4. Differential Diagnosis by Age

A. Chronic Diarrhea in Early Age (Birth - 30 days):

• Acrodermatitis enteropathica (Zinc deficiency)
• Congenital chloridorrhea
• Abetalipoproteinemia
• Congenital microvillus atrophy
• Glucose-galactose malabsorption
• Cystic Fibrosis
• Cow’s milk protein allergy
• Visual Integration: Histological image showing abnormal mucosal cells alongside an image of abnormal, spiked red blood cells (acanthocytes), which are classic for Abetalipoproteinemia.

B. Chronic Diarrhea in Later Age (Infants/Toddlers/Children):

• Chronic infections
• Post-infectious diarrhea
• Food allergy
• Celiac disease
• Chronic non-specific diarrhea (Toddler's diarrhea)
• Inflammatory Bowel Disease (IBD)

5. Specific Disease Profiles

Cow’s Milk Protein Allergy (CMPA)

• The most common food allergy in infancy (up to 5% incidence).
• Very diverse clinical presentation and differential diagnosis.
• Diagnosis is achieved by dietary elimination and subsequent challenge.
• Treatment: Exclusive breastfeeding (mother avoids dairy) or use of a hydrolyzed formula.
• Prognosis: Typically resolves before 3 years of age.

Celiac Disease

• Age of onset: Correlates directly with the time of cereals introduction.
• Implicated food: Wheat, barley, rye, and possibly oats.
• Pathology: Villus atrophy, elongated crypts, increased Intraepithelial Lymphocytes (IEL).
• Presentation: Distention, diarrhea, Failure to Thrive (FTT).
• Screening: The best method to test for celiac disease is using the Tissue Transglutaminase IgA antibody (tTG-IgA), combined with a total IgA antibody level (to prevent false negatives in IgA deficient patients).
• Treatment: Strict, lifelong Gluten-Free Diet (GFD).
• Visual Integration: An anatomical graphic shows the intestines, indicating the primary site of autoimmune damage in Celiac disease.

Cystic Fibrosis

• Presents in the neonatal period with intestinal obstruction; meconium ileus.
• Associated with recurrent or persisting cough, often with wheeze.
• Malabsorption presents with large, pale, bulky, and offensive stools.
• Complications include failure to thrive, rectal prolapse, and rarely, heat stroke.
• Diagnosis: Sweat chloride concentration is elevated (↑). Microbiology often shows Staphylococcus + Pseudomonas aeruginosa.
• Management: Physiotherapy, Enzyme replacement, and increasing fluid and salt intake during hot weather.

Inflammatory Bowel Disease (IBD)

Toddler’s Diarrhea (Chronic Non-Specific Diarrhea)

• Most common cause of chronic diarrhea between 2 and 4 years of age.
• Intermittent and self-limited.
• Presents with no pain, no distension, and no vomiting.
• Crucially, it has no effect on weight and no effect on nutrition.
• Highly associated with a large consumption of juices.
• Characterized by undigested food particles in the stool.
• Visual Integration (Stool Sample): A clinical photograph shows a stool sample in a white bowl. The stool contains highly visible, totally undigested macroscopic food fragments. Lines point to specific elements: "distal end", "mesentary", "proximal end", "carrot", "corn kernel", and "string bean fragment". This perfectly visually demonstrates the harmless, rapid-transit nature of toddler's diarrhea.

6. Investigations for Chronic Diarrhea

• Feces: Stool analysis and culture, pH and Reducing substances, Fat, Elastase, Alpha 1 antitrypsin, Calprotectin.
• Blood Tests: CBC and blood film, Serum electrolytes, Inflammatory parameters (CRP, ESR), blood cultures, Nutritional status (Ferritin, folate, serum protein), Celiac disease serology.
• Imaging: Barium follow-through, CT, MRI, Ultrasound.
• Endoscopy & Pathology: Direct visualization and tissue biopsy.

7. Treatment & Facts

• Supportive: Manage dehydration, correct electrolyte imbalances, provide specific nutrients.
• Empirical: Antidiarrheal drugs.
• Curative: Antibiotics, Pancreatic enzymes, Dietary modifications.
• Key Facts:
  • 1% of acute diarrheas become chronic, leading to malnutrition and high morbidity and mortality.
  • Most chronic cases are not of infectious origin and require extensive workup for diverse diseases (Eosinophilic disorders, IBD, CF, Exocrine pancreatic insufficiency, Celiac, congenital/hereditary disorders, functional disorders).
  • Preventable causes/exacerbating factors include: Poor management of AGE, bottle feeding, unrecognized milk allergy, inappropriate antibiotic use, age below 18 months, and a malnourished child baseline (low Zinc, low Vitamin A).

PART 3: LIVER DISEASES IN CHILDRENYear 6

(Note: The lecture includes a preface outlining gastrointestinal educational modules accessible via Indiana University, utilizing the EDactic platform. Login details (mfeist / student) and search parameters for specific GI case studies are provided for the students' self-directed learning.)

1. Liver Anatomy and Physiology

• Anatomy: The liver is the largest solid organ in the body.
  • Visual Integration (Gross Anatomy): A 3D illustration shows the right lobe, left lobe, falciform ligament, coronary ligament, ligamentum teres (round ligament), the gallbladder nestled underneath, and the major vessels (aorta, inferior vena cava) running behind it.
• Liver Segments:
  • Visual Integration (Couinaud Segments): Detailed anatomical maps divide the liver into 8 surgical segments based on the Cantlie's line (which divides right and left lobes).
    • Right Lobe (Anterior section: Segments 5, 8. Posterior section: Segments 6, 7).
    • Left Lobe (Medial section: Segment 4. Lateral section: Segments 2, 3). Segment 1 is the caudate lobe (posterior).
  • Visual Integration (Hand Mnemonic): A photograph shows a closed human fist with numbers mapped onto the knuckles and fingers, demonstrating a physical mnemonic for memorizing the 8 liver segments.
• Blood Supply:
  • Visual Integration (Vascular Tree): Diagrams detail the dual blood supply.
    • Hepatic Portal Vein (from the small/large intestines, bringing nutrient-rich, oxygen-poor blood): Contributes 75% of blood supply and 50% of O2 supply.
    • Hepatic Artery (from the aorta, bringing oxygen-rich blood): Contributes 25% of blood supply and 50% of O2 supply.
    • Blood exits via the Hepatic Vein to the body.
• Microscopic Anatomy (Liver Lobule):
  • Visual Integration: A hexagonal diagram shows the basic structure of a liver lobule. The Central Vein is in the middle. The corners contain the portal triads (Hepatic Portal Vein, Hepatic Artery, Bile Duct). Blood flows inward via venous sinuses; bile flows outward via bile canaliculi produced by hepatocytes.
• Liver Functions:
  • Synthesis and storage of amino acids, proteins, vitamins, and fats.
  • Detoxification.
  • Blood glucose regulation.
  • Bile drainage.
  • Blood circulation and filtration.
  • Key Feature: The liver possesses the unique ability of auto-regeneration.

2. Bile and Digestion

• What is bile? A yellowish, blue, and green fluid secreted by hepatocytes. It is composed of water, ions, bile acids, and organic molecules.
  • Visual Integration (Bile Composition Pie Chart): The exact composition is: Bile salts (50%), Phospholipids (40%), Cholesterol (4%), Bilirubin (2%), and Other (4%).
  • Function: Aids the process of digestion of lipids (which are insoluble in water) by emulsification.
• Lipid Absorption (MCT vs LCT):
  • Visual Integration (Intestinal Villi Diagram): Shows differing absorption pathways. Short and Medium-chain fatty acids (MCTs) are absorbed directly into the capillary network and transport straight to the liver via blood vessels. Long-chain fatty acids (LCTs) require bile to form micelles, are broken down by lipase into monoglycerides, enter the cell to form chylomicrons, and are transported via the lacteal (lymphatic system) before eventually reaching the bloodstream.

3. The Bilirubin Pathway

• Visual Integration (Bilirubin Flowchart):
  1. Red blood cell hemolysis produces unconjugated bilirubin.
  2. Unconjugated bilirubin binds to albumin in the blood and travels to the liver.
  3. A hepatocyte takes it up.
  4. The enzyme UGT 1A1 conjugates the bilirubin.
  5. Conjugated bilirubin is excreted into the small intestine.
  6. It can either be excreted in the stool, OR an enzyme called β-glucuronidase deconjugates it back into unconjugated bilirubin, which is reabsorbed via enterohepatic circulation back to the liver.

4. Spectrum of Liver Diseases

A conceptual tree mapping the broad categories of liver disease:

1. Infections: Hepatitis (A, B, C, E, D), EBV, CMV, Herpes simplex, HHV6, Parvovirus, Yellow fever, Dengue fever, Hantavirus.
2. Vascular
3. Autoimmune
4. Drug Induced
5. Structural: Biliary atresia, Choledochal cyst, Caroli syndrome, Alagille syndrome, choledocholithiasis.
6. Tumors
7. Inherited Metabolic

5. Cholestasis and Neonatal Jaundice

• Cholestasis Definition: Decreased or impaired bile flow. This can be due to mechanical obstruction or due to down-regulation/absence of transport proteins.
• Pathophysiology: This results in the retention of bile components in the liver, which are harmful to the hepatocytes and will lead to severe liver damage if left "undrained".
  • Visual Integration: A cellular diagram shows hepatocytes suffering from "Hepatocellular cholestasis" and "Ischemia/hypoxic injury" leading to cell death and the release of proinflammatory cytokines, which attract neutrophils and Kupffer cells, causing further ductular cholestasis and obstruction.
• Laboratory Definition: Cholestasis presents as Direct hyperbilirubinemia.
  • Bilirubin Math / Delta Bilirubin: Total bilirubin = Conjugated + Unconjugated + Delta.
  • Delta Bilirubin: Conjugated bilirubin that is covalently bound to albumin.
  • Visual Integration (Bilirubin Measurements Case Study): A clinical text box explains that traditional lab tests measure Total Bilirubin (TB) and Direct Bilirubin (DB). Direct bilirubin includes both conjugated and delta fractions. Example given: If TB = 9.0, Unconjugated (UB) = 3.2, and Conjugated (CB) = 4.8, then Delta = TB - (UB+CB) = 9.0 - (3.2+4.8) = 1.0. Cholestasis is traditionally defined as a direct (or conjugated) bilirubin that is greater than 20% of the total measured bilirubin.

• Progressive Familial Intrahepatic Cholestasis (PFIC)
  • Visual Integration (PFIC Diagnostic Table):

• Neonatal Jaundice: Evaluation and Red Flags
  • Differentiate physiologic vs. pathological jaundice.
  • Age threshold to rule out cholestasis: 2 weeks in formula-fed infants; 3 weeks in breastfed infants.
  • Screening step: The most important thing for a primary care physician to do is FRACTIONATE THE BILIRUBIN!!! If neonatal cholestasis is present, pediatric gastroenterology consultation is warranted. Review the newborn screen and consider blood/urine cultures.
  • Red Flags by History: Irritability or vomiting, Dark urine, Acholic (pale/white) stools, Poor intrauterine growth.
  • Red Flags by Physical Exam: Abnormal facies, Microcephaly, Cataracts.
    • Heart murmur or other signs of cardiac disease, Hepatomegaly, Splenomegaly.
    • Visual Integration (Alagille Syndrome Facies): Five photographic angles of a young boy demonstrate characteristic abnormal facies (broad forehead, deep-set eyes, pointed chin, saddle-nose) indicative of Alagille syndrome, a genetic cause of cholestasis.

• Biliary Atresia
  • It is critical to rule this out in a timely manner because earlier intervention is associated with a much better outcome.
  • Patients are typically well-appearing at the time of presentation.
  • Visual Integration (Pathology): A diagram shows "The Liver" with an "Abnormal Gallbladder" and an obstructed "Cystic Duct" acting as a blind pouch, indicating "No Bile Flows into the Intestine".
  • Surgical Procedure: Kasai portoenterostomy.
  • Visual Integration (Kasai Procedure): Side-by-side diagrams compare a normal biliary system to the Kasai procedure, where the atretic extrahepatic ducts are excised, and a loop of the jejunum (small intestine) is brought up and surgically anastomosed directly to the hilum of the liver to restore bile flow.

• Other Causes of Neonatal Cholestasis
  • The two most common causes (besides biliary atresia) are:
    1. Idiopathic neonatal hepatitis
    2. α1-antitrypsin deficiency (very rare in Jordan/Middle East).
  • Other causes: Hypothyroidism, Galactosemia, Fructosemia, Tyrosinemia, TPN-induced, Sepsis or UTI, Choledochal cyst, Alagille syndrome, Cystic fibrosis, Bile acid synthesis defects.

• Diagnostic Testing
  • Ultrasound: First-line, highly useful.
  • DISIDA or HIDA scan (Tc99): Visual Note: A bright blue arrow points to a box stating "Not helpful", emphasizing its limited utility in modern workups.
  • Liver biopsy: Gold standard for tissue diagnosis.
  • Intraoperative cholangiogram: Definitive anatomical mapping during surgery.

• Management (Mx) of the Cholestatic Infant
  1. Treat the underlying cause.
  2. Decrease cholestasis / improve bile flow using Ursodeoxycholic acid (URSA).
  3. Improve nutrition using an MCT formula (bypasses the need for bile salts for absorption).
  4. Vitamin supplement: ADEK (Fat-soluble vitamins A, D, E, K).
     • Visual Integration: A photo of a medication box labeled "PediaVIT Multi Oral Solution". The accompanying text prescribes the exact dosage: "5 ml po q day + Vit K 2 mg".
  5. Watch for cirrhosis complications: Portal Hypertension (PHTN), Splenomegaly, Ascites, Esophageal varices, Hepatorenal syndrome, Hepatopulmonary syndrome, Malignancy.

6. Hepatitis

• Acute Hepatitis
  • Causes: Hepatitis A is most common. Hepatitis B and C. EBV, CMV, other viruses. Non-infectious causes.
  • Evaluation: Hepatitis panel +/- EBV and CMV serologies. Liver function tests. If Hep B or C is (+), or no cause is found, refer the patient.
• Acute Hepatic Failure
  • May result from a variety of causes.
  • Management: Provide IV glucose, try to lower ammonia levels, try to correct coagulopathy, and initiate transfer to a transplant center.
• Chronic Hepatitis
  • Causes: NASH, Hepatitis B or C, Autoimmune, Wilson’s disease, α1-antitrypsin deficiency, Medication-related.
  • Evaluation: Hepatitis panel, liver function tests, referral to pediatric gastroenterologist.
  • NASH (Non-Alcoholic Steatohepatitis): Most common liver disease in the U.S. Linked to obesity and insulin resistance. It causes fatty infiltration of the liver with inflammation. Must rule out other causes. Treatment: Weight loss is the first-line treatment.
  • Autoimmune Hepatitis: More common in females. Personal/family history often positive for autoimmune diseases.
    • Labs: ANA, anti-SMA (Type I); Anti-LKM1 (Type II); Elevated IgG (either type).
    • Treatment: Steroids +/- azathioprine.
  • Wilson’s Disease: Presents with liver disease, CNS disease, psychiatric disease (depression/withdrawal), and signs of hemolysis. Usually affects older children or adolescents. Kayser-Fleischer rings (faint brown rings at the edge of the iris) are highly suggestive.
    • Labs: Decrease in serum ceruloplasmin; Elevated 24-hour urine copper.
    • Treatment: Penicillamine or trientine +/- zinc.

7. Hepatitis B Serologies Interpretation

Understanding the profile is critical for diagnosing the stage of Hepatitis B.

• HBsAg = Infected.
• Anti-HBs = Protected.
• Anti-HBc IgM = Primary infection (recent).
• Anti-HBc IgG = Primary infection (remote).
• HBeAg = Viral replication or increased infectivity.

Interpretation Guide:

• Anti-HBs (+) and anti-HBc (+) → Resolved infection.
• HBsAg (+) and anti-HBc IgG (+) → Chronic infection.
• Anti-HBs (+) and anti-HBc (-) → Immunized (via vaccine).
• HBsAg (+) and anti-HBc IgM (+) → Acute infection.

8. Clinical Case Studies

• Case 1 (Physiologic Jaundice): 18-day-old male breastfed infant. Normal weight gain. Mom notes improving yellow color. PE: mild jaundice/scleral icterus. No red flags for cholestasis. Assessment: Likely breast milk/physiologic jaundice. Action: Order fractionated bilirubin to definitively rule out direct hyperbilirubinemia.
• Case 2 (Neonatal Cholestasis/Biliary Atresia): 4-week-old breastfed male. Red flags: Stools are almost white (acholic), urine is dark brown, liver palpable 3 cm below costal margin. Assessment: Classic presentation of neonatal cholestasis. Action: Fractionate bilirubin, order ultrasound, urgently refer to pediatric GI to evaluate for Biliary Atresia.
• Case 3 (Acute Hepatitis A): 14-year-old female. Fever, nausea, vomiting for 3 days. New yellow eyes/skin. Mild RUQ tenderness. Labs show massive transaminitis: ALT 4000, AST 3100. Alk phos 280. Total bili 7.8, Conj bili 5.6. Assessment: Acute viral hepatitis. Action: Order Hep A IgM (+). Treat supportively. (If Hep A IgM was negative, must screen for other causes like autoimmune or Wilson's).
• Case 4 (Autoimmune Hepatitis): 9-year-old female. Jaundice. Family history of autoimmune disease (hypothyroidism). PE normal except jaundice. Labs: ALT 2300, AST 2200, Alk phos 300, Total Bili 12.2, Conj Bili 8.8. Standard hepatitis screen is (-). Action: Order EBV/CMV (came back negative) and autoimmune markers. Results: IgG elevated, ANA (+), anti-SMA (+). Diagnosis: Autoimmune Hepatitis Type I. Treatment: Steroids.
• Case 5 (Wilson's Disease): 17-year-old male. Jaundice, very withdrawn, recently diagnosed with depression. Liver edge palpable 6 cm below margin. Faint brown rings noted at the edge of the iris (Kayser-Fleischer rings). Action: Order ceruloplasmin (decreased) and 24-hour urine copper (extremely elevated). Diagnosis: Wilson's disease. Treatment: Penicillamine or trientine.
• Case 6 (NASH): 13-year-old male, asymptomatic yearly checkup. Severely obese, acanthosis nigricans present. Liver palpable 3 cm below margin. Labs: Mild transaminitis (ALT 180, AST 110), Alk phos 200, Bili 0.8. Action: Fasting blood glucose and insulin elevated. Hepatitis panel (-). Diagnosis: Non-Alcoholic Steatohepatitis (NASH). Treatment: Weight loss.

Genetics

1. Bone and Skeletal Dysplasias

Rickets

Rickets presents clinically with skeletal deformities such as genu varum (bowing of the legs).

• Clinical Presentation: Patients present with dental abnormalities (missing incisors), and characteristic skeletal signs.
  • [Visual depicted: A close-up of a child's mouth revealing significant dental abnormalities, specifically missing upper and lower incisors.]
  • [Visual depicted: A pediatric wrist X-ray demonstrating osteopenia alongside classic "cupping, fraying, and widening" of the distal metaphyses of the radius and ulna.]
  • [Visual depicted: A child exhibiting the "Rachitic Rosary" (visible swelling/beading at the costochondral junctions) and marked widening of the wrist joints.]

• Biochemical Differentiation: To determine the specific etiology of rickets, biochemical investigations beyond X-rays are required.
  • Hypophosphatemic Rickets (Vitamin D Resistant Rickets):
    • Labs: Calcium is normal, Phosphorus is very low, Alkaline Phosphatase (ALP) is very high.
    • PTH: Parathyroid hormone is normal (PTH is only triggered by hypocalcemia or hyperphosphatemia, neither of which are present here).
    • Genetics: X-linked dominant. It affects both sexes but is usually lethal in males (resulting in stillbirths). Females survive but are affected. Rule: X-linked inheritance shows no male-to-male transmission.
    • Treatment: Supplementation with 1-alpha Vitamin D and high doses of phosphate given in large amounts every 4 hours.

Table 1: Comparison of Rickets Etiologies

Osteogenesis Imperfecta & Achondroplasia

• Osteogenesis Imperfecta: Caused by a defect in Type 1 collagen.
  • Clinical Sign: Sclera becomes very transparent, appearing blue.
  • [Visual depicted: Close-up of an older patient's eyes showing a distinct bluish tint to the sclera.]
  • Clinical Pearl: Blue sclera can be a normal finding in the neonatal and infancy periods due to underdevelopment.
  • Terminology Note: Rickets in the elderly is termed Osteomalacia. If the eye is affected by a similar softening process, it is termed Keratomalacia.
• Achondroplasia: The most common congenital skeletal dysplasia causing extremely short stature.
  • [Visual depicted: A child standing, exhibiting disproportionate short stature with noticeably shortened limbs relative to the trunk.]
  • Inheritance: Autosomal Dominant.

2. Hypoglycemia & Metabolic Storage Diseases

Evaluating hypoglycemia requires distinguishing between metabolic storage diseases and endocrine abnormalities. A key principle: Any patient, even if diabetic, who is tired and agitated must have their glucose level checked immediately.

• Initial Management: Administer IV glucose. [Visual depicted: A lethargic, hypoactive baby receiving IV glucose through a scalp vein cannula, demonstrating an alternative vascular access route in infants.]

Glycogen Storage Diseases (GSD)

• Classic Presentation: Massive hepatomegaly, severe hypoglycemia, and notably, no splenomegaly.
  • [Visual depicted: An infant lying on their back with a massive, tautly distended abdomen indicative of severe hepatomegaly.]
  • Pathophysiology: Splenomegaly is absent because glycogen deposition specifically targets only three areas: the liver, muscles, and kidneys.
• Diagnosis Limitation: A simple liver biopsy only shows glycogen deposition; it cannot specify the type of GSD. Exact diagnosis requires specific enzyme assays or genetic (mutation-based) testing.
• Genetics: All GSDs are inherited as Autosomal Recessive, EXCEPT Type 9, which is X-linked. (Note: The lecture notes that literature also cites Type 8 as X-linked recessive and Type 11 as either X-linked or AR).

Endocrine Causes of Hypoglycemia

• Clinical Presentation: Hypoglycemia without hepatomegaly. The patient may appear chubby with red cheeks, but possess scars from previous liver biopsies.
  • [Visual depicted: Close-up of a chubby toddler's face with pronounced, rosy red cheeks.]
• Diagnosis: If a patient presents with the above, plus hypoplastic genitalia and a micropenis, the diagnosis points toward Hypopituitarism and Growth Hormone Deficiency, not a GSD.
• Other Endocrine Causes: Hyperinsulinoma, idiopathic hyperinsulinemia.
• Treatment: Growth hormone replacement therapy (though starting at age 2 may be slightly delayed, it is still indicated). The deficiency can be primary (generalized/specific) or secondary (destructive lesions).

Table 2: Differentiating Causes of Pediatric Hypoglycemia

Beckwith-Wiedemann Syndrome

• Clinical Presentation: Characterized by hyperinsulinemia causing hypoglycemia, facial hemangiomas, and characteristic physical anomalies.
  • [Visual depicted: Three images showing features of the syndrome: 1) A child with macroglossia (an enlarged, protruding tongue). 2) An infant's abdomen showing an umbilical hernia. 3) A close-up of an ear demonstrating a distinct earlobe crease.]
• Triad of Hyperinsulinemia:
  1. Macrosomia or overgrowth.
  2. Difficulty controlling hypoglycemia (Requires >15mg/kg/min of glucose, compared to the normal requirement of 4-8mg/kg/min).
  3. Urine ketones are always negative.

3. Lysosomal Storage Diseases & Amino Acidopathies

General Inheritance Rule: All lysosomal storage diseases are Autosomal Recessive EXCEPT Hunter syndrome (MPS II), which is X-linked recessive.

Lipid Storage Diseases (e.g., Gaucher Disease)

• Clinical Presentation: Abdominal distention, everted umbilicus, and massive hepatosplenomegaly.
  • [Visual depicted: A child's torso showing a grossly distended abdomen with a prominent, protruding (everted) umbilicus due to organomegaly.]
• Gaucher Disease: The most common lipid storage disease. Other examples include Tay-Sachs and Wolman’s disease.
• Management: If enzyme replacement therapy is unavailable or too expensive, palliative care includes splenectomy to improve the quality of life.
  • [Visual depicted: A post-operative image of a child's flat, non-distended abdomen, illustrating the physical result following splenectomy/enzyme replacement.]

Mucopolysaccharidosis (MPS)

• Clinical Presentation: Thick hair, coarse facial features, hirsutism, widening of the wrists, and hepatosplenomegaly leading to umbilical hernias.
  • [Visual depicted: A child with distinctive coarse facial features and thick hair/eyebrows. A secondary image shows the child's hands and noticeably widened wrists. A third image shows an infant's abdomen with an umbilical hernia secondary to organomegaly.]
• Complications: Patients are highly prone to injuries. If a patient presents with "raccoon eyes" (bluish discoloration around the eyes), it is critical to rule out a basal skull fracture.
  • [Visual depicted: A pediatric patient presenting with severe bilateral periorbital ecchymosis, classically known as "raccoon eyes."]

Amino Acid Disorders

• Maple Syrup Urine Disease (MSUD):
  • Clinical Presentation: Severe muscle wasting, "skin and bone" appearance, inability to walk, bedridden, and diaper dependent.
  • [Visual depicted: An emaciated child lying in bed, demonstrating profound severe muscle wasting in the upper and lower extremities.]
  • Neurological context: Muscle wasting occurs in both Upper Motor Neuron (UMN) and Lower Motor Neuron (LMN) lesions, but is more excessive in LMN. MSUD presents as a UMN disease.
  • Amino Acid Profile: Shows significantly increased levels of valine, leucine, and isoleucine.
• Phenylketonuria (PKU):
  • Clinical Presentation: Mental retardation, seizures, and characteristic hypopigmentation (e.g., blue eyes, blond hair, even if parents have dark hair).
  • [Visual depicted: An image of an infant with very pale skin, blonde hair, and blue eyes. A contrasting image shows a blonde child crying while being held by a father with very dark hair and complexion.]
  • Pathophysiology: Phenylalanine is an essential amino acid necessary for brain growth, but the body cannot salvage it properly. It must be provided in the diet in highly controlled and monitored amounts.
• Tyrosinemia Type 2:
  • Clinical Presentation: Hyperkeratosis of the toes and corneal ulcers.
  • [Visual depicted: The soles of a patient's feet showing thickened, yellowish, hyperkeratotic skin lesions.]

Galactosemia

• Clinical Presentation: Hypoglycemia, hepatomegaly, and absent red reflex (cataracts).
  • [Visual depicted: A close-up of a child's eye lacking a normal red reflex, showing a dense, white pupillary reflex (leukocoria) indicative of a cataract.]
• Danger: Giving a standard lactose-containing formula to a neonate with classical galactosemia can be fatal within the first week of life. Early diagnosis is vital for prevention.
• Rule: Classical galactosemia is the only contraindication for breastfeeding in metabolic diseases.

4. Neurocutaneous Syndromes

General Inheritance Rule: All neurocutaneous diseases discussed are inherited as Autosomal Dominant, EXCEPT Sturge-Weber syndrome, which is sporadic.

Neurofibromatosis (NF)

• Neurofibromatosis Type 1 (NF1):
  • Café au lait spots: The hallmark of NF1. Many people have them, but they are only diagnostically significant if:
    • Prepubertal: >6 spots, size >0.5 cm.
    • Postpubertal: >6 spots, size >1.5 cm.
    • [Visual depicted: A child's torso scattered with multiple light-brown, well-circumscribed flat lesions (café au lait spots).]
  • Axillary Freckling: A major clinical diagnostic criterion.
    • [Visual depicted: A close-up of a patient's axilla (armpit) showing multiple small, hyperpigmented freckles.]
• Neurofibromatosis Type 2 (NF2):
  • Hallmark: Bilateral acoustic neuromas.
  • [Visual depicted: Two images showing cutaneous neurofibromas (fleshy, soft skin nodules). One image shows a nodule on the patient, and the second image shows similar nodules on the patient's father, highlighting the Autosomal Dominant inheritance.]

Tuberous Sclerosis

A neurocutaneous disease characterized by both CNS and skin manifestations.

• Skin Manifestations:
  • Angiofibromas: Presents as severe, non-resolving acne on the face.
    • [Visual depicted: Two images showing facial angiofibromas. One shows a boy with scattered red papules; the second is a severe, highly confluent red, bumpy rash across the nose and cheeks.]
  • Shagreen Patch: A leathery thickening of the skin.
    • [Visual depicted: The lower back of a patient showing a slightly elevated, irregularly shaped, textured skin patch (Shagreen patch).]
  • Ash-leaf Macules: Hypopigmented patches. Must have at least 3 for diagnostic significance.
    • [Visual depicted: An infant's back with three distinct, oval-shaped hypopigmented areas circled in red.]
• CNS Manifestations: Seizures and Periventricular calcifications (also called the "Candle sign").
  • Imaging Rule: MRI is not sensitive for demonstrating calcifications. You must order a CT scan.
  • [Visual depicted: A non-contrast head CT scan showing multiple bright white, hyperdense nodules (calcifications) lining the walls of the lateral ventricles.]
  • Differential: Congenital Cytomegalovirus (CMV) also causes periventricular calcifications and microcephaly.

Sturge-Weber Syndrome

• Clinical Presentation: Seizures and a facial Port-wine hemangioma.
  • [Visual depicted: A patient's face featuring a large, dark red/purple, flat vascular malformation (Port-wine stain) covering the right side of the face.]
• Neurological Rule: Hemiplegia occurs contralateral to the facial lesion (e.g., right-sided facial lesion = left-sided hemiplegia).
• Ophthalmologic Risk: If the ophthalmic branch (V1) of the trigeminal nerve is involved, there is a high risk of developing glaucoma.
• Inheritance: Sporadic (not inherited).

5. Dermatologic & Element Deficiencies

Ectodermal Dysplasia

• Clinical Presentation: Patients present with fevers of unknown origin. Physical exam reveals swollen lips, peg teeth, absent sweating (anhidrosis), and scanty eyebrows.
  • [Visual depicted: A close-up of a child's open mouth showing conical, pointed, widely spaced "peg" teeth.]
  • Pathophysiology: The defect is in the ectoderm, affecting sweat glands, teeth, and hair. The inability to sweat leads to dangerous increases in body temperature.
• Differential Diagnosis for Fever of Unknown Origin (FUO): Infection, Collagen vascular diseases, Malignancy, Munchausen by proxy.
• Types & Inheritance:
  • Anhidrotic ectodermal dysplasia: X-Linked.
  • Hidrotic ectodermal dysplasia: Autosomal Dominant.

Acrodermatitis Enteropathica & Element Deficiencies

• Clinical Presentation: Chronic severe diarrhea, severe dermatitis, and alopecia.
  • [Visual depicted: A severely ill-looking infant lying on a bed with extensive, raw, erythematous dermatitis, particularly affecting the diaper area and extremities.]
• Diagnosis: Related to Zinc deficiency. Diagnosis can be made clinically without a skin biopsy.
• Treatment & Inheritance: Complete rapid recovery occurs within days of starting zinc therapy. Inherited as Autosomal Recessive.
• Differential Note (B3/Niacin Deficiency): Causes Pellagra, characterized by the triad of Dementia, Diarrhea, and Dermatitis.

6. Hyperlipidemia

• Clinical Presentation: Severe acute abdominal pain (caused by acute pancreatitis), with plasma that looks like butter after centrifugation. Skin lesions on elbows and knees.
  • [Visual depicted: A patient's arm/elbow showing clusters of yellowish-orange bumps (xanthomas).]
  • [Visual depicted: Two test tubes containing centrifuged blood; the plasma layer is thick, opaque, and milky/yellow, resembling butter, indicating extreme lipemia.]
• Pathology: Defects in apoproteins cause lipid levels to rise into the thousands. Patients are very difficult to treat and often die early from myocardial infarctions (MI).
• Physical Signs:
  • Xanthomas: Found on the extensor surfaces of joints.
  • Xanthelasma: Similar lipid deposits found on the eyelids.
• Genetics:
  • Adult Hypercholesterolemia type 2a: Autosomal Dominant.
  • Mixed Hypertriglyceride-cholesterolemia: Autosomal Recessive.
• Differential: Celiac disease also has vesicular skin lesions on buttocks/lower limbs, but no abdominal pain is typically associated with the rash (Dermatitis Herpetiformis).

7. Chromosomal Abnormalities & Genomic Imprinting

Basic Chromosomal Definitions:

• Haploid: 23 chromosomes.
• Polyploid: Exact increments of haploid sets (e.g., 46, 69).
• Aneuploid: Any number that is not a true polyploid set (e.g., 47).

Down Syndrome (Trisomy 21)

• The most common aneuploidy.
• Risk Factor: The most important history question to ask the mother is regarding maternal age, as trisomies are strongly associated with increased maternal age.
• Physical Signs:
  • [Visual depicted: A neonatal foot demonstrating a significantly wide gap between the big toe and the second toe, known as the "sandal sign" or hallux varus.]
  • [Visual depicted: A child's hand showing clinodactyly (inward curving of the little finger).]
  • [Visual depicted: The palm of a hand showing a single, continuous transverse palmar crease (simian crease).]
• Complications: Bile-stained vomiting at 12 hours of age suggests Duodenal Atresia (biliary obstruction distal to the ampulla of Vater).
  • [Visual depicted: An infant with a distended abdomen. Alongside it, a plain abdominal X-ray demonstrating the classic "double bubble sign" indicative of duodenal atresia.]

Congenital Heart Defects in Genetic Syndromes

Table 3: Common Cardiac Associations

Fragile X Syndrome

• Most common cause of inherited mental retardation in males.
  • [Visual depicted: A young boy smiling, exhibiting characteristic facial features such as a slightly elongated face and prominent ears.]
• Inheritance: X-linked trinucleotide repeat expansion.
• Female Involvement: Females can be affected depending on the number of trinucleotide repeats.
  • Premutation: 50 - 200 repeats.
  • Fragile X Syndrome (Full Mutation): > 200 repeats.

Genomic Imprinting (Prader-Willi & Angelman Syndromes)

• Concept: Normally, a person inherits 23 chromosomes from the mother and 23 from the father (46 total). For certain chromosomes (like Chromosome 15), the clinical manifestation of a deletion depends entirely on the parent of origin.
• Uniparental Disomy: A phenomenon where, instead of receiving one copy of a chromosome from each parent, the child receives two copies from one parent and zero from the other.
• Prader-Willi Syndrome (PWS):
  • Genetics: Deletion of Chromosome 15 from the Father.
  • Clinical: Infancy presents with extreme hypotonia and refusal to breastfeed. After 1 year, they develop an exaggerated appetite (hyperphagia) leading to extreme obesity and developmental delay. They do not feel full regardless of intake.
  • [Visual depicted: An older, extremely obese male patient, demonstrating the classic hyperphagic phenotype of PWS.]
• Angelman Syndrome:
  • Genetics: Deletion of Chromosome 15 from the Mother.
  • Clinical: Characterized by inappropriate, frequent laughing and developmental delay.
  • [Visual depicted: A young girl exhibiting a broad, wide smile and laughing expression, characteristic of the "happy puppet" phenotype of Angelman syndrome.]

8. Miscellaneous Conditions

Congenital Microcephaly

• Normal Growth: Head circumference at birth is ~35 cm.
  • 1st Year: Increases by 12 cm (6 cm in 1st 3 months, 3 cm in 2nd 3 months, 3 cm in last 6 months). This is the period of maximum brain growth.
  • 2nd Year: Increases by 2 cm.
• Pathology: Failure to meet this growth trajectory results in microcephaly.
  • [Visual depicted: Two twin girls sitting together in a hospital bed, both exhibiting noticeably small head circumferences relative to their body size.]
• Inheritance: Can be Autosomal Dominant, Autosomal Recessive, or X-Linked.

Waardenburg Syndrome

• Clinical Presentation: Heterochromia iridis (differently colored eyes), hypertelorism (widely spaced eyes), and deafness.
  • [Visual depicted: Two images. The first shows a child with widely spaced eyes and distinct heterochromia (one blue eye, one dark eye). The second shows the child's mother with the exact same eye features.]
• Inheritance: Autosomal Dominant (demonstrated by the direct mother-to-daughter transmission).

Ophthalmic Diagnostic Pearls

• Congenital Glaucoma: Defined as any glaucoma diagnosed within the first 3 years of life.
  • [Visual depicted: A child with buphthalmos (abnormally large, enlarged eyes) and excessive tearing/photophobia, classic signs of congenital glaucoma.]
• Congenital Rubella: Typical congenital infection strongly associated with the development of cataracts.
• Ataxia Telangiectasia: Inherited as Autosomal Recessive. Presents with ataxia and distinct vascular eye changes.
  • [Visual depicted: A close-up of an eye showing prominent, dilated, tortuous blood vessels (telangiectasia) traversing the sclera/conjunctiva.]
• Mongolian Spots: A bluish discoloration of the back/buttocks. Usually a normal finding. However, if they are excessive and extensive, metabolic diseases must be suspected.
  • [Visual depicted: An infant's lower back showing large, diffuse, bluish-grey patches on the skin.]
  • Social Pearl: If such bruising appears suddenly (rather than congenitally), always suspect child abuse.

Growth & Development

Part 1: Normal Child Development

Child development is a dynamic, sequential process that begins in the embryonic stage and continues after birth. It is clinically assessed across four primary domains. Development is visually conceptualized as a continuous progression; for instance, observational milestones span from infants learning to grasp blocks, crawling, and reading books, to older children engaging in complex, coordinated activities like playing soccer or building complex structures.

Developmental Domains

• Gross Motor: Movements utilizing large muscle groups (e.g., walking, jumping).
• Fine Motor/Adaptive: Movements utilizing hands and smaller muscles, often involving activities of daily living and manipulation of objects.
• Language: Receptive and expressive communication, speech production, and nonverbal communication.
• Social/Behavioral: Attachment, emotional self-regulation, and interaction with peers and caregivers.

Normal Developmental Milestones

The acquisition of skills follows a predictable timeline. The tables below summarize key milestones across different domains during the first five years of life.

Table 1: Sensory Milestones (Vision and Hearing)

Table 2: Gross Motor Milestones

Table 3: Fine Motor Milestones

Table 4: Language Milestones

Table 5: Social Milestones

Part 2: Developmental Screening and Surveillance

The American Academy of Pediatrics (AAP) states that all infants and young children should be screened for developmental delays, and this screening must be incorporated periodically into ongoing healthcare.

• Routine Screening Timeline:
  • General development screening using standardized, validated tools is recommended at 9, 18, and 24 (or 30) months.
  • Autism-specific screening is recommended at 18 and 24 months.
  • Screening should also occur at any point when a caregiver or clinician raises a concern. Systematically eliciting parental concerns is a crucial diagnostic method.
• The Importance of Screening: Without formal screening tests, pediatric practices fail to identify 70% of children with developmental disabilities and 80% of children with mental health problems. With screening, 70-90% of these issues are correctly identified.
• Screening Mechanisms: Tools can be administered via Parents or Providers. They fall into two categories: Developmental and Behavioral.
  • Provider Tools: Include the Denver-II, CAT/CLAMS, Bayley Scales of Infant and Toddler Development, Brigance, and DIAL-R. Visual aids of these materials often depict complex charts (like the Denver-II stepping-stone graph) and standardized testing kits (like the Bayley Scales), emphasizing the structured nature of clinical evaluation.
  • Parent Tools: Ages and Stages Questionnaire (ASQ), Parent’s Evaluations of Developmental Status (PEDS).

Part 3: Approach to Developmental Delay

Developmental delay is defined as a slow progression in the attainment of developmental milestones, wherein a child does not reach expected milestones at the expected age, even after allowing for normal variations.

• Global Developmental Delay (GDD): Defined as a significant delay in two or more developmental domains.
• Psychomotor Regression: A distinct and highly concerning presentation defined by the loss of developmental milestones previously attained.

Consequences of Early Childhood Developmental Problems

Failure to identify and intervene early can lead to long-term consequences, including:

• Low self-esteem and poor relationship formation.
• Poor academic success, truancy, and school drop-out.
• Conduct problems and subsequent unemployment.
• Poor quality parenting skills in adulthood.

Red Flags in Development

The following delays are highly worrisome and warrant immediate investigation:

• No babbling by 12 months.
• No gesturing (e.g., pointing, waving bye-bye) by 12 months.
• No single words by 16 months.
• No two-word spontaneous (not just echolalic) phrases by 24 months.
• Loss of any language or social skills at any age.

Clinical Evaluation of Delay

Developmental surveillance involves observing the infant, taking a developmental history, and eliciting parental concerns. When a delay is identified, the clinician must answer several key questions:

1. Is the delay restricted to specific areas (e.g., predominant speech delay) or is it global?
2. Is development simply delayed, or is the child regressing?
3. Is the condition static or progressive?

Causes by Predominant Delay Type

• Predominant Speech Delay: Consider hearing impairment, Autism, bilateral hippocampal sclerosis, or congenital bilateral perisylvian syndrome.
• Motor Delay: Can manifest as ataxia, hemiplegia, paraplegia, hypotonia, or neuromuscular disorders.
  • Crucially, clinicians must differentiate if the motor delay is Central (Upper Motor Neuron disorder involving the brain) or Peripheral (Lower Motor Neuron disorder involving the spinal cord/nerves/muscle). Mixed presentations also exist (e.g., muscular dystrophies, leukodystrophies).

Table 6: Differentiating Central vs. Peripheral Motor Delay

Clinical visuals representing this dichotomy often contrast a brain schematic (Central) with a cross-section of a spinal cord, motor neuron axon, and muscle fibers (Peripheral).

Part 4: Specific Neurodevelopmental DisordersYear 6

1. Cerebral Palsy (CP)

• Definition: A non-progressive (static) disorder of motor function and movement that manifests early in life as a result of central nervous system damage to the developing brain.
• Epidemiology: Incidence is 1.5 to 2.5 per 1,000 live births. Slightly higher in males (1.5:1). It is more common in premature infants, though numerically, the majority of children with CP are born at term. Most are identified by age 2 due to delayed motor milestones.
• Etiology: 70-80% of cases are due to antenatal factors. Only 10-28% are due to birth asphyxia in term/near-term infants (contrary to outdated beliefs). It is often multifactorial. Poor prenatal care increases incidence.
• Diagnosis: Relies on history and physical exam. The diagnosis is always a motor deficit. Presentation is usually delayed motor milestones or handedness before age 3 (indicating relative weakness on one side). History confirms the child is not losing function (non-progressive). Examination reveals hypotonia, spasticity, persistent primitive reflexes, or underdeveloped parachute reflexes.
• Associated Conditions: Mental retardation (30-50%), Epilepsy (30-40%), Speech/language disorders (40%), Ophthalmologic defects (30%), Hearing impairment (10%).

Classifications of Cerebral Palsy

CP is classified by extremities involved, neurologic dysfunction, or functional level. Based on neurologic dysfunction, types include:

1. Spastic (70-80%): Most common.
2. Ataxic: Cerebellar involvement.
3. Dyskinetic (Extrapyramidal/Choreoathetoid): Basal ganglia involvement, often due to acute severe hypoxia or kernicterus. Movement disorders may appear later in life.
4. Mixed.

Specific Spastic Presentations:

• Hemiplegic CP: Arm is usually more affected than the leg. Gait is characterized by walking on tip-toes and swinging the affected leg in a semicircular arc. Visual representations clearly show the affected arm flexed and the leg extended with toe-walking. Corticosensory impairment is common. Seizures and mental retardation occur in about 1/3 of patients.
• Spastic Quadriplegic CP: Generalized increase in muscle tone, with legs often more affected than arms. Infants may show an opisthotonic posture. Visuals depict profound physical impairment requiring wheelchair support. High risk for swallowing/articulation difficulties, recurrent pneumonia (due to oropharyngeal incoordination), seizures (50%), and severe mental retardation.
• Diplegic CP: Bilateral leg involvement with commonly some degree of upper limb involvement. Infants present with scissoring of the legs, and older children present with tip-toe walking. Images typically demonstrate the profound inward rotation and crossing of the legs (scissoring) during assisted standing or walking.

• Management of CP: Requires a multidisciplinary team. The goal is to maximize function and optimize development. Interventions include physical therapy, orthopedic surgery (later), muscle tone management, and orthosis.

2. Attention-Deficit/Hyperactivity Disorder (ADHD)

• Definition: A disorder manifesting in early childhood featuring core symptoms of hyperactivity, impulsivity, and/or inattention that impair cognitive, academic, behavioral, emotional, and social functioning.
• Epidemiology: Prevalence in children varies from 2-18% (typically 8-11% in school-age children). It is one of the most common childhood disorders. Prevalence reporting increased from 7.8% (2003) to 11% (2013).
• Gender Ratio: More common in boys (4:1 for predominantly hyperactive type; 2:1 for predominantly inattentive type). One-third are diagnosed before age 6.
• Comorbidities: Can be primary or secondary (exacerbated by ADHD). They require treatment independent of the ADHD treatment.

Clinical Features & Timelines

ADHD is divided into two core symptom categories. Impaired social function is a hallmark; inattention limits acquiring social cues, and impulsivity causes peer rejection, leading to poor self-esteem, anxiety, and depression.

Evaluation and Diagnosis

• Evaluation: Includes comprehensive medical, developmental, educational, and psychosocial reviews. Medical evaluation looks for prenatal exposures (tobacco, drugs), perinatal complications, CNS infections, head trauma, and sleep disturbances. A cardiac history is crucial before initiating medications. Ancillary evaluations may include speech/language, occupational therapy, mental health, lead levels, thyroid panels, or genetics (e.g., Fragile X).
• Physical Exam: Usually normal, but needed to rule out dysmorphic features or neurocutaneous abnormalities.
• DSM-5 Diagnostic Criteria:
  • Children <17 years: Requires ≥6 symptoms of hyperactivity/impulsivity OR ≥6 symptoms of inattention.
  • Adolescents ≥17 and Adults: Requires ≥5 symptoms in either category.
  • Modifiers: Symptoms must occur often, be present in >1 setting (home and school), persist for at least 6 months, be present before age 12, impair function, and be excessive for developmental level.

Management

• Principles: Involves care coordination (patient/family) and realistic, measurable goals (e.g., "completes assignments," "plays without fighting").
• Preschool (4-5 years): Initial therapy recommendation is behavior therapy (administered by parents/teachers), not medication.
• School-age (≥6 years): Initial recommendation is stimulant medication combined with behavioral therapy.
• Pharmacology:
  • Stimulants: Methylphenidate, Amphetamines.
  • Non-stimulants: Atomoxetine (selective norepinephrine reuptake inhibitor).
  • Alpha-2-adrenergic agonists: Extended-release clonidine or guanfacine.

3. Autism Spectrum Disorder (ASD)

Visually represented as a child looking through a puzzle-piece glass, highlighting the complex, fragmented nature of the disorder and the barrier it creates in social communication.

• Definition: A biologically based neurodevelopmental disorder characterized by impairments in two major domains: (1) deficits in social communication/interaction, and (2) restricted, repetitive patterns of behavior, interests, and activities. (Encompasses former diagnoses like classic autism, Asperger's, and PDD-NOS).
• Epidemiology: Prevalence has increased since the late 1990s. Approximately 4 times more common in males. Sibling recurrence rate is 3-10%.
• Pathogenesis: Incompletely understood; involves genetic, neurobiological, environmental/perinatal factors, and parental age. (Note: Associations with immunizations are questioned/discredited).
• Associated Conditions:
  • Intellectual Disability: Present in 50-75% of cases. Cognitive skills are uneven; verbal skills are usually weaker than nonverbal.
  • Special Skills: "Savant" skills in memory, math, or music (e.g., calendar calculation, hyperlexia).
  • Seizures: 11-39% of cases (higher with severe intellectual disability).
  • GI/Feeding: 19-24% experience diarrhea, constipation, feeding disturbances.
  • Sleep: Severe abnormalities in sleep-wake cycles (extreme latencies, awakenings).

Clinical Features & Diagnosis

• Impaired Social Communication (Hallmark):
  • Social Reciprocity: Deficits in emotional reciprocity.
  • Joint Attention: Reduced spontaneous seeking to share enjoyment/interests with others.
  • Nonverbal Communication: Impaired use/interpretation of eye contact, facial expressions, and gestures.
  • Relationships: Failure to develop peer relationships.
• Restricted and Repetitive Behaviors:
  • Stereotyped Behaviors: Motor mannerisms (flapping, rocking, toe-walking), present in 50-75% during preschool years. Echolalia. Self-injury (more common with cognitive disability).
  • Insistence on Sameness: Difficulty with transitions, needing identical routines.
  • Restricted Interests: Abnormal intensity or focus on unusual objects.
• Evaluation: History, Wood's lamp exam, growth parameters, neurological exam. Ancillary testing (vision, hearing, speech, developmental testing) is necessary to exclude other conditions.
• DSM-5 Criteria: Requires persistent deficits in social communication across multiple settings (reciprocity, nonverbal behaviors, relationships) AND at least 2 of the restricted/repetitive behavior patterns (stereotyped movements, insistence on sameness, fixated interests, hyper/hypo-reactivity to sensory input).

Management and Prognosis

• Management: Highly individualized, requiring a multidisciplinary approach (developmental pediatrician, neurologist, psychologist, geneticist, speech/occupational therapists, audiologist).
  • Goals: Improve social, communication, and adaptive skills; decrease negative behaviors.
  • Pharmacology: Risperidone and Aripiprazole are the only psychotropic medications approved by the FDA specifically for ASD treatment. Doses start low and increase slowly. Treat comorbidities (e.g., ADHD, anxiety).
• Prognosis: Difficult to predict <3 years old.
  • Favorable Factors: Presence of joint attention, functional play, higher cognition, decreased severity, early identification/intervention, inclusion with typical peers.
  • Less Favorable Factors: Lack of joint attention by age 4, lack of functional speech by age 5, IQ <70, seizures/comorbidities.

Part 5: Clinical and Genetic Clues in Global Developmental Delay (GDD)

When approaching a child with GDD, detailed history and physical examination are the most important guides for investigations.

• History Clues: Antenatal (trauma, infection, death of a twin, maternal HTN/Diabetes), Birth (gestational age, weight, hyperbilirubinemia), Past medical (meningitis, trauma, epilepsy). A detailed family history looking for consanguinity or early infant deaths is critical. (Clinical example presented: 20-month-old boy, delayed walking, right-sided weakness, decreased fetal movement, 28 weeks premature = typical presentation for Cerebral Palsy).

Physical Examination Clues

Specific physical findings point toward distinct genetic or metabolic syndromes causing developmental delay:

1. Dysmorphism/Metabolic Errors:
   • Phenylketonuria (PKU): Error of amino acid metabolism (autosomal recessive). Presents with no acute clinical symptoms at birth, but untreated leads to mental retardation, behavior disorders, cataracts, skin, and movement disorders. Detected by newborn screening (developed in 1959). Treated with a phenylalanine-restricted diet. Often suspected if there is a family history (e.g., a cousin with PKU) in the context of consanguinity, microcephaly, and epilepsy.
   • Facial dysmorphism (e.g., features typical of Down Syndrome or Mucopolysaccharidoses) requires targeted genetic testing.

1. Skin Findings (Neurocutaneous Disorders):
   • Neurofibromatosis Type 1 (NF1): Autosomal dominant, highly variable. The most common neurocutaneous syndrome. Characterized by macrocephaly, learning disabilities, seizures, and neoplastic risk. Visual clues include multiple flat, pigmented Cafe-au-lait spots on the back, and axillary freckling.
   • Tuberous Sclerosis: Autosomal dominant (TSC1/TSC2 genes). Causes epilepsy, developmental delay, and subependymal hamartomas. Visual skin clues include hypopigmented "ash leaf" spots on the trunk, raised "shagreen patches," and facial sebaceous adenomas (angiofibromas) manifesting as a red, papular rash across the nose and cheeks.
   • Rashes/Dermatitis: A severe, scaly, erythematous rash on the face or buttocks can indicate metabolic errors like Biotinidase deficiency, Propionic acidemia, or Refsum disease.

1. Hair Abnormalities:
   • Menkes Disease: Characterized by global delay and colorless, friable, "kinky" hair. Caused by low copper and ceruloplasmin levels.
   • Griscelli Syndrome: Characterized by distinct silvery-grey hair visually contrasting with normal pigmentation.

1. Ophthalmologic (Eye) Clues:
   • Cataracts: Seen in Galactosemia, Zellweger syndrome, Lowe syndrome. Visualized as an opaque, cloudy white reflex in the pupil.
   • Dislocated Lenses: Seen in Homocystinuria, Molybdenum co-factor deficiency, Sulfite oxidase deficiency, and Marfan syndrome. Visually, the lens can be seen shifted off-center (e.g., upward in Marfan's).
   • Retinal Degenerative Changes: Seen in peroxisomal disorders.
   • Cherry Red Spot: Pathognomonic for lipid storage diseases. Fundoscopy visualizes a bright red spot on the macula surrounded by a pale retina. Seen in Niemann-Pick, Tay-Sachs, GM1 gangliosidosis, Sandhoff disease, Metachromatic leukodystrophy, and mucolipidosis.

Stepwise Investigations for GDD

1. Clinical Assessment: If family history or exam yields a specific clue (e.g., ash leaf spot), order specific testing (FISH, PCR, single gene test).
2. Hearing and Vision: Must be assessed in all developmentally delayed children.
3. Metabolic & Thyroid: Routine workup.
4. EEG: Not recommended routinely unless the child has seizures.
5. Neuroimaging: MRI of the brain is highly useful, detecting abnormalities in 48-65% of GDD cases.
6. Genetic Testing (Advancements):
   • Chromosomal Microarray / Karyotyping: Routine screen (yield 3.7%), indicated even without dysmorphic features.
   • Fragile X Testing: Yield 2.6%, indicated especially with a positive family history (test females too).
   • High-resolution Chromosomal Microarray: Yields 15-20%.
   • Targeted Gene Panels: Yields 11-32%.
   • Whole Exome Sequencing (WES): Focuses on the 1% of the genome coding for proteins (which houses 85% of monogenic mutations). Yields 40-60%. A specific study in Jordan showed a 44.8% diagnostic rate. WES should be utilized if previous investigations reveal no cause.
   • Whole Genome Sequencing (WGS): Yields ~42%.

Hematology

PART 1: Bleeding Disorders in ChildrenYear 6

Physiology of Hematopoiesis and Hemostasis

• Hematopoiesis: The production of blood cells begins with a multipotential hematopoietic stem cell (Hemocytoblast).
  • Visual Element - Hematopoiesis Tree: A diagram illustrates this branching process. The stem cell divides into a Common Myeloid Progenitor (which yields erythrocytes, mast cells, myeloblasts [basophils, neutrophils, eosinophils, monocytes/macrophages], and megakaryocytes) and a Common Lymphoid Progenitor (which yields Natural Killer cells and small lymphocytes [T and B cells/plasma cells]).
• Megakaryocytes and Platelets: Megakaryocytes are giant, multinucleated cells derived from primitive stem cells. They fragment into platelets (thrombocytes).
  • Thrombopoietin is the primary regulator of platelet production.
  • Platelets lack a nucleus and circulate for 7 to 10 days.
  • They contain specific granules that release their contents upon stimulation, triggering platelet aggregation.
  • Platelets adhere to damaged endothelium and subendothelial surfaces via specific receptors for adhesive proteins, namely von Willebrand factor (vWF) and fibrinogen.
• Major Components of Hemostasis:
  • Visual Element - Hemostasis Diagram: A flowchart depicts the dual processes following vascular injury.
    • Primary Hemostasis: Involves immediate vasoconstriction and platelet activation (triggered by exposed collagen). Platelets utilize vWF and fibrinogen to aggregate, forming a primary "Platelet Plug."
    • Secondary Hemostasis: Concurrently, tissue factor released from the injury activates the Coagulation Cascade. This cascade results in the generation of Thrombin, which converts Fibrinogen into Fibrin. The fibrin mesh stabilizes the platelet plug, forming a definitive "Blood Clot." This clot is eventually broken down by Plasmin in a process called Fibrinolysis. Antithrombotic control mechanisms regulate the cascade to prevent excessive clotting.

The Coagulation Cascade and Clotting Factors

• Visual Element - Coagulation Cascade Diagram: An illustration maps the three pathways of blood coagulation:
  • Intrinsic Pathway: Activated by internal damaged surfaces. Involves factors XII → XI → IX → VIII.
  • Extrinsic Pathway: Activated by Tissue Factor released due to vascular injury. Involves factor VII.
  • Common Pathway: Both intrinsic and extrinsic pathways converge to activate factor X. Factor Xa, along with factor Va, converts Prothrombin (II) into Thrombin (IIa). Thrombin then converts Fibrinogen (I) into Fibrin (Ia). Thrombin also activates factor XIII, which stabilizes the fibrin clot.
• Properties of Coagulation Factors:
  • All coagulation factors are synthesized in the liver, except for vWF (synthesized in endothelial cells and megakaryocytes) and Factor XIII (synthesized in liver/macrophages).
  • Factor VII has the shortest half-life (3-6 hours) and is the earliest factor to drop in liver failure.
  • Factor XIII has the longest half-life (10 days).
  • Vitamin K-dependent factors include II, VII, IX, and X, as well as Protein C and Protein S.

Table 1: Summary of Key Coagulation Factors

Clinical Evaluation of Bleeding Disorders

• Functional Classification: Bleeding disorders are categorized into three main groups:
  1. Abnormal Vessels: Ehlers-Danlos syndrome, Henoch-Schönlein Purpura (HSP).
  2. Defects of Platelets:
     • Number: Infection, ITP, Leukemia.
     • Function: vWD, Bernard-Soulier (BS), Glanzmann Thrombasthenia (GT), Drugs.
  3. Abnormal Coagulation:
     • Congenital: Hemophilia A or B.
     • Acquired: Liver disease, Vitamin K deficiency, DIC.
• Clinical Findings (Purpuric vs. Coagulation):
  • Visual Element - Clinical Photographs: Several images demonstrate classic bleeding manifestations. One shows a forearm with fine, pinpoint red dots (petechiae). Another shows lower legs covered in larger, purple, non-blanching lesions (purpura and ecchymoses). A third image shows a massive, dark, raised bruise on an infant's thigh (soft tissue hematoma). Another displays severe bleeding and hematoma formation on the lips and oral mucosa. The final images show a swollen, distended knee joint (hemarthrosis), a hallmark of severe coagulation defects.

Table 2: Differentiating Clinical Findings

• History & Physical Examination:
  • History: Ask about neonatal bleeding, post-circumcision bleeding, delayed bleeding from umbilical stump (classic for Factor XIII deficiency), deep hematomas after IM injections, epistaxis (unilateral vs. bilateral), bleeding after tooth extraction/tonsillectomy, exact sites of bleeding, family history, drug exposure, and consider child abuse.
  • Physical Exam: Look for petechiae, ecchymosis, joint bleeding, deep hematomas, lymphadenopathy, hepatosplenomegaly, telangiectatic vessels, hemangiomas, and joint hypermobility/lax skin (Ehlers-Danlos). Assess if the child is active/playful or ill-looking.
• Classic Clinical Scenarios:
  • Male infant starting to walk with a painful swollen joint after a fall → Hemophilia until proven otherwise.
  • Adolescent girl with excessive menstrual bleeding, recurrent nosebleeds, and pallor → von Willebrand Disease (most common inherited disorder).
  • Well-appearing 5-year-old with acute mucocutaneous purpura following a viral infection → Acute Post-infectious ITP.
  • Teenage girl with easy bruising, mild pallor, and strong family history of autoimmune disease → Chronic ITP.
  • 10-day-old infant with bleeding from the umbilical stump or unexplained intracranial hemorrhage → Factor XIII deficiency.

Diagnostic Screening and Tests

• Common Screening Tests: Platelet count and morphology, Bleeding time, Partial Thromboplastin Time (aPTT), Prothrombin Time (PT), Thrombin Time (TT).
• Specialized Tests: Factor XIII quantitative test, Mixing studies, Specific factor assays, vWF quantitative assay, Platelet aggregation studies.
• Complete Blood Count (CBC):
  • Thrombocytopenia is defined as platelets < 150,000/mm³. It is the most common acquired cause of bleeding diathesis in children.
  • Pseudo-thrombocytopenia: Must be excluded by examining a peripheral blood smear. It is caused by in vitro platelet aggregation due to EDTA anticoagulant.
• Prothrombin Time (PT):
  • Measures the Extrinsic and Common pathways (requires Tissue Factor, VII, X, V, II, Fibrinogen).
  • Sensitive to Vitamin K-dependent factors (II, VII, X). Used to monitor Vitamin K antagonist therapy (e.g., Warfarin).
• Activated Partial Thromboplastin Time (aPTT):
  • Measures the Intrinsic and Common pathways.
  • Sensitive to deficiencies in XII, XI, IX, VIII, and inhibitors like heparin.
  • Less sensitive than PT to common pathway deficiencies; unaffected by VII and XIII.
• Thrombin Time (TT):
  • Measures the final step: conversion of fibrinogen to fibrin. Normal is 11-15 seconds.
  • Prolonged in hypofibrinogenemia, afibrinogenemia, and dysfibrinogenemia.
• Platelet Function Testing:
  • Bleeding Time: Assesses platelet-vascular wall interaction; difficult to standardize.
  • Platelet Function Analyzer (PFA-100): Evaluates early hemostasis under high shear stress using collagen-epinephrine or collagen-ADP. Reported as "closure time."
• Mixing Studies:
  • Used for unexplained prolongation of PT, aPTT, or TT. The patient's plasma is mixed 1:1 with normal plasma.
  • Correction of the prolonged time indicates a Factor Deficiency.
  • Failure to correct indicates the presence of an Inhibitor (e.g., lupus anticoagulant, acquired antibodies).
  • Visual Element - Algorithmic Flowchart: A diagram outlines the diagnostic approach based on PT/aPTT.
    • PT prolonged/aPTT normal → Factor VII deficiency or early liver disease/Vit K deficiency.
    • aPTT prolonged/PT normal → Intrinsic pathway defect (VIII, IX, XI, XII, vWD, Heparin).
    • Both prolonged → Common pathway defect (DIC, Liver disease, severe Vit K deficiency, supratherapeutic anticoagulation).
    • Both normal (with bleeding) → vWD, Factor XIII deficiency, platelet function disorders, vascular abnormalities.

Table 3: Interpretation of PT and aPTT

Disorders of Platelets

• Characterized primarily by mucocutaneous bleeding. Spontaneous bleeding risk increases significantly when platelets are < 20,000/mm³.
• Decreased Platelet Production: Usually associated with small platelets or low Mean Platelet Volume (MPV).
  • Thrombocytopenia with Absent Radii (TAR) syndrome: Severe thrombocytopenia with orthopedic abnormalities. Usually improves over time.
  • Congenital Amegakaryocytic Thrombocytopenia (CAMT): Severe thrombocytopenia, devoid of marrow megakaryocytes, progresses to aplastic anemia. No other anomalies.
  • Wiskott-Aldrich syndrome: X-linked. Triad of hypogammaglobulinemia, eczema, and thrombocytopenia (small platelets on smear).
  • Acquired decreased production: Rarely isolated; usually part of pancytopenia due to bone marrow failure (infiltration or aplasia).
• Increased Platelet Destruction: Usually associated with large platelets or high MPV.
  • Immune Thrombocytopenic Purpura (ITP): Autoimmune (IgG/IgM anti-platelet antibodies). Often follows acute viral infection. Macrophages phagocytose antibody-coated platelets in the spleen.
    • Clinical: Abrupt onset of petechiae/purpura 1-4 weeks post-virus. Normal WBC/RBC lines. No hepatosplenomegaly.
    • Bone Marrow: Indicated only if atypical findings present (to rule out leukemia/aplasia) or before steroid use. Shows increased megakaryocytes.
    • Treatment: Seldom indicated if platelets >20,000. For severe bleeding/<10,000: Prednisone, IVIG, or Anti-D Immunoglobulin. Platelet transfusions only for life-threatening bleeding. Splenectomy reserved for severe, refractory cases.
    • Prognosis: 80% resolve spontaneously within 6 months. Intracranial hemorrhage is rare (<1%). If >6-12 months, it is Chronic ITP (rule out SLE, HIV, immunodeficiency).
  • Hemolytic Uremic Syndrome (HUS): Toxin exposure causing endothelial injury, fibrin deposition, and platelet consumption.
  • Thrombotic Thrombocytopenic Purpura (TTP): Platelet consumption due to metalloproteinase (ADAMTS13) deficiency leading to uncleaved vWF multimers.
  • Disseminated Intravascular Coagulation (DIC): Consumption of clotting factors and platelets leading to widespread fibrin deposition, tissue ischemia, hemolytic anemia, and generalized hemorrhage. Triggered by sepsis, trauma, large hemangiomas (Kasabach-Merritt), etc. Labs show prolonged PT/aPTT, low fibrinogen, high FDP/D-dimers, and schistocytes.
• Disorders of Platelet Function: Prolonged bleeding time with generally normal platelet counts.
  • Glanzmann Thrombasthenia: Autosomal recessive. Deficient glycoprotein IIb/IIIa (fibrinogen receptor). Diminished aggregation.
  • Bernard-Soulier Syndrome: Autosomal recessive. Deficient glycoprotein Ib (collagen/vWF receptor). Decreased adhesion. Features large unusual platelets and mild thrombocytopenia.
  • Secondary Disorders: Uremia (kidney disease), Liver disease, Drugs (Aspirin, NSAIDs, Valproic acid).

Disorders of Clotting Factors

• von Willebrand Disease (vWD):
  • Most common inherited bleeding disorder (1:100 to 1:10,000). Gene on Chromosome 12.
  • vWF functions to tether platelets to the subendothelium and serves as a carrier protein protecting Factor VIII.
  • Classification:
    • Type 1: Quantitative reduction (most common, 85%, Autosomal Dominant).
    • Type 2: Qualitative abnormality (Autosomal Recessive or Dominant).
    • Type 3: Complete absence (Autosomal Recessive, severe).
  • Presentation: Mild to moderate mucocutaneous bleeding (epistaxis, menorrhagia). Hemarthroses are unusual (unless Type 3).
  • Diagnosis: Prolonged bleeding time, low vWF antigen/activity, variable reduction in Factor VIII activity. PTT may be prolonged in severe cases.
  • Treatment: DDAVP (Desmopressin) induces endothelial release of vWF (works for Type 1). For Types 2 and 3, plasma-derived vWF concentrates or Cryoprecipitate are required.
• Hemophilia A (Factor VIII Deficiency):
  • X-linked, 1 in 5,000-10,000 males.
  • Severities: Severe (<1% activity, spontaneous bleeding), Moderate (1-5% activity, bleeding with minor trauma), Mild (>5% activity, bleeding with surgery/major trauma).
  • Presentation: Hemarthroses (knees, elbows, ankles) and deep soft tissue bleeding (e.g., severe iliopsoas bleeds). 30% bleed at circumcision.
  • Diagnosis: Prolonged aPTT, normal PT/platelets/bleeding time. Low Factor VIII assay with normal vWF assay.
  • Treatment: Recombinant Factor VIII replacement (1 U/kg increases plasma level by 2%). Prophylactic therapy prevents chronic arthropathy. DDAVP for mild cases. Complications include inhibitor development (requires bypassing agents like NovoSeven).
• Hemophilia B (Factor IX Deficiency / Christmas Disease):
  • X-linked, 1 in 50,000 males. Clinically identical to Hemophilia A.
  • Diagnosis: Prolonged aPTT, low Factor IX assay.
  • Treatment: Recombinant Factor IX replacement (1.5 U/kg increases plasma level by 1%).
• Acquired Factor Disorders:
  • Vitamin K Deficiency: Essential for II, VII, IX, X. Causes Hemorrhagic Disease of the Newborn (prevented by routine IM Vit K at birth). May result from malabsorption, liver disease, or medications (warfarin, cephalosporins).
  • Liver Disease: Liver synthesizes most factors. Vit K dependent factors fall first. Results in prolonged PT/aPTT and thrombocytopenia (due to hypersplenism/low thrombopoietin). Treat with Vit K, FFP, platelets.

PART 2: Anemias and Hematologic Malignancies

Physiology and Classification of Anemia

• Definition: Reduction in red cell volume or hemoglobin concentration below the normal range for age.
• Physiology in Infancy: Newborns have naturally high Hb. A physiologic nadir (drop) occurs at 2-3 months. Premature infants experience an exaggerated physiologic anemia.
• Classification:
  1. Inadequate intake / Specific factor deficiency (Iron, B12, Folate).
  2. Decreased Production / Bone Marrow Failure (Congenital, Acquired, Ineffective erythropoiesis).
  3. Hemolytic Anemias (RBC defects, Enzyme defects, Hemoglobinopathies, Immune).
  4. Blood Loss.

Nutritional Anemias

• Iron Deficiency Anemia (IDA):
  • Most common anemia (5.5% of children). Peak age 9-24 months. Requirement: 2 mg/kg/day.
  • Causes: Inadequate diet (excess cow's milk), impaired absorption (Celiac), chronic blood loss (Meckel's diverticulum, GI bleed).
  • Tissue Effects: GI (pica, anorexia, glossitis), CNS (irritability, breath-holding spells), Cardiovascular (tachycardia, hypertrophy), Immune (impaired granulocyte killing).
  • Diagnosis: CBC shows low Hb, PCV, MCV, MCH, MCHC. High RDW (>15). High platelets. Low serum ferritin (<12 ng/ml). Low iron, High TIBC.
  • Visual Element - Blood Smear: An image shows microcytic (small) and hypochromic (pale) red blood cells with anisocytosis (variable sizes) and poikilocytosis (variable shapes).
  • Treatment: Oral ferrous sulfate (6 mg/kg/day in 3 doses) for 2-3 months. The first response is increased appetite and activity, followed by reticulocytosis (at 3-5 days), then Hb rise.
• Megaloblastic Anemias (Vitamin B12 & Folate):
  • Characterized by macrocytic RBCs and megaloblasts in the marrow due to impaired DNA synthesis.
  • Visual Element - Blood Smears: Images demonstrate distinctly large RBCs (Macrocytes) and hypersegmented neutrophils (neutrophils with >5 nuclear lobes or "nuclear sticks"), hallmark signs of megaloblastic anemia.
  • Folic Acid Deficiency: Caused by poor diet (goat's milk), malabsorption, or increased demand (hemolysis). Onset usually 4-7 months. Treatment: Folic acid 5 mg/day.
  • Vitamin B12 Deficiency: Caused by inadequate intake (vegan mother), intrinsic factor lack, GI disease (Crohn's, surgery), or transport defects. Onset later (9 months - 10 years). Can cause neurologic symptoms (ataxia, paresthesia, subacute combined degeneration of the cord). Treatment: IM Vit B12.

Hemolytic Anemias

• Signs of Hemolysis: Decreased PCV, Increased indirect bilirubin, Increased reticulocyte count, Decreased haptoglobin.
• Hereditary Spherocytosis: Autosomal Dominant (75%). Defect in RBC membrane proteins (spectrin, ankyrin). Clinical: Jaundice, splenomegaly, gallstones. Lab: Low MCV, High MCHC, positive osmotic fragility test, high flow cytometry sensitivity.
  • Visual Element - Blood Smear: Spherocytes are visible as small, perfectly round, dense red blood cells lacking the normal central area of pallor.
• Hereditary Elliptocytosis:
  • Visual Element - Blood Smear: Shows numerous red blood cells that are elongated or cigar-shaped (elliptocytes).
• G6PD Deficiency: X-linked (mostly males). Most common RBC enzyme defect. Hemolysis triggered by oxidant stress (infections, fava beans, drugs like sulfa, aspirin, nitrofurantoin). Results in Hb precipitation and RBC membrane damage.
  • Visual Element - Blood Smear (Supravital Stain): Shows "Heinz Bodies"—small, round, dark-blue inclusions situated close to the inner RBC membrane, representing denatured, precipitated hemoglobin.
• Immune Hemolytic Anemia:
  • Isoimmune: Rh or ABO incompatibility between mother and fetus.
  • Autoimmune: Idiopathic (IgG warm antibodies or IgM cold antibodies), secondary to infection (EBV, CMV), drugs, or malignancy (lymphoma). Shows spherocytes and a positive Coombs test.
• Sickle Cell Disease:
  • Autosomal recessive. Valine substitutes for Glutamic acid at the 6th position of the Beta-globin chain.
  • Heterozygotes (Sickle Trait) have a benign course (8% of African Americans).
  • Homozygotes (HbSS) present after 1 year of age (as HbF falls).
  • Manifestations: Painful vaso-occlusive crises (dactylitis), strokes, Acute Chest Syndrome, Splenic sequestration (shock), Aplastic crises (Parvovirus B19), Sepsis (encapsulated organisms due to functional asplenia).
  • Visual Element - Blood Smears:
    • HbSS Smear: Shows classic elongated, crescent-shaped "sickle cells," "boat cells," and "target cells." Howell-Jolly bodies indicate functional asplenia.
    • Sickle-Thalassemia Smear: Shows microcytosis with far fewer sickle cells, indicating a milder anemia compared to homozygous HbSS.
  • Treatment: Hydration, analgesia, antibiotics, transfusions/exchange transfusions for acute chest, hydroxyurea, splenectomy, rarely BMT.
• Thalassemia:
  • Defective erythropoiesis due to globin gene mutations. Normal adult Hb (HbA1) is composed of 2 alpha and 2 beta chains.
  • Alpha Thalassemia: Involves 4 genes on Chromosome 16. Deletion of 1 (silent), 2 (trait), 3 (HbH disease), or 4 (Hydrops Fetalis - lethal).
  • Beta Thalassemia: Involves 2 genes on Chromosome 11. Point mutations.
    • Visual Element - Genetics Diagrams: Graphics illustrate the 4-gene vs 2-gene nature of the diseases. A silhouette graphic demonstrates Mendelian inheritance: if both parents are carriers, there is a 25% chance of Thalassemia Major, 50% Minor (carrier), 25% Normal.
    • Clinical (Major): Chronic hemolytic anemia, skeletal deformities (frontal bossing), hepatosplenomegaly, heart failure, iron overload, growth impairment.
    • Labs: Microcytosis, hypochromia, target cells. Hb electrophoresis shows increased HbF, decreased HbA1.
    • Treatment: Chronic hypertransfusion (maintains Hb > 10.5 to suppress extramedullary hematopoiesis), Chelation therapy (Desferal, Ferriprox, Deferasirox) to prevent iron overload toxicity. Bone Marrow Transplant is curative (success depends on the "Pesaro classification" risk factors: hepatomegaly, liver fibrosis, chelation quality).

Bone Marrow Failure Syndromes

• Can be single-line or multi-line (pancytopenia).
• Single Line Failure:
  • RBCs: Diamond-Blackfan anemia, Transient Erythroblastopenia of Childhood (TEC).
  • WBCs: Shwachman-Diamond Syndrome, Kostmann Syndrome.
  • Platelets: TAR syndrome, Congenital Amegakaryocytic Thrombocytopenia.
• Pancytopenia / Aplastic Anemia:
  • Definition: At least two of: Hb < 10, Neutrophils < 1.5 x 10⁹/L, Platelets < 50 x 10⁹/L, plus a hypocellular bone marrow.
  • Visual Element - Histology Comparison: Side-by-side microscopic images contrast a "Normal" bone marrow (densely packed with purple-staining hematopoietic cells) with "Aplastic Anaemia" marrow (predominantly empty, white fat spaces with sparse cellularity).
  • Causes: Idiopathic (80%), Post-viral (Hepatitis, EBV, HIV), Drugs/chemicals, PNH, or Congenital (Fanconi).
  • Fanconi Anemia: Inherited bone marrow failure.
    • Visual Element - Clinical Photographs: Images of patients with Fanconi anemia show marked microsomy (short stature), microcephaly, and distinct thumb anomalies (hypoplastic or absent thumbs).
    • Table 4: Fanconi Anemia Physical Abnormalities

PART 3: Pediatric Hematologic MalignanciesYear 6

• Defining Malignancy: There is no single criterion. Diagnosis relies on establishing clonality, assessing maturity/differentiation, and finding specific genetic factors/mutations. It is a multi-step process involving genetics, mutagens, and immune tolerance.
• Lineage Classification:
  • Visual Element - Venn Diagrams: Graphics illustrate the overlap in hematologic malignancies. One diagram shows the overlapping relationships between Lymphoid and Myeloid cell lines. Another shows the significant clinical/phenotypic overlap between Acute Lymphoblastic Leukemia (ALL) and Lymphoma. A third Venn diagram shows the shared pathophysiologic mechanisms among Bone Marrow Failure syndromes: Aplastic Anemia (AA), Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome (MDS), and Acute Myeloid Leukemia (AML).

Clinical Suspicion

• Diagnosis is often delayed due to nonspecific complaints. Suspect malignancy in cases of: unexplained prolonged fevers, cranial nerve palsies, abnormal gait, abdominal distention, severe fatigue/weight loss, or unexplained anemia in a post-pubertal male.

Acute Leukemias

• Acute Lymphoblastic Leukemia (ALL):
  • Most common pediatric cancer. Peak age is early childhood (2-5 years).
  • Can involve the CNS or testes.
  • Subtypes include B-cell and T-cell lineage. (T-cell lymphoblastic leukemia exists on a spectrum with T-lymphoblastic lymphoma).
  • Treatment: Mainstay is chemotherapy. Excellent overall long-term survival (>90%). High-risk patients may require BMT.
• Acute Myeloid Leukemia (AML):
  • Visual Element - Incidence Graphs: Bar and line charts plot age vs. incidence rate. They clearly show ALL spiking dramatically between ages 1-5 and then declining, whereas AML incidence remains lower and relatively flat throughout childhood, gradually rising in adulthood. CML is shown as very rare in childhood, rising steeply in older age.
  • Diagnosis Definitions:
    • WHO criteria: Relies on clinical/molecular data. Requires 20% blasts. Categorizes based on prior chemo (therapy-related t-AML), Down syndrome association, specific recurrent genetic abnormalities (e.g., t(8;21), inv(16), t(15;17) - these do not require a minimum blast %), or myelodysplasia-related changes.
    • FAB criteria: Relies purely on morphology and phenotype. Requires 30% blasts.

Table 5: Key AML Subtypes and Cytogenetics (FAB Classification)

• APML (AML M3) and ATRA:
  • Visual Element - APML Mechanism Diagram: A diagram illustrates the pathophysiology of APML. A PML-RARA fusion protein blocks myeloid differentiation at the promyelocyte stage. Administering ATRA (All-trans retinoic acid) overcomes this block, inducing the malignant promyelocytes to differentiate into mature segmented neutrophils.
  • Treatment can cause "Differentiation Syndrome" (formerly ATRA syndrome).

Lymphomas

• Hodgkin Lymphoma:
  • Presents most commonly as painless neck or chest adenopathy.
  • Visual Element - CT Scan: Coronal and sagittal CT slices display a massive mediastinal tumor (lymphadenopathy) compressing the heart and airway structures.
  • Often associated with EBV infection. "B symptoms" (fever, weight loss, night sweats) carry a worse prognosis.
  • Subtypes: Classic (most common) and Nodular Lymphocyte-Predominant (NLPHL).
  • Hallmark cell: Hodgkin Reed-Sternberg cell ("owl eye" appearance).
  • Excellent outcomes in low-stage disease.
• Non-Hodgkin Lymphomas (NHL):
  • Burkitt Lymphoma: A mature B-cell lymphoma. t(8;14) translocation. Extremely high proliferation rate. High risk for tumor lysis syndrome. Excellent prognosis if treatment is prompt.
    • Sporadic form: 15% EBV associated. Abdominal mass, marrow, CNS.
    • Endemic form (Africa): 95% EBV associated. Jaw mass, abdomen.
  • Anaplastic Large Cell Lymphoma: A mature T-cell lymphoma. Most common genetic abnormality is t(2;5) involving the ALK (anaplastic lymphoma kinase) gene.

Table 6: Summary of Lymphoma Cell Lineages

Myelodysplastic Syndrome (MDS)

• Defined by dysplastic bone marrow changes, an increased blast population (but below leukemia threshold), and MDS-defining cytogenetic abnormalities (e.g., Monosomy 7).
• Can be de novo or secondary (e.g., following radiation/chemotherapy or arising from congenital bone marrow failure syndromes).
• Key Concept: In childhood, MDS is very frequently secondary to an underlying genetic or bone marrow failure condition, unlike in adults where it usually evolves de novo. Left untreated, it progresses to Acute Myeloid Leukemia (AML). Definitive treatment requires a Bone Marrow Transplant.

Infectious Diseases

Part 1: Approach to the Febrile Infant and ChildYear 6

1. Definition and Assessment of Fever

• Clinically Significant Fever: In children > 3 months of age, a clinically significant fever is defined as a temperature measured rectally of ≥ 38°C (100.4°F).
• Clinical Evaluation: An ill-appearing child with a fever requires a detailed history and physical examination (H&P). Crucial history points include vaccination status, recent travel, and animal contacts.
• Fever of Unknown Origin (FUO): Defined as a fever lasting > 7 days without an identifiable focus or source.

2. Common Sources of Acute Fever (< 5 Days Duration)

• Respiratory Infections: Includes both upper and lower respiratory tracts; this is the most common source across all pediatric age groups.
• Urinary Tract Infections (UTIs): Highly common in infants < 3 months of age and in older children with specific risk factors.
• Gastrointestinal Infections: Common in formula-fed infants and preschool-aged children. This category includes infectious Hepatitis.
• Skin and Soft Tissue Infections.
• Bone and Joint Infections.
• Meningitis and Meningoencephalitis.

3. Evaluating the "Ill" Febrile Child

Determining if a child is truly "ill" or toxic relies heavily on the general physical exam and vital signs.

General Examination Parameters

• Level of consciousness and overall activity level.
• Presence of distress (e.g., respiratory distress, agitation).
• Abnormal skin color (central cyanosis, pallor, jaundice).
• Poor perfusion (mottled skin, delayed capillary refill time [CRT], weak pulses).
• Hydration status (assessed via skin turgor, sunken eyes, depressed fontanelle, presence/absence of tears, sweat, and urine output).

Vital Signs and Adjunct Tests

• Temperature: Infants and children may present with fever, but paradoxically, severe illness can present with hypothermia.
• Heart Rate (HR): Usually tachycardic for age, but bradycardia may occur in severe decompensation.
  • < 12 months: Normal up to 160 beats/min.
  • 1-2 years: Normal up to 150 beats/min.
  • 3-5 years: Normal up to 140 beats/min.
• Respiratory Rate (RR): Look for tachypnea, hypopnea, or periods of apnea.
• Blood Pressure (BP): Often initially normal due to compensatory mechanisms, but later drops (hypotension). Note: A patient can be in profound shock while maintaining a normal BP.
• Mandatory Bedside Tests for the Ill Child:
  • Pulse oximetry (SaO2).
  • Capillary Refill Time (Normal is < 2 seconds).
  • Blood glucose: Must be > 40 mg/dL in newborns and > 60 mg/dL in children.

Risk Stratification: The Traffic Light System

To aid in clinical decision-making, patients are stratified into risk categories based on clinical signs. (The following table is integrated based on the visual chart provided in the lecture material).

4. SIRS and Sepsis Definitions

• SIRS (Systemic Inflammatory Response Syndrome): A widespread inflammatory response that may or may not be associated with infection. Diagnosis requires the presence of two or more of the following criteria (one of which must be an abnormal temperature or leukocyte count):
  • Core temperature: > 38.5°C or < 36°C.
  • Tachycardia: HR > 2 standard deviations (SD) above normal for age. In children < 1 year, bradycardia (< 10th percentile for age) also qualifies.
  • Tachypnea: Mean RR > 2 SD above normal for age, or need for mechanical ventilation for an acute process.
  • Leukocyte Count: Elevated or depressed for age, or > 10% immature neutrophils (bands).
• Sepsis: SIRS occurring in the presence of suspected or proven infection.
• Severe Sepsis: Sepsis associated with cardiovascular dysfunction, Acute Respiratory Distress Syndrome (ARDS), or dysfunction in two or more other organ systems.
• Septic Shock: Sepsis presenting with cardiovascular dysfunction.
• Refractory Septic Shock: Fluid-refractory and catecholamine-resistant septic shock.

Criteria for Multiple Organ Failure in Sepsis

• Cardiovascular: Hypotension, elevated arterial lactate, oliguria, or prolonged capillary refill.
• Respiratory: Hypoxia (needing > 40% FiO2), hypercarbia, or requiring mechanical ventilation.
• Neurologic: Glasgow Coma Score (GCS) ≤ 11 or acute change in mental status.
• Hematologic: Thrombocytopenia, Disseminated Intravascular Coagulation (DIC).
• Renal: Serum creatinine ≥ 2 times upper limit of normal for age, or a 2-fold increase in baseline creatinine.
• Hepatic: Total bilirubin ≥ 4 mg/dL (not applicable to newborns) or ALT > 2 times the upper limit for age.

5. Pathogens Causing Pediatric Infection

Bacterial Pathogens:

• Staphylococcus aureus (including MRSA).
• Coagulase-negative Staphylococcus (especially in neonates/young infants with indwelling vascular catheters).
• Streptococcus pneumoniae.
• Group B Streptococcus (GBS) (primarily in neonates).
• Neisseria meningitidis.
• Streptococcus pyogenes.
• Haemophilus influenzae type b (Hib).
• Pseudomonas aeruginosa (including carbapenem-resistant strains).
• Escherichia coli and Klebsiella species (including Extended-Spectrum Beta-Lactamase [ESBL] producing strains).

Viral Pathogens:

• Influenza A & B, Parainfluenza, Adenovirus, RSV, Human Metapneumovirus, SARS-CoV-2 (COVID-19).
• EBV, CMV, HSV, Enteroviruses.

Other Pathogens: Candida species, Rickettsial infections (e.g., Rocky Mountain spotted fever).

6. Occult Bacteremia

• Definition: The isolation of a bacterial pathogen in a blood culture taken from an otherwise well-appearing febrile child.
• The risk heavily depends on the child's immunization status.
• Historical Context: Before the routine use of PCV7/PCV13 (Pneumococcal) and Hib conjugate vaccines, the predominant pathogens were: S. pneumoniae (80%), Hib (20%), N. meningitidis, S. aureus, Group A and B Strep, Salmonella, and E. coli.

7. Septic Workup

• WBC and ANC: Absolute Neutrophil Count (ANC) may be a better predictor of occult bacteremia in incompletely immunized children than total WBC.
• Biomarkers: Procalcitonin (PCT) levels rise more rapidly in response to bacterial infections compared to C-Reactive Protein (CRP) or ANC. PCT is also more specific for bacterial infection than a standard WBC count.
• Cultures: Blood, Urine, CSF, Sputum, or other relevant body fluids.
• Molecular Assays: PCR and detection of bacterial 16S ribosomal RNA genes or host RNA signatures.

8. Management of the Febrile/Septic Child

• Supportive: Airway, Breathing, Circulation (ABC's). Determine disposition (Admission to pediatric floor vs. PICU). Manage fluids, glucose, and electrolytes.
• Antimicrobial Therapy (Empiric):
  • Infants < 90 days: Cefotaxime or Amikacin + Ampicillin ± Acyclovir (if HSV suspected).
  • Infants > 90 days (without a clear focus):
    • Looking well: Ceftriaxone.
    • Looking ill: Ceftriaxone + Vancomycin.

9. Specific Post-Infectious/Inflammatory Syndromes

Kawasaki Disease Diagnostic Criteria

(Integrated from lecture visual table) Diagnosis requires fever lasting ≥ 5 days without other explanation, combined with at least 4 of the 5 following criteria. (Note: If ≥4 criteria are present, diagnosis can be made on day 4 of illness).

1. Bilateral bulbar conjunctival injection (non-purulent).
2. Oral mucous membrane changes (injected/fissured lips, injected pharynx, strawberry tongue).
3. Peripheral extremity changes (erythema of palms/soles, edema of hands/feet in acute phase; periungual desquamation in convalescent phase).
4. Polymorphous rash.
5. Cervical lymphadenopathy (at least 1 lymph node > 1.5 cm in diameter).

MIS-C (Multisystem Inflammatory Syndrome in Children) WHO Criteria

(Integrated from lecture visual table)

All 6 criteria must be present:

1. Age 0 to 19 years.
2. Fever for ≥ 3 days.
3. Clinical signs of multisystem involvement (at least 2 of the following):
   • Rash, bilateral non-purulent conjunctivitis, or mucocutaneous inflammation (oral, hands, feet).
   • Hypotension or shock.
   • Cardiac dysfunction, pericarditis, valvulitis, or coronary abnormalities (echo findings or elevated troponin/BNP).
   • Evidence of coagulopathy (prolonged PT/PTT; elevated D-dimer).
   • Acute GI symptoms (diarrhea, vomiting, abdominal pain).
4. Elevated markers of inflammation (ESR, CRP, Procalcitonin).
5. No other obvious microbial cause of inflammation (excluding bacterial sepsis, staph/strep toxic shock syndromes).
6. Evidence of SARS-CoV-2 infection (Any of: Positive RT-PCR, Positive serology, Positive antigen test, or Contact with an individual with COVID-19).

Part 2: Meningitis in Children

1. Pathogenesis & Pathophysiology

• Meningitis involves a complex interplay between pathogen virulence factors and the host's immune response. A significant amount of neurological damage is actually caused by the host's inflammatory response and cytokines released within the Cerebrospinal Fluid (CSF).
• Sequence of Infection:
  1. Colonization of respiratory, GI, or lower genital tracts (pathogens use fimbriae/pili to adhere to receptors).
  2. Invasion into the bloodstream.
  3. Survival in the bloodstream (facilitated by the pathogen's protective polysaccharide capsule).
  4. Entry into the subarachnoid space.
• Direct Entry Routes:
  • Contiguous infections (sinusitis, mastoiditis, preorbital cellulitis).
  • Trauma, neurosurgery, or CSF leaks.
  • Medical devices (CSF shunts, cochlear implants).

2. Predisposing Risk Factors

• Immunodeficiency: Congenital or acquired (asplenia, complement deficiency, hypogammaglobulinemia, HIV, glucocorticoid use, diabetes mellitus).
• Anatomic defects: Dermal sinus tracts, brain/inner ear defects.
• Recent history: Recent respiratory or ear infections, recent exposure to meningitis, or recent travel to endemic areas (e.g., sub-Saharan Africa "meningitis belt").
• Physiological Vulnerabilities:
  • Normal CSF contains no neutrophils or immunoglobulins, making it an ideal environment for bacterial multiplication once penetrated.
  • The Blood-Brain Barrier (BBB) is a primary protective mechanism; however, in newborns, the BBB is poorly developed. Consequently, up to 20% of neonatal sepsis cases may be associated with meningitis.

3. Epidemiology & Incidence (USA Data)

• < 2 months: Highest incidence at 81 per 100,000 population.
• 2 months to 2 years: 7 per 100,000.
• 2 to 10 years: 0.6 per 100,000.
• 11 to 17 years: 0.4 per 100,000.

4. Microbiology by Age Group

• Infants < 3 months:
  • Group B Streptococcus (GBS)
  • Escherichia coli
  • Listeria monocytogenes
• Older infants and children:
  • Streptococcus pneumoniae
  • Neisseria meningitidis
  • Haemophilus influenzae type b (Hib)
  • Other gram-negative organisms
• Adolescents:
  • Neisseria meningitidis

Clinical Visual Context (Integrated from Microscopy slides):

• S. pneumoniae: Appears on gram stain as gram-positive diplococci, often forming short chains.
• H. influenzae: Appears as small, pleomorphic gram-negative coccobacilli.
• N. meningitidis: Appears as gram-negative diplococci, characteristically seen both intracellularly (inside polymorphonuclear leukocytes/neutrophils) and extracellularly.

5. Clinical Presentation

Clinical Visual Signs (Integrated from clinical imagery)

• Meningococcal Rash: The hallmark rash of N. meningitidis presents as diffuse, non-blanching petechiae and large purpuric lesions across the trunk and extremities. A "glass test" (pressing a clear glass against the rash) shows the lesions do not fade under pressure, indicating extravasation of blood.
• HSV Infection (Neonatal): Can present with grouped, crusting vesicular lesions on an erythematous base, often on the face, scalp, or near the eye.
• Enteroviral Infection: Can present as Hand-Foot-Mouth disease, showing distinct blister-like sores on the palms, soles, and oral mucosa.

Symptoms by Age

• Infants: Often present atypically with fever or hypothermia, bulging fontanel, lethargy, irritability, seizures, respiratory distress, poor feeding, and vomiting.
• Children: More classic presentation including fever, severe headache, photophobia, meningismus (stiff neck), nausea/vomiting, confusion, lethargy, and irritability.

6. Laboratory Testing and Diagnosis

• Systemic Labs: Blood culture, CBC with differential and platelets, Inflammatory markers (CRP, Procalcitonin), Serum electrolytes, BUN, Creatinine, Glucose, and Coagulation profile (PT, INR, PTT).
• Lumbar Puncture (LP) & CSF Analysis:
  • Analyze for: Cell count and differential, glucose, protein concentration, Gram stain, Culture, and specific PCRs (S. pneumo, MRSA, HSV, Enteroviruses).
  • Contraindications to LP: Cardiopulmonary compromise, clinical signs of increased intracranial pressure (ICP), papilledema, focal neurologic signs, or skin infection overlying the LP site.
• **Neuroimaging Indications Before LP:**
  • Severely depressed mental status (coma).
  • Papilledema.
  • Focal neurologic deficit (exception: isolated Cranial Nerve VI or VII palsy).
  • History of hydrocephalus or presence of a CSF shunt.
  • Recent history of CNS trauma or neurosurgery.

Typical CSF Findings in Meningitis

(Integrated from lecture data and comparison tables)

7. Management of Meningitis

Supportive Care

• Ensure adequate oxygenation, ventilation, and circulation.
• Obtain reliable venous access.
• Continuous cardio-respiratory monitoring during lab draws.
• Keep the head of the bed elevated at 15 to 20 degrees (to aid venous drainage and manage ICP).
• Correct hypoglycemia, acidosis, and coagulopathy.

Antimicrobial Therapy

• Must be initiated immediately following the LP if suspicion is high.
• Empiric regimen: Vancomycin (15 mg/kg IV) + Ceftriaxone (50 mg/kg IV) OR Cefotaxime (100 mg/kg IV).

Adjunctive Dexamethasone Therapy

• Dose: 0.15 mg/kg IV every 6 hours for 2-4 days.
• Timing: Must be administered before, or immediately after, the first dose of antibiotic therapy to mitigate the inflammatory response to bacterial lysis.
• Indications (Consider in specific risk groups):
  • Unimmunized patients.
  • Young children (age ≥ 6 weeks to ≤ 5 years).
  • Children with sickle cell disease or asplenia.
  • Known/suspected Hib infection (based on gram stain).
  • Adults with pneumococcal meningitis.
  • Patients with pneumococcal meningitis caused by highly penicillin/cephalosporin-resistant strains.
  • Note: Use in neonates is not definitively proven.

Duration of Antimicrobial Therapy

• N. meningitidis: 7 days
• H. influenzae: 7 days
• S. pneumoniae: 10-14 days
• S. agalactiae (GBS): 14-21 days
• Aerobic gram-negative bacilli: 21 days (or 2 weeks beyond the first sterile culture, whichever is longer).
• L. monocytogenes: 21 days or longer.

Contact Prophylaxis

• Prophylaxis is mandated for very close/household contacts of patients with Hib and Meningococcal infections, regardless of the contact's age.
• Risk of secondary case in households is ~1%.
• Regimen: Rifampin, Ceftriaxone, or Ciprofloxacin PLUS administration of the meningococcal vaccine.

8. Complications and Outcomes

• Mortality: Overall mortality for bacterial meningitis is 5-10%. In neonates, it is higher (15-20%), while in older children it is 3-10%.
  • S. pneumoniae has a high mortality rate (26.3-30%).
  • N. meningitidis generally has the lowest mortality (3.5-10%), however, progression to fulminant meningococcemia carries a very high mortality rate unless identified rapidly.
• Neurological Complications:
  • Subdural effusion / empyema.
  • Hearing deficit (occurs in 7-30% of survivors).
  • Decreased IQ (occurs in 30-50% of survivors).
  • Seizures.
  • Hemiparesis and other focal neurological deficits.

Part 3: Viral ExanthemsYear 6

1. Dermatological Definitions

• Exanthem (exanthema): Greek origin meaning "a breaking out." A rash that appears abruptly and affects several areas of the skin simultaneously.
• Enanthem (enanthema): An eruption occurring upon a mucous membrane.
• Morbilliform: A rash composed of erythematous macules and papules that resemble a measles rash. It is notoriously difficult to distinguish from a drug eruption.
• Lesion Morphology and Size:
  • Macule: Flat lesion < 1cm. Patch: Flat lesion > 1cm.
  • Papule: Raised lesion < 1cm. Plaque: Raised lesion > 1cm.
  • Nodule: Small/deep solid lesion. Tumor: Large solid lesion.
  • Petechiae: Non-blanching hemorrhages < 3mm. Purpura: Non-blanching hemorrhages > 3mm.
  • Vesicle: Fluid-filled blister < 1cm. Bullae: Fluid-filled blister > 1cm.
  • Pustule: Pus-filled lesion.
  • Wheal: A transient, raised, itchy lesion (hives) that "comes and goes."

2. The Classic Historical "Six Diseases" of Childhood

1. First Disease: Measles
2. Second Disease: Scarlet Fever
3. Third Disease: Rubella
4. Fourth Disease: Dukes Disease
5. Fifth Disease: Erythema Infectiosum
6. Sixth Disease: Roseola Infantum (Exanthem Subitum)

Measles (Rubeola)

• Incubation / Spread: 10 days; spread via respiratory droplets.
• Contagious Period: 4 days prior to the rash until 4 days after the eruption of the rash.
• Symptoms: Prodrome of fever, conjunctivitis, coryza (runny nose), cough, and photophobia.
• Signs & Visual Findings:
  • Enanthem: Koplik spots appear early. Clinically visualized as tiny, white, grain-like spots on an erythematous base on the buccal mucosa.
  • Exanthem: Non-pruritic, erythematous macules and papules that begin on the face and spread in a distinct cephalocaudal (head-to-toe) pattern. Visualized as a densely clustered, reddish-brown maculopapular rash on the skin.
• Complications: CNS involvement, issues during gestation, pneumonia, ophthalmic complications.
• Treatment: Vitamin A, IVIg, Supportive. Prevention via vaccination.

Rubella (German Measles)

• Incubation / Spread: 14-21 days (peak winter/spring); spread via droplets.
• Symptoms: Malaise, headache, sore throat, coryza.
• Signs & Visual Findings:
  • Starts with tender lymphadenopathy.
  • 1-5 days post-prodrome, a discrete pink/red fine maculopapular rash develops. Visualized as very fine, distinct pinkish spots on the skin, less confluent and lighter in color than measles.
  • Starts on the face, spreads cephalocaudal rapidly, and clears quickly in 2-3 days.
• Complications: Congenital Rubella Syndrome; infection in the first trimester carries the highest risk of severe teratogenicity.
• Treatment: Supportive. Prevention via vaccination.

Erythema Infectiosum (Fifth Disease)

• Etiology: Parvovirus B19.
• Incubation / Spread: 1-2 weeks; spread via saliva. Most infectious before the rash appears.
• Symptoms: Fever, myalgias, headache. Usually affects ages 4 to 10 years.
• Signs & Visual Findings:
  • Phase 1: Confluent, erythematous, edematous plaques on the cheeks. Clinically visualized as the classic "slapped cheek" appearance.
  • Phase 2: An erythematous reticular (lace-like) eruption on the trunk and extremities. Clinically visualized as an intricate, fading red network of lines on the skin.
  • Rash resolves in 5-10 days but can recur with heat and sun exposure for months afterward.
• Complications: Chronic hemolytic anemia, aplastic crisis (especially in sickle cell patients).
• Treatment: Supportive; possibly IVIg for severe cases/immunocompromised.

Roseola Infantum (Exanthem Subitum / Sixth Disease)

• Etiology: Human Herpesvirus 6 (HHV-6).
• Epidemiology: Most common before 2 years of age.
• Symptoms & Signs:
  • Begins with a sudden high-grade fever which may trigger febrile convulsions.
  • After the fever breaks, the rash appears.
  • Visual Findings: Pink macules and papules characteristically surrounded by a white halo. It starts on the trunk and spreads outward. Clinically visualized as scattered pink spots on the chest and back.
• Complications: Febrile seizures.
• Treatment: Supportive.

3. Other Significant Viral Cutaneous Infections

Varicella (Chickenpox)

• Incubation / Spread: 10-21 days; airborne spread.
• Symptoms: Fever, headache, malaise.
• Signs & Visual Findings:
  • 1-2 days post-prodrome, a rapid eruption of tiny erythematous papules occurs.
  • These quickly change to vesicles with red halos (classic "dew drop on a rose petal" appearance).
  • Highly pruritic (itchy). Lesions present in multiple stages simultaneously (macules, papules, vesicles, crusts). Clinically visualized as scattered, fluid-filled blisters on red bases.
• Complications: Secondary bacterial skin infections, pneumonia, CNS complications. Teratogenic risk if maternal infection occurs in the first half of pregnancy.
• Treatment & Exposure Management:
  • Antiviral therapy if started early; consider presumptive therapy.
  • Give prophylaxis (Varicella IVIg) within 4 days of exposure to high-risk individuals: Immunocompromised patients, newborns with infected mothers, and premature/very low birth weight infants.

Hand-Foot-Mouth Disease

• Etiology: Coxsackievirus mostly, but also Enterovirus or Echovirus.
• Incubation: 4 to 6 days.
• Symptoms: Fever, malaise, sore mouth, anorexia.
• Signs & Visual Findings:
  • Enanthem: Oral shallow yellow ulcers with red halos. Clinically visualized as distinct aphthous-like ulcers on the soft palate, tongue, or buccal mucosa.
  • Exanthem: Oval-shaped vesicles with erythematous halos on the hands and feet. May also involve the buttocks. Clinically visualized as distinct, thick-walled blisters on the palms and soles.
• Complications: Aseptic meningitis, myocarditis/pericarditis.
• Treatment: Supportive.

Infectious Mononucleosis

• Etiology: Epstein-Barr Virus (EBV).
• Incubation: 1-2 months.
• Symptoms: Fever, severe sore throat, fatigue, malaise.
• Signs & Visual Findings: Lymphadenopathy, splenomegaly, enlarged tonsils (often with thick white exudate), diffuse maculopapular rash, and palatal petechiae.
• Investigation: VCA-IgM antibodies.
• Complications: Associated with certain malignancies (e.g., lymphomas).
• Treatment: Supportive, steroids (if severe airway swelling), strict avoidance of sports (to prevent splenic rupture).

Warts

• Etiology: Human Papillomavirus (HPV).
• Signs & Visual Findings: Hyperkeratotic papules with a rough, irregular surface. Commonly found on fingers, hands, and feet. Clinically visualized as raised, verrucous (cauliflower-like) solitary or clustered bumps. Genital warts occur in older age groups.
• Complications: Malignancy risk specific to certain strains causing genital warts.
• Treatment: Removal if symptomatic.

Molluscum Contagiosum

• Etiology: Poxvirus.
• Incubation / Spread: 7 weeks; spread via direct contact and self-inoculation (scratching).
• Signs & Visual Findings: Sharply circumscribed, dome-shaped papules with waxy surfaces, characteristically featuring umbilicated centers (a central dimple). Usually single or multiple. Clinically visualized as clusters of small, pearl-like, dimpled bumps on the skin.
• Treatment: Removal if symptomatic; however, usually resolves spontaneously without scarring in 2-3 years.

Dengue Fever

• Spread: Mosquito-borne.
• Incubation: 1-7 days.
• Symptoms: Biphasic fever, severe myalgia/arthralgia ("breakbone fever"), nausea, vomiting. Can progress to severe hemorrhage or shock.
• Signs & Visual Findings: Infectious thrombocytopenic purpura. Presents with a red, widespread maculopapular rash often described as "white islands in a red sea," which characteristically spares the palms and soles.
• Complications: DIC (Disseminated Intravascular Coagulation).
• Treatment: Supportive.

Monkeypox (Mpox)

• Incubation / Spread: 3 weeks; spread via direct contact. Contagious 4 days prior to rash eruption.
• Symptoms: Flu-like symptoms, fever, chills, headache.
• Signs & Visual Findings: Lymphadenopathy (distinguishes it from smallpox). Presents with an itchy, tender skin rash that is papular and progresses through multiple distinct stages (macules -> papules -> vesicles -> pustules -> scabs).
• Complications: Secondary bacterial infections, pneumonia.
• Treatment: Supportive.

Neonatology

PART 1: NEONATAL SEPSISYear 6

Definition and Classification

Neonatal sepsis is a clinical syndrome in an infant 28 days of life or younger, manifested by systemic signs of infection and the isolation of a bacterial pathogen from the bloodstream. It is a major cause of morbidity and mortality, accounting for 30-50% of total neonatal deaths in developing countries. It is classified by the onset of symptoms:

• Early-Onset Sepsis (EOS): Occurs within the first 72 hours of life. It is transmitted vertically by ascending contaminated amniotic fluid or during vaginal delivery from bacteria in the mother's lower genital tract.
• Late-Onset Sepsis (LOS): Occurs after 72 hours of age. Transmission can be vertical (neonatal colonization evolving into infection) or horizontal (nosocomial/hospital-acquired or community-acquired).

Etiologic Agents and Risk Factors

The lecture features a comparative table detailing the microbial pathogens and risk factors associated with both EOS and LOS.

Clinical Features

Signs vary by gestational age and severity, often presenting subtly initially. A high index of suspicion is required.

• Temperature Instability: Hypothermia is common, especially in preterm/LBW infants. Fever is rare unless the mother is febrile.
• General Signs: Lethargy, poor cry, poor feeding, hypotonia, absent neonatal reflexes.
• Respiratory: Pneumonia is a frequent presenting infection (apnea, tachypnea, grunting, flaring, retractions).
• Cardiac/Hemodynamic: Cyanosis, desaturation, bradycardia, poor perfusion, reduced capillary refill, hypotension, shock.
• Metabolic: Hypo/hyperglycemia, metabolic acidosis.
• Note: Symptoms are generally more severe with Gram-negative and fungal infections compared to Gram-positive infections.

Evaluation and Investigations

Differentiating sepsis from non-infectious pathologies with overlapping features is a primary NICU challenge.

• EOS Calculator: A web-based tool estimating EOS risk based on maternal/neonatal factors (GBS status, temp, rupture duration). It guides whether diagnostic evaluation and empiric antibiotics are warranted. Symptomatic neonates require full evaluation and empiric therapy; well-appearing infants with risk factors (e.g., GBS) may only need observation for 36-48 hours.
• Blood Culture: The gold standard, requiring a 1-mL sample before starting antibiotics. Sensitivity is ~90%. Automated systems detect positivity within 24-48 hours.
• Complete Blood Count (CBC):
  • WBC counts (5,000-30,000/mm³) have poor predictive value.
  • Absolute Neutrophil Count (ANC): Neutropenia (<1800/mm³ at birth; <7800/mm³ at 12-14 hrs) is concerning.
  • Immature to Total Neutrophils (I/T ratio): A ratio of >0.2 is suspicious for sepsis.
  • Note: Platelet counts are characterized by poor sensitivity/specificity and are unreliable for initiating/stopping antibiotics.
• Biomarkers:
  • C-Reactive Protein (CRP): Acute phase reactant produced in the liver. A late but useful marker for monitoring treatment response. Synthesized 6-8 hours post-exposure, half-life of 19 hours. Can be elevated in non-infectious stress (fetal distress, asphyxia, IVH).
  • Procalcitonin (PCT): Propeptide of calcitonin. An early marker with a rapid rise. Half-life is 24h. More specific for bacterial sepsis than viral infections and correlates with severity.
  • Cell Surface Markers: Neutrophil CD64 is highly sensitive (80%) and specific (79%) with a cutoff of 4.02.
• Lumbar Puncture (LP): Indicated for strong clinical suspicion, signs of meningitis, or a positive blood culture. CSF may show pleocytosis, low glucose, and/or elevated protein.
• Urine Culture: Recommended for all cases of LOS (via suprapubic puncture or catheterization). Not part of traditional EOS evaluation.
• Radiology: Chest X-ray for respiratory distress; Abdominal X-ray to diagnose necrotizing enterocolitis (NEC).

Management

• Supportive Care: Thermo-neutral environment, oxygen/ventilation, IV fluids for hemodynamic instability, volume expansion (crystalloids/colloids), inotropes for perfusion, and blood products for anemia/bleeding.
• Adjunctive Therapy: Insufficient evidence currently supports the routine use of IVIG or G-CSF. Exchange transfusion is poorly studied but may be used cautiously in sepsis with neutropenia, early DIC, and severe metabolic acidosis (pH <7.2).
• Empiric Antimicrobial Therapy:
  • EOS: Ampicillin + Aminoglycoside (Gentamicin) covers GBS and E. coli. A 3rd-generation cephalosporin (e.g., Cefotaxime) is added if meningitis is present.
  • LOS (Community): Ampicillin + Gentamicin or Ampicillin + Cefotaxime.
  • LOS (Hospitalized since birth): Vancomycin (substituting Ampicillin) + Meropenem (for ESBL-producing E. coli or highly resistant organisms).
  • Note on 3rd Gen Cephalosporins: Good CSF penetration, but routine use increases risks of ESBL infections, NEC, death, and invasive candidiasis.
• Duration of Therapy: Review progress at 36 hours. Stop if cultures are negative. If positive, refer to the following treatment durations presented in the lecture:

PART 2: WELL NEWBORN CARE

Delivery Room Care & The Golden Hour

• Delayed Cord Clamping (DCC): Visual infographics in the lecture demonstrate the transfer of blood from placenta to infant. Clamping 10-15 seconds post-birth transfers 67% of blood; waiting 1 minute transfers 80% (79-80 mL).
  • Benefits: Increased iron stores, less infant anemia, 59% reduction in IVH, 62% reduction in NEC, and 29% reduction in late-onset sepsis for preterms.
  • Guidelines: AAP/ACOG recommend 30-60 seconds for vigorous infants. WHO recommends 1-3 minutes or until the cord is pulseless.
  • Contraindications: Placental abruption/previa, cord avulsion.
• Thermal Care ("Dry and Warm"): Maintain normal temperature between 36.5–37.5°C. Visuals depict heat loss mechanisms (radiation, conduction, convection, evaporation). Prevent heat loss via immediate drying, skin-to-skin contact, breast feeding, and covering the head with a hat.
• Apgar Score: Assessed at 1 and 5 minutes. A 5-minute score of 7-10 is normal. It assesses transition but should not guide resuscitation efforts or predict long-term neurologic outcomes.

Initial Newborn Assessment & Routine Care

• Performed immediately after delivery by a nurse or birth attendant. Checks for anomalies, assesses gestational age/weight, and reviews maternal risk factors.
• Vitamin K Prophylaxis: Given intramuscularly in the first hour to prevent Vitamin K Deficiency Bleeding (VKDB), which occurs due to immature gut flora, poor transplacental passage, low hepatic storage, and breast milk being a poor source of Vit K. VKDB can cause fatal intracranial hemorrhage.
• Eye & Cord Care: Skin is wiped of blood/meconium. Sponge baths are recommended until the umbilical cord detaches (10-14 days). Keep the cord clean and dry; topical antiseptics are unnecessary unless in highly contaminated areas.
• Voiding & Stooling:
  • Urine: First urination occurs within 24 hours (normal: 4-6 times/day). "Brick dust" urine is caused by benign urate crystals, which must be differentiated from blood.
  • Stool: First meconium (black, tarry) passes within 48 hours. Transitions to seedy/yellow as milk increases. Delayed stool (>48h) requires imaging (barium enema/biopsy) to rule out imperforate anus, meconium plug, or Hirschsprung disease.

Growth Assessment

• Measurements include weight, length, and head circumference (normal HC: 33-35 cm).
• Visual charts (WHO for breastfed term infants, CDC for US term infants, Fenton and Intergrowth for preterms) are utilized to classify infants as AGA, SGA, or LGA.

Support Breastfeeding (Baby Friendly)

• Initiate within the first hour. Utilize skin-to-skin contact. Avoid dextrose/sterile water. Provide rooming-in.
• Adequate feeding is indicated by swallowing sounds, softened breasts post-feed, 4-6 wet diapers/day, and weight gain. (Newborns typically regain birth weight by 2 weeks).

Anticipatory Guidance & Discharge

• Safe Sleep: To prevent SIDS, place babies completely on their back in a bare crib (no quilts, positioners, or stuffed animals). A pacifier can be offered once breastfeeding is established.
• Discharge Criteria: Normal vital signs, documented passage of stool and urine, completed screenings (Hearing, Metabolic, CCHD).
• Screenings:
  • Hearing: "1-3-6 Principle" (Screen by 1 month, Identify by 3 months, Intervene by 6 months).
  • Metabolic: Tested at 2 weeks in Jordan (TSH, G6PD, PKU).
  • Critical Congenital Heart Disease (CCHD): Measured via pre-ductal (right hand) and post-ductal (either foot) pulse oximetry. Normal: ≥95% and ≤3% difference between hand/foot.

PART 3: THE PRETERM BABY

Definitions and Classification

A preterm baby is born alive before 37 completed weeks of gestation.

• Extremely preterm: < 28 weeks
• Very preterm: 28 to < 32 weeks
• Moderate to late preterm: 32 to 37 weeks
• Low Birth Weight (LBW): < 2,500g; VLBW: < 1,500g; ELBW: < 1,000g.
• Gestational age can be assessed via LMP, 1st-trimester ultrasound, or postnatally using the New Ballard Score (assessing physical and neuromuscular maturity). Distinguishing physical features of preterms include lack of sole creases, absent breast nodules, poorly developed ear cartilage, wooly lanugo hair, and underdeveloped genitalia (undescended testes, widely separated labia).

Causes and Prevention of Prematurity

• Maternal Factors: Previous preterm delivery, infections (GBS, UTI), preeclampsia, malnutrition, drug abuse.
• Uterine/Pregnancy Factors: Placenta previa/abruption, PROM, polyhydramnios, cervical incompetence, bicornuate uterus.
• Fetal Factors: Distress, multiple gestation, congenital malformations, TORCH infections.
• Prevention bundles:
  1. Cervical length measurement (<25mm at <24 weeks prompts cerclage).
  2. Progesterone administration to reduce delivery rates.
  3. In utero transfer to tertiary NICUs.
  4. Antibiotics for pPROM.
  5. Magnesium Sulphate (MgSO4): Given <32 weeks for neuroprotection (reduces cerebral palsy by 30%).
  6. Antenatal Corticosteroids: Single course given 24-34 weeks to accelerate fetal lung maturity.

NICU Management Stages and Complications

• Unstable Stage (Birth to 3-5 days):
  • Hypothermia Prevention: Preterms lack subQ fat, brown adipose tissue, and shiver reflex. Hypothermia leads to hypoxia, hypoglycemia, metabolic acidosis, and death.
  • Respiratory Distress Syndrome (RDS): Caused by immature surfactant and lung vascularization. Chest X-ray reveals "hyaline membrane disease" (ground-glass appearance, air bronchograms). Managed with CPAP, ventilation, and Surfactant administration (LISA method). Be aware of air leaks (pneumothorax).
  • Pulmonary Hemorrhage: Occurs 2-4 days post-birth; presents as bleeding into lungs requiring increased ventilation.
  • Patent Ductus Arteriosus (PDA): Fails to close, leading to congestive heart failure. Treated with fluid restriction, NSAIDs/Paracetamol, or catheter/surgical closure.
  • Metabolic/GI: Immature kidneys lead to Na/K/Ca imbalances. Poor GI motility and risk of Necrotizing Enterocolitis (NEC - intestinal necrosis, pneumatosis intestinalis on X-ray). Early trophic enteral feeding (breast milk) is crucial.
• Stable Stage (> 3-5 days):
  • Apnea of prematurity (>20 sec cessation of breathing or shorter with bradycardia/desaturation). Treated with CPAP or caffeine/theophylline.
  • Infections (Nosocomial).
• Neurologic and Long-Term Complications:
  • Intraventricular Hemorrhage (IVH): Can lead to post-hemorrhagic hydrocephalus.
  • Periventricular Leukomalacia (PVL): Softening of brain tissues around ventricles.
  • Metabolic Bone Disease of Prematurity (MBDP): Decreased bone mineral content due to lack of intrauterine Ca/P supply. Detected by Low P, High Alkaline Phosphatase (>600). Treated with fortified breast milk and Vitamin D.
  • Anemia of Prematurity: Due to blood loss, short RBC lifespan, and inadequate production.
  • Retinopathy of Prematurity (ROP): Incomplete retinal vascularization.
  • Bronchopulmonary Dysplasia (BPD) / Chronic Lung Disease.

PART 4: NEONATAL JAUNDICE (HYPERBILIRUBINEMIA)

Definition and Metabolism

• Neonatal Jaundice: Yellowish discoloration of skin/conjunctiva due to bilirubin deposition.
• Severe Hyperbilirubinemia: Total Serum Bilirubin (TSB) > 25 mg/dL.
• Bilirubin Metabolism: Visual diagrams illustrate the pathway. Old RBCs are broken down by macrophages in the reticuloendothelial system (spleen/bone marrow) into Heme and Globin. Heme oxygenase converts Heme to Biliverdin, which is reduced to Unconjugated Bilirubin (UCB). UCB binds reversibly to albumin in plasma. It enters hepatocytes via OATP-2 transporter, is conjugated by the enzyme UGT1A1 (uridine diphosphate glycosyltransferase 1A1), and actively excreted into bile via MRP2. In the gut, beta-glucuronidase can deconjugate bilirubin, allowing reabsorption into the blood (Enterohepatic Circulation - EHC).

Types of Neonatal Jaundice

1. Physiologic Jaundice: Caused by high RBC mass, short RBC lifespan, immature hepatic uptake/conjugation, and increased enterohepatic circulation.
   • Pattern: Peaks at 3-4 days in term infants (5-7 in preterms). Resolves by 1-2 weeks. Rate of rise is <5 mg/dL/day. The baby is well.
2. Pathologic Jaundice: A medical emergency. Recognized by early onset (<24 hours), rapid rise (>5 mg/dL/day), persistence (>2 weeks term, >3 weeks preterm), or direct bilirubin >20% of total.
   • Causes of Increased Production: Hemolysis (Isoimmune ABO/Rh incompatibility, G6PD, spherocytosis), Sepsis, Polycythemia, Cephalohematoma.
   • Causes of Decreased Clearance: UGT1A1 defects (Crigler-Najjar, Gilbert syndrome), Galactosemia, Hypothyroidism.
   • Causes of Increased Enterohepatic Circulation: Bowel obstruction, NPO status.
3. Breastfeeding Jaundice (BFJ): Occurs in the first few days due to low caloric intake, dehydration, and increased EHC. Managed by increasing feeding frequency; formula supplementation only if severe weight loss occurs.
4. Breast Milk Jaundice (BMJ): Develops after 4-7 days and can last 3-12 weeks. Caused by milk inhibitors (e.g., beta-glucuronidase) that increase EHC. Generally benign.

Assessment and Management

• BIND (Bilirubin-Induced Neurologic Dysfunction): Free bilirubin crosses the blood-brain barrier. Acute Bilirubin Encephalopathy (ABE) presents with lethargy, poor feeding, retrocollis, opisthotonus, and a shrill cry. Chronic, permanent damage is termed Kernicterus.
• Risk Assessment: Visual inspection is unreliable. Use Transcutaneous Bilirubin (TcB) or TSB and plot on the Bhutani Nomogram (graphs TSB against infant age in hours to stratify risk zones).
• Phototherapy: Uses blue/green light (425-475 nm wavelength). The mechanism involves changing the bilirubin isomer to water-soluble forms via Configurational Isomerization and Structural Isomerization (forming lumirubin). Guidelines dictate therapy thresholds based on gestational age and risk factors.
• Exchange Transfusion: Indicated for TSB > 25 mg/dL, failure of phototherapy, or signs of acute encephalopathy.
• IVIG: Recommended for isoimmune hemolytic disease if TSB rises despite phototherapy.

PART 5: NEONATAL OPHTHALMOLOGIC PROBLEMS

A clinical assessment of common and emergent neonatal eye issues.

• 1. Watery Eyes (Congenital Nasolacrimal Duct Obstruction - CNLDO):
  • Affects ~20% of infants, lying in a mechanical obstruction distally at the valve of Hasner.
  • Presents as unilateral excessive tearing and mucoid discharge. Eye exam shows a clear cornea, negative conjunctival/scleral redness, and normal pupillary reflex.
  • Management: Simple observation, eye cleaning, Crigler massage (lacrimal sac massage 10x, 3x/day). Topical antibiotics only if superinfection occurs. Most resolve by 1 year.
• 2. Squint (Strabismus):
  • "Transient neonatal strabismus" often presents as intermittent looking sideways. It usually resolves by 2-4 months. Differentiate from true strabismus or pseudo-strabismus (optical illusion due to wide nasal bridge). Asymmetrical pupillary light reflex requires investigation.
• 3. Abnormal Red Reflex (Leukocoria):
  • Assessed using a direct ophthalmoscope 2-3 feet away in a dark room.
  • Leukocoria (white pupil) is an urgent finding. Differentials include:
    • Retinoblastoma: A malignant tumor. (Estimate: 1 case per 18,000-30,000 births).
    • Congenital Cataract: Opacification of the lens. Often genetic (Autosomal Dominant), or due to systemic associations like metabolic disorders (Galactosemia) or TORCH infections (Rubella). Requires urgent surgical intervention to prevent amblyopia.
• 4. Primary Congenital Glaucoma (PGG):
  • Due to a developmental defect in the trabecular meshwork and anterior chamber angle, preventing aqueous humor drainage and elevating Intraocular Pressure (IOP).
  • Symptoms: Enlarged eye globe (buphthalmos), horizontal corneal diameter > 10.5 mm (measurements >12 mm are highly indicative), corneal cloudiness/edema, tearing, photophobia, and blepharospasm. Usually bilateral.
  • Risk Factors: Family history, Sturge-Weber syndrome (facial port-wine stain), congenital rubella.
  • Management: Top surgical emergency to prevent optic nerve damage.

Nephrology

Part 1: Acute Kidney Injury (AKI) & Chronic Kidney Disease (CKD)

Acute Kidney Injury (AKI)

Definition & Outcomes

• Defined as an abrupt loss of kidney function resulting in a decline in glomerular filtration rate (GFR). This causes the retention of urea and nitrogenous waste products and leads to the dysregulation of extracellular volume and electrolytes.
• Clinical manifestations range from a minimal elevation in serum creatinine to anuric renal failure.
• Outcomes: Pediatric AKI is an independent risk factor for prolonged stay in the PICU, longer duration of mechanical ventilation, and higher morbidity/mortality. Survivors have a high prevalence of progressing to CKD, hypertension, and proteinuria.

Epidemiology

The incidence of AKI varies by clinical setting:

• Present in >30% of all preterm infants and 50% of neonates with asphyxia.
• Children undergoing cardiac surgery for congenital heart disease: 30-40%.
• Children undergoing Bone Marrow Transplant (BMT): 15-35%.
• Children admitted to the PICU: 5-10% (some studies report up to 30%).
• PICU children receiving mechanical ventilation and vasopressors: up to 82%.

Diagnosis & Biomarkers

Diagnosis is made clinically (signs/symptoms) and via laboratory findings.

• Serum Creatinine (SCr) Limitations: SCr is a poor biomarker for early AKI. It is insensitive to small changes in GFR, may not rise until up to 50% of kidney function is lost, and can lag by up to 72 hours post-insult. It is also affected by age, sex, muscle mass, and volume status.
• Novel Biomarkers: NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury molecule-1), IL-18, liver-type fatty acid-binding protein, and Cystatin C show promise for early intervention but are not yet frequently used in routine clinical setups due to cost and validation limits.

Table 1: Pediatric RIFLE (pRIFLE) Classification of AKI

Table 2: Pediatric KDIGO Criteria for AKI (2012)

Classifications of AKI

1. Prerenal Disease (Volume-Responsive AKI): Most common pediatric form. Caused by reduced renal perfusion (e.g., true volume depletion from bleeding/GI loss/burns, or decreased effective circulatory volume from heart failure/septic shock/cirrhosis).
   • Mechanism: Tubular function remains intact. Sodium and water are reabsorbed in response to hypoperfusion, leading to oliguria.
   • Visual Integration (Renal Compensatory Mechanisms): The lecture includes an anatomical diagram of the glomerulus showing autoregulation. To maintain intra-glomerular hydrostatic pressure when perfusion drops, vasodilatory prostaglandins dilate the afferent arteriole, and Angiotensin II constricts the efferent arteriole. NSAIDs (e.g., Ibuprofen) inhibit prostaglandins, and ACE inhibitors block Angiotensin II, both of which can precipitate AKI by destroying these compensatory mechanisms.
2. Intrinsic Renal Disease: Structural damage to the renal parenchyma. Causes include prolonged hypoperfusion (Acute Tubular Necrosis - ATN), sepsis, vasculitis, glomerular disease (PSGN, HUS, HSP), acute interstitial nephritis, rhabdomyolysis, and nephrotoxins.
   • Visual Integration (Urine Casts): An image of a "muddy brown" granular urine cast is provided, which is the pathognomonic microscopic finding for Intrinsic AKI (specifically ATN).
3. Postrenal Disease: Obstructive AKI resulting from anatomic obstructions to the lower urinary tract (e.g., stones, strictures, clots, neurogenic bladder, or Posterior Urethral Valves [PUV]).

Table 3: Differentiating Prerenal vs. Intrinsic AKI

Clinical Picture & Management of AKI

• Urine Output Definitions: Anuria (no output); Oliguria (< 1 mL/kg/hr in infants; < 0.5 mL/kg/hr in children/adults for > 6 hours); Nonoliguria (majority of neonates with AKI); Polyuria (concentrating defect).
• Management: No effective medications exist for established AKI; care is supportive.
  • Hypovolemia: 0.9% Normal Saline bolus (10-20 mL/kg over 30 mins, repeat x3). Monitor CVP if unresponsive.
  • Euvolemia: Diuretic challenge (Furosemide). Replace insensible fluid (300-400 mL/m²/day) + output using 1/2 NS.
  • Hypervolemia (>20% fluid overload negatively impacts outcomes): Restrict fluids to insensible losses without replacement. If unresponsive to diuretics, initiate Renal Replacement Therapy (RRT).
• Hyperkalemia Management:
  • Visual Integration (ECG): An ECG strip illustrates tall, peaked, symmetrical T-waves, the first sign of hyperkalemia (> 7.0 meq/L), which progresses to prolonged PR, flattened P waves, widened QRS, and ventricular fibrillation.
  • Treatment Steps: 1) Stabilize myocardium (Calcium gluconate 10% IV - immediate). 2) Shift K+ into cells (IV Glucose + Insulin, Inhaled albuterol, Sodium bicarbonate - onset 15-30 mins). 3) Remove K+ (Sodium polystyrene sulfonate, Furosemide, Hemodialysis - onset 1-2 hours).

Chronic Kidney Disease (CKD)

• Definition: Structural or functional kidney abnormalities persisting for at least 3 months. (Not applied to children < 2 years).
• Epidemiology: Incidence is 11–12 per million age-related population (pmarp); prevalence is ~55–60 pmarp. Greater in males due to higher frequency of CAKUT (Congenital Anomalies of the Kidney and Urinary Tract). Main causes: Obstructive uropathy, renal hypoplasia/dysplasia, reflux nephropathy, and childhood nephritis (mainly FSGS).
• Pathophysiology: Initially, adaptive hyperfiltration in remaining normal nephrons maintains normal SCr and electrolytes. In the long run, this irreversibly damages remaining glomeruli, causing proteinuria and progression to ESRD. ~70% of children with CKD develop ESRD by age 20.
• Complications:
  • Anemia: Due to primary deficiency of erythropoietin (90% produced by kidneys). Treated with EPO replacement and iron (maintain Hb 11-12 g/dL).
  • CKD-Mineral and Bone Disorder (CKD-MBD):
    • Visual Integration (Pathophysiology Flowcharts): Two diagrams outline CKD-MBD. Diagram 1 shows decreased GFR leading to phosphate retention, and tubular damage leading to decreased 1,25-Vit D synthesis and poor Calcium absorption. Both trigger secondary hyperparathyroidism. Diagram 2 shows that retained phosphate triggers increased FGF23 release, which inhibits Vitamin D activation, worsening the cycle.
    • Treatment: Restrict dietary phosphate, use phosphate binders, and add active Vitamin D once phosphate is controlled. Target intact PTH is 200-300 pg/mL in stage V disease. Maintain Calcium-Phosphorus product < 55 mg²/dL².
  • Hypertension: Independent predictor of progression. Target BP < 90th percentile. ACEi/ARBs slow progression and control proteinuria.
  • Metabolic Acidosis: Typically present when eGFR < 30 (Stage IV). Treat with Sodium Bicarbonate (maintain HCO3 ~22 mmol/L).

Part 2: Approach to a Child with Dysuria & UTIs

History and Differential Diagnosis of Dysuria

• Dysuria: Sensation of burning/pain upon urination.
• History: Ask about urgency, frequency, hematuria, loin/suprapubic pain, fever, vaginal discharge/itching, bowel habits, previous UTIs, and toilet training.
• Physical Exam: Check temperature, renal angle tenderness, look for vulvitis/meatal stenosis/labial adhesions, and check the back for a sacral dimple (indicating potential neurogenic bladder).
• Differential Diagnosis: Genitourinary infections (pyelonephritis, cystitis), vulvovaginitis, chemical irritation (soaps, poor hygiene), stones (hypercalciuria), labial adhesions, sexual abuse, pinworms, trauma.

Urinary Tract Infections (UTI)

• Epidemiology: By age 8, 8% of girls and 2% of boys have had a UTI. Highest incidence is in the first year of life (Males > Females in neonates, higher if uncircumcised). Recurrence rate is 12-30% within 6-12 months.
• Pathogenesis: 80% caused by E. coli (strong adhesive capacity).
  • Visual Integration (Pathophysiology): An illustration shows P-fimbriated E. coli binding to TLR4 and CD14 receptors on uroepithelial cells, triggering the NF-kB pathway to release cytokines (TNF-α, IL-8), leading to massive neutrophil recruitment, vascular permeability, and subsequent scar formation.

Table 7: Positive Likelihood Ratios (LH) for UTI Symptoms/Signs

• Diagnosis (AAP Guidelines): To establish a UTI diagnosis, clinicians require both an abnormal urinalysis (pyuria and/or bacteriuria) and the presence of at least 50,000 CFU/mL of a uropathogen cultured from a urine specimen obtained via catheterization or Suprapubic Aspiration (SPA). Bag specimens have a high false-positive rate and should not be used.
• Treatment: Initiating treatment orally or parenterally is equally efficacious. Duration should be 7 to 14 days. If a patient remains febrile after 48 hours, upgrade antibiotics due to potential resistance or complications (bacteremia, acute lobar nephronia, abscesses).

Table 8: NICE Guidelines - Definition of Atypical UTI

Imaging and Vesicoureteral Reflux (VUR)

• Imaging: RBU (Renal and Bladder Ultrasound) is recommended for febrile infants with UTIs. VCUG (Voiding Cystourethrogram) should not be performed routinely after the first febrile UTI unless RBUS reveals hydronephrosis, scarring, or if the UTI is "atypical" (see Table 8).
• VUR (Vesicoureteral Reflux): Present in 33% of UTI cases. Incidence in siblings is 27-45%.
  • Visual Integration (VUR Staging): A diagram pairs anatomical illustrations of ureter/pelvis dilation with actual fluoroscopic VCUG images to define Stages I through V. Stage I is limited to the ureter; Stage V involves severe tortuosity and gross dilation with loss of papillary impressions.
• Scarring: 10-40% develop scarring, leading to proteinuria, HTN, and CKD. Detected by DMSA scan 4 months post-UTI.

Table 9: Rate of Spontaneous VUR Resolution Over 5 Years

Nocturnal Enuresis & Overactive Bladder

• Nocturnal Enuresis (NE): Intermittent incontinence while asleep after age 5. (15-20% prevalence at age 5; 15% become dry each year without treatment).
  • Primary NE Causes: Delayed maturation, genetics (75% have affected relative), psychiatric disorders.
  • Pathophysiology: Intersects three factors: 1) Nocturnal polyuria (lack of ADH), 2) Reduced nocturnal functional bladder capacity, and 3) Impaired arousal response.
  • Treatment: Behavioral therapy (frequent voiding, fluid restriction at night, star charts, treat constipation). Pharmacologic therapy includes Desmopressin (Minirin) and Anticholinergics.
• Overactive Bladder: Characterized by urge incontinence, frequency, detrusor overactivity, and holding maneuvers (squatting, curtsey sign).
  • Diagnosis: Reduced bladder capacity. Expected Bladder Capacity (EBC) = 30 x (age + 1) mL. Overactive is defined as Maximum Voided Volume (MVV) < 65% of EBC.
  • Treatment: Bladder training, Anticholinergics (Oxybutynin, Tolterodine, Solifenacin), Botox, Neuromodulation.

Part 3: Dehydration, Fluid Therapy, & Acid-Base Disorders

Body Composition & Osmolality

• Total Body Water (TBW): Varies with age. Water is 50-75% of body weight (higher in younger age). Averages 60% (40% Intracellular, 20% Extracellular). ECF is divided into 15% interstitial and 5% blood.
• Osmolality Formula: Blood osmolality (mmol/L) = 2 × Na + [Glucose (mg/dL) / 18] + [BUN (mg/dL) / 2.8]. Normal is 286-295. Urea is an ineffective osmole.

Table 10: Factors Affecting Insensible Water Losses (ISW)

Fluid Calculations

• Maintenance Fluids: Calculates daily requirements to prevent dehydration and ketoacidosis.
  • Method 1 (Holliday-Segar): First 10 kg = 100 mL/kg/day; Second 10 kg = 50 mL/kg/day; Subsequent kg = 25 mL/kg/day. Maximum 2.5 L/day.
  • Method 2 (BSA): 1500 mL/m² BSA.
  • Method 3: Urine output + Insensible water losses.
• Electrolyte Requirements: Na: 2-3 mmol/kg/day; K: 1-2 mmol/100 mL.
• Common IV Fluids: Normal Saline (0.9%) contains 154 mmol Na/L. Glucose 5% in 0.45% Saline contains 75 mmol Na/L.

Table 11: Clinical Assessment of Dehydration Severity

• Fluid Repletion Strategy:
  1. Emergent Phase (Severe/Shock): 20 mL/kg Normal Saline bolus over 20 mins. Reassess, up to 60 mL/kg total.
  2. Deficit Calculation: Deficit (mL) = Weight (kg) × 10 × % dehydration.
  3. Total Fluid: Add Deficit + Maintenance. Divide total: give half over the first 8 hours, and the remaining half over the next 16 hours.

Sodium Imbalances

Table 12: Etiology of Hyponatremia (Na < 130 mmol/L)

• Hypernatremia (Na > 150 mmol/L): Loss of water in excess of salt. Child presents irritable with "doughy" skin. Risk of cerebral thrombosis/hemorrhage. Treatment: Avoid hypotonic solutions. Correct slowly over 48-72 hours to prevent cerebral edema.

Acid-Base Disorders

• Anion Gap (AG): Na - (Cl + HCO3). Normal is up to 14-16.
• Metabolic Acidosis (High AG): Endogenous acid (DKA, lactic acidosis) or exogenous (ethylene glycol) or uremic acidosis.
• Metabolic Acidosis (Normal AG / Hyperchloremic):
  • Extrarenal: Diarrhea.
  • Renal Tubular Acidosis (RTA):
    • Visual Integration (Proximal Tubule - Type 2 RTA): A cellular diagram shows the Na+/H+ exchanger (NHE3) and Carbonic Anhydrase (CA II/IV) reabsorbing HCO3. Defect causes massive HCO3 loss, obligate Na/K loss, and hypokalemia. Urine pH can drop < 5.5.
    • Visual Integration (Distal Tubule - Type 1 RTA): A cellular diagram illustrates the H+-ATPase and the basolateral HCO3-/Cl- exchanger (AE1). Defect prevents urine acidification (urine pH stays > 5.5). Associated with nephrocalcinosis and hypocitraturia.
• Metabolic Alkalosis:
  • Chloride Responsive (Urine Cl < 10): Vomiting, NG suction, Cystic Fibrosis.
  • Chloride Resistant (Urine Cl > 20): Bartter syndrome, Gitelman syndrome, renal artery stenosis.

Part 4: Nephrotic Syndrome (NS)

Diagnosis and Pathophysiology

• Diagnostic Criteria:
  1. Heavy Proteinuria: > 50 mg/kg/day OR > 40 mg/m²/hour. Spot urine protein/creatinine ratio > 2.0. (Normal is < 0.2).
  2. Hypoalbuminemia: < 2.5 g/dL.
  3. Edema (Peripheral, ascites, scrotal/labial).
  4. Hypercholesterolemia.
• Mechanism of Edema:
  • Underfill Hypothesis: Heavy protein loss → low serum albumin → decreased oncotic pressure → fluid shifts to interstitium (edema). Intravascular hypovolemia activates renin/aldosterone. Signs: tachycardia, pallor, poor perfusion, FENa < 0.2%, UK/UK+Na > 60%.
  • Overfill Hypothesis: Primary renal defect causing sodium retention. Presents with normal/high BP, no tachycardia, FENa > 0.2%, and decreased circulating renin/aldosterone.

Histological Classifications

• Visual Integration (Renal Histopathology):
  • Minimal Change Disease (MCD): Light microscopy (LM) is entirely normal. However, Electron Microscopy (EM) demonstrates the classic effacement of visceral epithelial foot processes (podocytes). MCD accounts for >85% of childhood NS cases.
  • Focal Segmental Glomerulosclerosis (FSGS): LM shows sections of the glomerulus obliterated by pink, dense sclerotic scar tissue, while other segments remain open.
  • Membranous Nephropathy: LM reveals a globally thickened glomerular basement membrane with prominent, rigid capillary loops.

Management

• Non-Pharmacological: Low salt diet, restricted fatty foods. Fluid restriction is only indicated if serum Na < 125 mEq/L or if there is concurrent ARF.
• Pharmacological:
  • Steroids: Prednisone is first-line. Initial episode dosing: 2 mg/kg/day (or 60 mg/m²/day) for 4 weeks, followed by 40 mg/m²/day given every other day (EOD) as a single morning dose for 4 weeks, then stop.
  • Steroid-sparing agents: Used for steroid-dependent or frequent relapsers (Levamisole, Cyclosporin, Tacrolimus, Mycophenolate).
• Albumin Infusions: Indicated for severe scrotal/labial edema, profound hypovolemia, or severe anasarca. Must be used cautiously (often with diuretics) if volume status is unknown to prevent pulmonary edema.
• Complications:
  • Disease-related: High risk of infections (peritonitis, cellulitis, UTI) due to loss of IgG and complement factors. High risk of hypercoagulability (thromboembolism).
  • Steroid-related: Growth restriction, bone disease, and posterior subcapsular cataracts (requires ophthalmology consult every 6 months).

Part 5: Approach to Hematuria in ChildrenYear 6

Evaluation of Hematuria

• Definition: Microscopic hematuria is > 5 RBCs per high-power field (HPF) in centrifuged urine. Macroscopic is visible red/brown urine. Isolated microscopic hematuria prevalence is 0.5-2%.
• Causes of Red Urine (Dipstick Positives & False Positives): Hematuria (RBCs), Hemoglobinuria (e.g., G6PD deficiency), Myoglobinuria (rhabdomyolysis), Drugs (Rifampin), food/dyes, urate crystals, or porphyrins.
  • Testing Algorithm: Centrifuge the urine. If sediment is red → Hematuria. If supernatant is red → test with dipstick. If dipstick heme is positive → Myoglobin or Hemoglobin. If dipstick is negative → Porphyria, drugs, or beets.

Table 13: Distinguishing Extraglomerular from Glomerular Hematuria

• Visual Integration (Urine Microscopy): A comparative image shows Phase-contrast microscopy of urine sediment. The glomerular sample reveals distinctly dysmorphic RBCs (acanthocytes) with vesicle-shaped protrusions (Mickey Mouse appearance), confirming glomerular bleeding.

Specific Hematuria Syndromes

1. Acute Post-Streptococcal Glomerulonephritis (APSGN)

• Follows GABHS infection (pharyngitis in winter, pyoderma in summer) after a latent period of 10-14 days (throat) or 3-6 weeks (skin).
• Clinical Phenotype: Macroscopic/gross hematuria (40%), Hypertension (60-75%), Azotemia (30-40%), Oliguria (25-35%).
• Labs: Positive ASOT, Low C3 level (resolves in 6-8 weeks). Urine shows RBC casts.
• Management: Fluid restriction, loop diuretics, antihypertensives. Gross hematuria resolves in ~1 week. Progression to ESRD is uncommon.
• Indications for Biopsy (Table 20-2): Short latent period, severe anuria, rapidly progressive course, HTN > 2 weeks, normal complement levels, or extrarenal manifestations.

2. IgA Nephropathy

• Most common in the second decade (males).
• Presentation: Recurrent macroscopic hematuria with loin pain during or immediately after (1-2 days) a viral URTI.
• Diagnosis: Immunofluorescence shows diffuse IgA and C3 mesangial deposits.
• Treatment (KDIGO 2021): RAS blockade (ACEi/ARB) for proteinuria > 200 mg/d. Glucocorticoids added if proteinuria > 1 g/d.

3. IgA Vasculitis (Henoch-Schönlein Purpura - HSP)

• Visual Integration (Clinical Sign): A photograph shows classic palpable purpura predominantly distributed on the lower limbs and buttocks of a child, the mandatory criterion for HSP.
• Presentation: Purpura, arthritis, abdominal pain. Renal involvement (20-55%) presents mostly as isolated microscopic hematuria. Requires monthly urinalysis screening for 3-6 months.

4. Hemolytic Uremic Syndrome (HUS)

• Visual Integration (Diagnostic Triad): A Venn diagram and blood smear establish the classic triad: 1) Acute Hemolytic Anemia (blood smear shows schistocytes/fragmented RBCs), 2) Thrombocytopenia, and 3) Reduced GFR (AKI).
• Pathogenesis: D+ HUS follows STEC (O157:H7) diarrheal infection. 5-15% of infected kids develop HUS. Risk increases with anti-motility drugs or antibiotic use (which causes rapid toxin release).

5. Hereditary Nephropathies

• Alport Syndrome: X-linked (80%). Deficiency of α5 chain of type IV collagen. Presents with microscopic hematuria, progressing to ESRD and high-frequency sensorineural deafness by age 30 (in males). Ocular changes include anterior lenticonus. EM shows splitting/lamination of the GBM ("basket weave").
• Thin Basement Membrane Nephropathy (Benign Familial Hematuria): Autosomal dominant. Persistent microscopic hematuria with NO progression to renal failure. EM shows isolated thinning of the GBM.

Neurology

Part 1: Pediatric Epilepsy, Paroxysmal Disorders, and Headache

1. Evaluation of Paroxysmal Events ("Spells") and Seizures

A meticulous history and physical exam are the cornerstones of evaluating paroxysmal events.

History of Spells

• Description & Onset: Ask for a detailed description and video footage if available. Determine if the onset and termination were abrupt or gradual.
• Specific Symptoms:
  • Abnormal tone: Going limp (atonic) or tensing up (tonic).
  • Abnormal eye movements: Staring, deviation, or flickering.
  • Color change: Cyanosis or pallor.
  • Awareness: Altered level of consciousness.
  • Interruption: Can the spell be stopped by touching or speaking to the child?
• Timing & Triggers: Note the duration, frequency, and whether spells cluster. Identify triggers (stress, crying, injuries, hyperventilation). Note relationship to meals, position, and sleep-wake transitions. Determine if spells occur during sleep.
• Associated Changes: Any changes in behavior or developmental regression since the spells began.
• General History: Review recent events (trauma, illness, new medications, social changes), perinatal history, developmental milestones, and family/past medical history.

Evaluation of Confirmed Seizures

• Physical Exam: Look for underlying provoking factors such as hypoglycemia, hypocalcemia, hyponatremia, head injury, drug ingestion, CNS infection, or tumors. Treat the provoking factor accordingly.
• Work-Up for Unprovoked Seizures:
  • Electroencephalogram (EEG): Required for risk stratification.
    • One unprovoked seizure + Normal EEG: Recurrence risk is ~40%.
    • One unprovoked seizure + Abnormal EEG: Recurrence risk is ~60%.
  • Neuroimaging: A brain MRI is specifically indicated if there is a concern for focality based on history or examination.
  • Additional Tests: Consider genetic, metabolic, and CSF studies based on the clinical picture.

2. Definitions and ILAE Classifications

• Seizure: A transient occurrence of signs or symptoms resulting from abnormal excessive or synchronous neuronal activity in the brain.
• Epilepsy: A disease of the brain defined by any of the following:
  1. At least two unprovoked (or reflex) seizures occurring >24 hours apart.
  2. One unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures over the next 10 years.
  3. Diagnosis of an epilepsy syndrome.

ILAE 2017 Classification of Seizure Types

Visual Integration: The lecture presents the ILAE 2017 block chart, categorizing seizures by their anatomical onset.

• Focal Onset: Can be Aware or Impaired Awareness. Subdivided into Motor Onset (automatisms, atonic, clonic, epileptic spasms, hyperkinetic, myoclonic, tonic) and Nonmotor Onset (autonomic, behavior arrest, cognitive, emotional, sensory). Can evolve from focal to bilateral tonic-clonic.
• Generalized Onset:
  • Motor: Tonic-clonic, clonic, tonic, myoclonic, myoclonic-tonic-clonic, myoclonic-atonic, atonic, epileptic spasms.
  • Nonmotor (Absence): Typical, atypical, myoclonic, eyelid myoclonia.
• Unknown Onset: Motor (tonic-clonic, epileptic spasms), Nonmotor (behavior arrest), or Unclassified.

Table 1: Clinical Definitions of Major Seizure Types

ILAE Diagnostic Framework (4 Steps)

Visual Integration: A 4-step flowchart illustrates the progression of epilepsy diagnosis.

• Step 1: Seizure Type (Focal, Generalized, Unknown).
• Step 2: Epilepsy Type (Focal, Generalized, Combined Generalized & Focal, Unknown).
• Step 3: Etiology
  • Structural: Vascular, trauma, tumor, cortical dysplasia, HIE.
  • Genetic: Trisomies, Angelman, Klinefelter, Tuberous Sclerosis, GLUT1 deficiency, Dravet.
  • Immune: Rasmussen syndrome.
  • Infectious, Metabolic, Unknown.
• Step 4: Epilepsy Syndromes (Combining age, seizure type, EEG, and etiology).

ILAE Terminology Updates

• Encephalopathy Definitions:
  • Developmental Encephalopathy: Developmental impairment without frequent epileptic activity causing regression.
  • Epileptic Encephalopathy: No preexisting delay; the epileptic activity itself causes developmental slowing. Both can co-exist.
• Removal of "Benign": The descriptor "benign" is replaced by:
  • Self-limited: Refers to the likely spontaneous resolution of the syndrome.
  • Pharmacoresponsive: Means the syndrome is likely to be controlled with appropriate therapy.

3. Epilepsy Syndromes by Age

Visual Integration: Slide 11 categorizes syndromes into neonate/infantile, childhood, adolescent/adult, and variable age groups based on age of onset, seizure types, EEG, and etiology.

Neonatal/Infantile Syndromes (ILAE 2022 Updates)

• Self-Limited: Self-limited neonatal epilepsy (SeLNE), Self-limited familial neonatal-infantile epilepsy (SeLFNIE), Self-limited infantile epilepsy (SeLIE), Genetic epilepsy with febrile seizures plus (GEFS+), Myoclonic epilepsy in infancy (MEI).
• Developmental/Epileptic Encephalopathies (DEE): Early infantile DEE (EIDEE), Epilepsy in infancy with migrating focal seizures (EIMFS), Infantile epileptic spasms syndrome (IESS), Dravet syndrome (DS).
• Etiology-Specific: KCNQ2-DEE, Pyridoxine/Pyridoxal-5'-Phosphate dependent DEE, CDKL5-DEE, GLUT1 Deficiency, Sturge Weber, Gelastic seizures with hypothalamic hamartoma.

Table 2: Classic Pediatric Epilepsy Syndromes

Epidemiology Note: A demographic study in Jordan (Out of 663 patients) found that 90.2% had one seizure type (53% focal, 41.5% generalized). BECTS was the most common electroclinical syndrome (27.1%). Structural-metabolic causes (especially perinatal insults) accounted for 41.9%.

4. Treatment of Epilepsy

• Anti-Seizure Medications (ASMs):
  • Aim for the least number of medications at the lowest effective dose.
  • 70% of patients become seizure-free on monotherapy; an additional 15% on polypharmacy. 15% remain intractable.
  • Visual Integration: A graph shows AED development over time. Pre-1990 drugs include Bromide, Phenobarbital, Phenytoin, Primidone, Ethosuximide, Valproate, Carbamazepine. Post-1990 shows a rapid explosion of new drugs (Lamotrigine, Topiramate, Levetiracetam, etc.).
• Mechanism of Action:
  • Voltage-Dependent Sodium Channels: Old (Carbamazepine, Phenytoin), New (Lamotrigine, Oxcarbazepine, Zonisamide, Lacosamide, Rufinamide).
  • Calcium Currents: Ethosuximide.
  • GABA Activity: Benzodiazepines, Barbiturates, Gabapentin.
  • Glutamate Receptors: Topiramate.
  • Multiple Mechanisms: Topiramate, Valproic acid.
  • Unknown: Levetiracetam.
• Drug-Resistant Epilepsy (DRE):
  • Defined as failure of seizure control after adequate therapy with two or more appropriate ASMs.
  • Options: Ketogenic diet, Vagal Nerve Stimulation (VNS), Epilepsy surgery (resection, callosotomy).
  • Visual Integration: Diagram of VNS showing a pacemaker-like device in the chest connected to the vagus nerve in the neck.
  • Note: Surgery is indicated earlier if drug-resistance is highly expected (e.g., mesial temporal lobe epilepsy with hippocampal sclerosis).

5. Status Epilepticus (SE)

• Definition: Ongoing seizure activity for >5 minutes, or recurrent seizures with no return to baseline for >30 minutes. Results from failure of seizure termination mechanisms or initiation of abnormal prolongation mechanisms. Can cause neuronal death and network alterations.

Table 3: Operational Dimensions of SE (ILAE 2017)

• Evaluation and Treatment Timeline:
  • Initial: ABCs, Check serum glucose, Vital signs. Evaluate etiologies (noncompliance, infection, meningitis, toxicity, head injury).
  • 0–5 minutes: IV Benzodiazepine (Diazepam, Midazolam).
  • 5–10 minutes: Benzodiazepine (second dose).
  • 10–15 minutes: Fosphenytoin (second line), Phenobarbital.
  • 15–30 minutes: Phenobarbital, Valproic acid, Pyridoxine.
  • >30 minutes (Refractory SE): Obtain anesthesiology consult. Use continuous infusions of Midazolam, Pentobarbital, Thiopental, Propofol, or Ketamine (titrated with EEG).

6. Neonatal and Febrile Seizures

• Febrile Seizures: Occur between 6 months and 5 years, associated with fever, without CNS infection, previous unprovoked/neonatal seizures.
  • Simple: <15 minutes, generalized, does not recur within 24 hours.
  • Complex: >15 minutes, focal, and/or recurs within 24 hours.
  • Management: Evaluation directed at fever etiology; routine tests not done. Daily prophylactic ASMs are not used. Antipyretics do not prevent seizures. Rescue rectal/nasal Diazepam used if >4 minutes.
• Neonatal Seizures: Incidence is highest during this period (60/1000 in <1.5kg; 3/1000 in 2.5-4kg).
  • Types: Subtle (transient eye deviations, nystagmus, blinking, apnea, mouthing—most common in preterms), Clonic, Tonic, Spasms, Myoclonic.
  • Etiology by Age:
    • 1-4 Days: HIE, drug withdrawal/toxicity, intraventricular hemorrhage, acute metabolic.
    • 4-14 Days: Infection, metabolic, drug withdrawal, Benign familial, Kernicterus.
    • 2-8 Weeks: Infection, head injury, inherited metabolic, cortical malformations (Lissencephaly, Tuberous Sclerosis).
    • Any Age: Pyridoxine deficiency.
  • Treatment: Treat underlying cause. Phenobarbital is 1st line. Others: Phenytoin, Levetiracetam, Lorazepam, Midazolam.
  • Prognosis: Mortality has decreased to 20%. Poor predictors: Abnormal EEG background, prolonged electrographic seizures (>10 min/hr), multifocal periodic discharges, contralateral spread.

7. Epilepsy Imitators

• Syncope and Anoxic Seizures:
  • Affects all ages, brief (seconds to minutes), preceded by triggers. Upright posture causes lightheadedness, pallor, sweating. Convulsive movements occur in 50%.
  • Breath-holding attacks / Reflex anoxic seizures: Affect preschool children. Start with crying -> stop breathing in expiration -> turn blue/pale -> go into transient syncope with possible tonic posturing. Worse with iron deficiency anemia (Check Ferritin).
  • Cardiac Syncope: Long QT syndrome, Ventricular tachyarrhythmia (triggered by fright, surprise, water immersion). Syncope in sleep or family history of sudden death mandates cardiac workup. Visual: ECG comparing a Normal ECG to a Long-QT ECG.
• Behavioral/Psychiatric: Daydreaming, infantile gratification (rhythmic hip flexion/adduction in preschool girls with flushed face, followed by sleepiness), tantrums, panic attacks, non-epileptic seizures.
• Sleep-Related: Hypnogogic jerks, parasomnias, REM sleep disorders, Narcolepsy-cataplexy, Benign neonatal sleep myoclonus (myoclonic jerks only in sleep, healthy newborn, normal exam, resolves without intervention).
• Paroxysmal Movement Disorders:
  • Tics: Involuntary, sudden, rapid, non-rhythmic. Waxes and wanes. Suppressible with an urge to perform.
  • Stereotypies: Semi-voluntary, non-rhythmic, involves arms/legs more than face. Early childhood onset, persists. No urge, easily interrupted by distraction. Common in autism.
  • Hyperekplexia: Exaggerated normal startle response. Evident from neonatal period. Responds to benzodiazepines.
• Migraine-Associated Episodic Syndromes: Cyclical vomiting, Abdominal migraine, Benign paroxysmal vertigo (brief vertigo without warning, resolves spontaneously in minutes to hours), Benign paroxysmal torticollis.
• Miscellaneous: Sandifer syndrome (arching of back, dystonic posturing of limbs/head, seen with GERD after feeding).

8. Headache in Children

• Prevalence: 35-50% in 7-year-olds; 60-80% by age 15.
• ICHD-3 Classification:
  1. Primary Headaches (Migraine, Tension, Trigeminal autonomic cephalalgias, Other).
  2. Secondary Headaches (Attributed to trauma, vascular disorder, substance withdrawal, infection, homeostasis, psychiatric).
  3. Painful cranial neuropathies and other facial pains.
• Primary Headaches:
  • Migraine: Affects 5%. Equal in young males/females; shifts to female predominance in adolescence. Pathophysiology involves elevated Calcitonin gene-related peptide (CGRP). Symptoms: Throbbing, nausea/vomiting, photophobia, phonophobia, aura. Not necessarily unilateral. Tx: Lifestyle, CBT, Rescue (Acetaminophen, NSAIDs, Triptans), Prophylaxis (Propranolol, Topiramate, Amitriptyline).
  • Tension Headache: Affects 5-10%. Equal male/female. Symptoms: Bilateral, pressing/tightening, mild-moderate, "featureless". Tx: Lifestyle, Acetaminophen/NSAIDs. Prophylaxis usually not needed.
• Secondary Headaches & Red Flags:
  • Red Flags: Side-locked, worse laying down/Valsalva/cough, worse standing upright, wakes patient from sleep, new-onset with meningitis signs, focal neurologic signs, abnormal exam (papilledema), immunocompromised.
  • Causes: Tumor, bleeding, Concussion, Infection, TMJ.
  • Idiopathic Intracranial Hypertension (IIH): Visual Integration: MRI shows classic signs: Bilateral papilledema (arrows pointing to flattened posterior sclera in orbits), Empty sella turcica (arrow pointing to flattened pituitary gland in sagittal view), and slit-like ventricles (arrow pointing to compressed lateral ventricles in axial view).

Part 2: Approach to the Hypotonic Infant

1. Introduction and Pathophysiology

• Hypotonia: Decreased resistance to passive movement (a "floppy" infant). Hyperextensibility of joints usually accompanies it but is not pathognomonic.
• Weakness: Reduction in the maximum power generated. Note: Weak infants always have hypotonia, but hypotonia may exist without weakness.
• Muscle Tone Definitions:
  • Phasic Tone: Rapid, short-lived resistance resulting from rapid stretching of a tendon/muscle (mediated by the muscle spindle).
  • Postural Tone: Steady, restrained stretch on tendons/muscles resulting in protracted contraction (gravity is the main stimulus).
• Pathophysiology:
  • The central and peripheral nervous systems modify tone, but intrinsic physical characteristics of tendons, joints, and muscles contribute.
  • The final common pathway of tone modification is the gamma loop (fusimotor) system.
  • Visual Integration (Muscle Spindles & Golgi Tendon Organs): Detailed diagrams show stretch-sensitive receptors.
    • Muscle Spindles: Located in parallel with muscle fibers. Contain intrafusal fibers (nuclear chain, dynamic/static nuclear bag fibers). Sensory endings wrap around the central sections to monitor stretch. Gamma motor neurons (efferent) innervate the contractile ends, maintaining sensitivity to stretch.
    • Golgi Tendon Organs: Located in series with skeletal muscle fibers at the tendon. Afferent axons are compressed during muscle contraction, transmitting impulses.

2. Clinical Evaluation

• History:
  • Age of onset, prenatal history (decreased fetal movement, fluid levels), maternal exposures (toxins/infections).
  • Low Apgar scores suggest sepsis (a hypotonic newborn is septic until proven otherwise). A healthy term infant becoming floppy at 12-24 hours suggests an inborn error of metabolism.
  • Course: Fluctuating, static, or progressive. Acute progressive weakness suggests Infantile Botulism.
  • Family history is crucial (positive in ~50% of hypotonic infant neuromuscular cases).
• Physical Examination:
  • Fixed Contractures: Suggests antenatal insult or primary bone/muscle disorder preventing fetal movement.
  • Visual Integration of Postures & Signs:
    • "Frog-leg" Position: Infant lies supine with lower limbs externally rotated and abducted.
    • Plagiocephaly: Frequently present due to immobility.
    • Facial Weakness: Myopathic facies, poor suck/swallow, ptosis (suggests genetic myopathies). Visual: Photos of infants with tented upper lips and expressionless, myopathic faces.
    • Tongue: Check for atrophy and fasciculations (hallmark of SMA). Visual: Photo showing scalloped, fasciculating tongue.
    • Chest: Pectus excavatum/bell-shaped chest indicates intercostal muscle weakness.
    • Locomotion: Combat crawl, W-sitting, astasia (inability to stand), waddling gait.
    • Suspension Tests:
      • Horizontal: Infant drapes in an inverted "U" shape over the examiner's hand.
      • Vertical: Infant "slips through" the examiner's hands when held under the arms.
      • Traction: Severe head lag/hyperextension when pulled to a sitting position.
    • Scarf Sign: Arm wraps easily across the chest beyond the midline.
    • Heel-to-Ear: Extreme passive foot dorsiflexion touching the ear.

3. Differentiating Central vs. Peripheral Hypotonia

• Epidemiology: Central causes = 60-80%; Peripheral causes = 15-30%.
• Central Clues: Failure to track visually, lack of facial imitation, lethargy, normal strength with hypotonia, hyperactive/normal reflexes, dysmorphic features, fisting of hands, scissoring, seizures, apnea.
• Peripheral Clues: Alert, normal sleep-wake patterns, profound weakness, hyporeflexia/areflexia, muscle atrophy, respiratory/feeding impairments.

Table 4: Localization of Disorders Producing Hypotonia

4. Etiologies of Hypotonia

Upper Motor Unit (Central) Diseases:

• Cerebral insults: HIE, hemorrhage, thrombosis.
• Chromosomal: Angelman, Down syndrome, Prader-Willi.
• Metabolic: Carnitine deficiency, Gangliosidosis, Tay-Sachs, Lowe's syndrome, organic acidemias.
• Toxicity: Bilirubin, Magnesium, Phenobarbital, Sedatives.
• Trauma: Brain, Spinal Cord.

Lower Motor Unit (Peripheral) Diseases:

• Anterior Horn Cell: SMA, Kugelberg-Welander, Poliomyelitis.
• Peripheral Nerve: Familial dysautonomia, Guillain-Barre, CMT.
• NMJ: Botulism, Myasthenia Gravis (transient or congenital).
• Muscle: Congenital myopathies, Glycogen storage diseases (Pompe), Myotonic dystrophy.

5. Diagnostic Yield and Workup

Table 5: Diagnostic Yield for Hypotonia

• Laboratory Evaluation: First rule out systemic disorders (sepsis). Check electrolytes, liver function, ammonia, glucose, CK.
  • If acidosis is present: Check plasma amino acids, urine organic acids, lactate, pyruvate, acylcarnitine. Very long-chain fatty acids indicate peroxisomal disorders.
  • TORCH titers: If hepatosplenomegaly and calcifications are present.
• Diagnostic Algorithms:
  • Visual Integration (EMG/MNCV Flowchart):
    1. Denervation (Large CMAPs, Fibrillations) -> SMA genetic test (SMN 1/2).
    2. Myopathy + Irritability (Small CMAPs) -> Acid Maltase Enzyme assay (Pompe).
    3. Myopathic (Small CMAPs) -> Muscle Biopsy.
  • Visual Integration (Muscle Biopsy Flowchart):
    1. Nonspecific -> Check for Myotonic/Duchenne.
    2. Characteristic Pathology (Central core, Nemaline) -> Genetic confirmation.
    3. Dystrophic Muscle -> Differentiate by Brain Involvement (Merosin stains).
• Radiologic Evaluation: MRI delineates structural defects.
  • Visual Integration: MRI images show an abnormal corpus callosum in Smith-Lemli-Opitz syndrome, deep white matter changes in Lowe syndrome (peroxisomal defect), and structural brain abnormalities/heterotopias in congenital muscular dystrophy.

6. Specific Case Studies in Hypotonia

1. Pompe Disease (Acid Maltase Deficiency): 6-month-old, large tongue, normal labs, massive cardiomegaly on CXR. Autosomal recessive lysosomal storage disease. Causes hypertrophic cardiomyopathy, weakness, respiratory failure. Tx: Enzyme replacement therapy.
2. Infantile Botulism: 3-month-old, sudden onset weakness, poor head control, ptosis, sluggish pupils, poor suck, absent DTRs. Grandma fed him honey. Toxin blocks pre-synaptic acetylcholine. Tx: Botulism immune globulin.
3. Spinal Muscular Atrophy Type 1 (Werdnig-Hoffman): 5-month-old, unable to raise body, but socially interactive (squealed/responded to name - normal intellect). Marked hypotonia, absent DTRs, tongue fasciculations. Normal CK/MRI. EMG shows anterior horn cell dysfunction. Dx via SMN gene testing.
4. Kabuki Syndrome: Dysmorphic features, prominent fingertip pads, hypotonia, skeletal abnormalities, mild-moderate ID. Mutated KMT2D or KDM6A genes.
5. Fragile X Syndrome: Mild infantile hypotonia, macrocephaly, prominent ears, large testicles. Trinucleotide repeat (CGG) in FMR1 gene.
6. Prader-Willi Syndrome: Neonatal profound hypotonia and feeding problems, evolving to hyperphagia and obesity by 1 year. Almond-shaped eyes, small hands/feet. Caused by deletion of paternal chromosome 15q11-q13 (75%), maternal uniparental disomy (20%), or imprinting mutation (5%).

Part 3: Localization-Based Neurological Diseases in ChildrenYear 6

This section localizes diseases along the neuroaxis using clinical and diagnostic markers.

Visual Integration (Neuroaxis Diagram): A schematic maps diseases to anatomy:

• Cerebrum: Autoimmune Encephalitis, ADEM.
• Cerebellum: Opsoclonus Myoclonus Ataxia Syndrome.
• Spinal Cord: Transverse Myelitis, Acute Flaccid Myelitis, Spinal Muscular Atrophy, Poliomyelitis.
• Peripheral Nerve: Guillain-Barre Syndrome, Charcot-Marie-Tooth.
• Neuromuscular Junction: Myasthenia Gravis, Botulism.
• Muscle: Duchenne Muscular Dystrophy, Dermatomyositis.

Table 6: UMN vs. LMN Lesions

1. Central Nervous System Diseases

Autoimmune Encephalitis

• Overview: Immune-mediated inflammatory brain disorder. Subacute presentation.
• Symptoms: Encephalopathy, psychosis, movement disorders, focal deficits. In children, symptoms may initially be subtle behavioral or sleep disturbances.
• Investigations:
  • CSF: Elevated protein, lymphocytic pleocytosis, elevated IgG index, oligoclonal bands.
  • Labs: Anti-NMDA, Anti-GAD65 antibodies.
  • EEG: Abnormal in 90% (generalized slowing).
  • MRI: Visual Integration: MRI slices show hyperintense inflammatory signaling in cortical and subcortical regions (e.g., Anti-NMDA encephalitis).
• Treatment: IV steroids, IVIG, plasmapheresis. (Second line: Rituximab, cyclophosphamide). Risk of relapse.

Acute Disseminated Encephalomyelitis (ADEM)

• Overview: Immune-mediated inflammatory demyelinating condition of CNS white matter. Usually affects pre-pubertal children (<10 yrs). Typically preceded by a febrile infection or immunization (Peaks Oct-March).
• Symptoms: Fever, acute encephalopathy (sleepiness to coma), polyfocal neurologic deficits (ophthalmoplegia, vision loss, ataxia, cranial nerve abnormalities). 85% show hyperreflexia, clonus, upgoing toes.
• Investigations: Visual Integration: MRI shows diffuse, poorly demarcated large hyperintense lesions predominantly in the white matter.
• Treatment & Prognosis: IV steroids, IVIG. Typically monophasic with excellent recovery. Poorest recovery in children <2 yrs or with severe edema. A subset has anti-MOG antibodies and is prone to relapse.

Opsoclonus Myoclonus Ataxia Syndrome (OMAS)

• Overview: Rare immune-mediated disease. 50% of pediatric cases have an underlying Neuroblastoma; the rest are post-infectious/autoimmune.
• Symptoms: Opsoclonus (chaotic eye movements), Myoclonus, Ataxia (wide-based gait, titubation, dysmetria), behavioral/mood issues. Visual Integration: Videos/Photos show a child with erratic eye movements and unsteady, wide-based stance.
• Investigations: Serum/CSF antibodies. Body imaging (US/CT/MRI) to hunt for neuroblastoma. Visual Integration: Brain MRI shows progressive cerebellar atrophy over 5 years (widened sulci and extracerebellar spaces).
• Treatment: IV steroids, IVIG, treatment of underlying neuroblastoma.

Transverse Myelitis (TM)

• Overview: Inflammatory demyelinating disorder of the spinal cord. Bimodal age distribution (<5 yrs and >10 yrs). Preceded by infection/vaccination in up to 66%.
• Symptoms: First presentation in children is usually back pain. Rapidly progressive lower extremity weakness. Initially flaccid/areflexic, evolving to increased tone/DTRs below the lesion. Sensory level is typically thoracic. Sphincter/urinary dysfunction is common.
• Investigations: Visual Integration: Sagittal spinal MRI with contrast reveals a longitudinally extensive, hyperintense enhancing lesion in the spinal cord across one or two vertebral segments (e.g., T6-T10). Cytoalbuminologic changes in CSF.
• Prognosis & Recurrence: ~50% recover after 2 years. Worse outcome in infants, rapid onset, complete paraplegia. Predictors of recurrence: extensive MRI lesions, autoantibodies (ANA, dsDNA, NMO-IgG anti-Aquaporin-4), oligoclonal bands.

Acute Flaccid Myelitis (AFM)

• Overview: Viral infection of anterior horn cells. Resembles polio. Median age 6 years. Strongly associated with Enterovirus EV-D68 (also EV-D71, coxsackievirus).
• Symptoms: Respiratory prodrome (cough/fever) followed in 1-10 days by acute, asymmetric flaccid limb weakness favoring upper limbs and proximal muscles. Hyporeflexia, cranial nerve/diaphragm weakness.
• Investigations: CSF pleocytosis (virus usually not detected in CSF; check respiratory/stool samples). NCS shows motor neuronopathy. Visual Integration: MRI is the most helpful test, showing longitudinally extensive lesions largely restricted to the gray matter (bright "H" sign on axial views), mostly in the cervical cord.
• Treatment & Prognosis: Supportive (airway, rehabilitation). Steroids/IVIG not proven helpful. Poor prognosis (<10% achieve full recovery).

2. Peripheral Nervous System Diseases

Guillain-Barre Syndrome (GBS)

• Overview: Autoimmune post-infectious demyelinating polyneuropathy. Typical age 4-8 yrs.
• Pathology: Main type is AIDP (acute inflammatory demyelinating polyneuropathy). Triggers: Campylobacter, CMV, EBV, Mycoplasma, vaccines, surgery.
• Symptoms: Ascending symmetric weakness starting with paresthesias in toes/fingertips, progressing to arms/respiratory muscles. Flaccid paralysis, absent reflexes. Pain is prominent in children.
• Investigations:
  • Antibodies: GM1, GM1b, GD1a in AIDP. GQ1b in Miller Fisher variant.
  • CSF: Cytoalbuminologic dissociation.
  • NCS: Conduction block.
  • Visual Integration: Axial MRI with contrast shows classic nerve root enhancement.
• Treatment & Prognosis: IVIG or Plasma exchange. Steroids are not helpful and may be harmful. Outcome in children is favorable; recovery takes 6-12 months.

Charcot-Marie-Tooth Disease (CMT)

• Overview: Hereditary peripheral neuropathy. >50% caused by duplication of PMP22 gene on chromosome 17.
• Symptoms: Distal weakness, decreased sensation, absent reflexes. Visual Integration: Clinical photos demonstrate the "inverted champagne bottle" sign (distal muscle atrophy of the calves), high arched feet (pes cavus), and hammer toes.
• Investigations: NCS shows delayed motor/sensory velocities. EMG differentiates from myopathy.

3. Neuromuscular Junction Diseases

Infantile Botulism

• Overview: Ingestion of C. botulinum spores (dust, soil, raw honey) which colonize the GI tract and release toxin. Ages 2-26 weeks.
• Pathophysiology: Visual Integration: Synapse diagram shows the botulinum toxin blocking the release of acetylcholine vesicles at the pre-synaptic membrane.
• Symptoms: Constipation and poor feeding -> descending flaccid paralysis. Cranial nerves first (poor suck/gag, ptosis, pupillary paralysis) -> trunk/extremity weakness -> respiratory failure.
• Treatment: Botulism immune globulin IV (BIG-IV / BabyBIG).

Myasthenia Gravis (MG)

• Overview: Autoimmune antibody-mediated disease affecting the post-synaptic NMJ. Visual Integration: Synapse diagram shows antibodies blocking post-synaptic receptors, reducing transmission.
• Types: Transient neonatal (10-15% of babies born to MG mothers). Congenital myasthenia is genetic, not autoimmune.
• Symptoms: Ptosis, diplopia. Exacerbated by activity (fatigability), relieved by rest.
• Investigations: Ice pack test, Anti-AChR/Anti-MuSK antibodies, EMG/NCS.
• Treatment: Pyridostigmine, immunotherapy, thymectomy.

4. Muscle Diseases

Duchenne Muscular Dystrophy (DMD)

• Overview: X-linked recessive disorder caused by a defective DMD gene on the X chromosome, halting dystrophin production. Visual Integration: Pedigree chart proves X-linked inheritance (affects males, females are carriers).
• Symptoms: Progressive proximal muscle weakness, cardiomyopathy, cognitive dysfunction.
• Physical Exam:
  • Pseudohypertrophy: Enlarged calf muscles (replaced by fat).
  • Gower's Sign: Positive. Visual Integration: Sequential photos show a child using his hands to "walk" up his own legs to stand due to proximal pelvic girdle weakness.
• Investigations: Serum CK is massively elevated. DNA testing identifies the mutation (has largely replaced muscle biopsy).
• Treatment: Supportive, Steroids. Gene therapy (converts DMD to the milder Becker Muscular Dystrophy phenotype).

Nutrition

Part 1: The Physiology and Benefits of Breast Milk

1. Composition of Human Breast Milk

Breast milk is a dynamic, highly specialized fluid. An infographic in the lecture illustrates the composition of breast milk as a stack of building blocks: Macronutrients (water, protein, carbohydrates, fats) form the foundation, overlaid with Micronutrients (vitamins and minerals), and topped with highly specialized Immune Components (anti-parasites, anti-allergies, anti-viruses, hormones, and antibodies).

A. Macronutrient Breakdown

A pie chart detailing the specific macronutrient composition of human breast milk (in g/100mL) illustrates the following proportions:

• Water: 85%
• Carbohydrates (Lactose & HMOs): 7% (7.0 g/100ml)
• Lipids (Fats): 3.6 - 4% (3.8 g/100ml)
• Proteins: 0.9% (0.9 g/100ml)

B. Human Milk Oligosaccharides (HMOs)

HMOs are the third most abundant solid constituent in human milk (after lactose and lipids), existing in concentrations similar to proteins (~5-15 g/L).

• Structure: A diagram demonstrates that all HMOs are built on a foundational lactose molecule (which is the most abundant carbohydrate and energy source in all mammalian milk).
• Cross-Species Comparison: A gel electrophoresis diagram visually compares human milk to the milk of pigs, sheep, goats, and cows. The diagram clearly shows that human milk possesses the highest concentration and the most diverse repertoire of oligosaccharides among these species.
• Diversity: Over 200 HMO structures have been identified, with ~20 being "Major Structures."
• The Most Abundant HMO: 2'-Fucosyllactose (2'-FL) is a trisaccharide (lactose + fucose) and is the most abundant HMO, present in ~75-80% of mothers' breast milk (concentration ranging from 0.06 – 4.65 g/L).
• Function: HMOs serve as prebiotics. A diagram of the infant gut illustrates how HMOs pass through the digestive tract to promote the growth of beneficial bacteria (like Bifidobacterium), prevent harmful bacteria from adhering to the gastrointestinal mucosal surfaces, and stimulate the maturation of the intestinal epithelial surface.

C. Lipids (Fats)

Lipids are the major energy source in human milk, covering about half of the infant's energy supply.

• Human milk lipids are more unsaturated than cow's milk fat, making them better absorbed.
• Fatty Acids: Include saturated, monounsaturated, and polyunsaturated fatty acids (PUFAs).
• Omega-3 and Omega-6 PUFAs (DHA and Arachidonic Acid): These are essential because the human body cannot produce them. They must be supplied through the diet and are critical for supporting brain structure and function.

D. Immune Components and Bioactive Molecules

Breast milk provides both passive and active immunity, protecting against infection and inflammation while contributing to immune maturation and organ development.

• Cells: White blood cells (B cells produce antibodies; T cells regulate immune responses) and Macrophages (phagocytose and destroy pathogens). Neutrophils provide first-line defense.
• Secretory Immunoglobulin A (IgA): Found in high concentrations in colostrum. It is critical for antiviral/antibacterial defense as it coats the lining of the infant's intestines, preventing germ leakage. Breast milk also contains IgG and IgM.
• Lysozyme: Provides antimicrobial protection by breaking down bacterial cell walls. It is highly effective against gram-positive bacteria.
• Cytokines and Chemokines: Molecules such as IL-1, IL-6, TNF-α, and TGF-β regulate immune responses, inflammation, and cell signaling.
• Extracellular Vesicles (EVs) & Exosomes: Diverse membrane-bound particles that play a role in cell-to-cell communication, reducing inflammation, and enhancing gut health.
• Stem Cells: Can cross the infant's GI tract, enter the circulatory system, populate distant organs, and contribute to tissue repair and development.

2. Dynamic Nature of Breast Milk

Breast milk changes in composition depending on the time since birth and the duration of a single feeding session.

Colostrum vs. Mature Milk

Foremilk vs. Hindmilk

A visual graphic of two baby bottles demonstrates the dynamicity of milk during a single feed:

• Foremilk: The milk at the beginning of a feed. It is visually watery and blue/clear-ish. It is high in water and lactose, serving to quench the baby's thirst.
• Hindmilk: The milk at the end of a feed. It is visually creamy and white/yellow. It contains significantly more fat and calories, providing satiety and energy for growth.

3. Benefits of Breastfeeding

Infographics in the lecture highlight the profound protective effects of human milk on both infant and maternal health.

• Infant Health Benefits (Reduced Risks):
  • Infectious: Severe lower respiratory tract infections (LRTI), Acute gastroenteritis (AGE), Acute otitis media (AOM). Breastfed children have a substantially lower risk of dying from infectious diarrhea (which claims 2,195 children under 5 daily).
  • Inflammatory/Autoimmune: Necrotizing enterocolitis (NEC) in preterms (human milk lowers the 5% risk by 6- to 10-fold), Childhood asthma, Atopic dermatitis, Type 1 Diabetes, Crohn's disease, Ulcerative colitis.
  • Other: Sudden infant death syndrome (SIDS), Childhood leukemia, Obesity.
• Cognitive Benefits: Rapid brain growth in the first 1000 days. Breastfed infants score higher on cognitive tests, linked to essential fatty acids (DHA), sphingolipids (axonal maturation), and sialic acid (cell-to-cell interaction).
• Maternal Benefits: Helps with weight loss, stimulates uterine contraction post-delivery, aids in ridding the body of pregnancy hormones, acts as a contraceptive (Lactation Amenorrhea Method - LAM), and lowers the long-term risk of Breast Cancer, Cardiovascular Disease (CVD), and Type 2 Diabetes.
• Economic Benefits: Investing in breastfeeding yields an estimated global economic gain of US$302 billion/year due to increased productivity associated with higher intelligence, and reduces annual healthcare costs by hundreds of millions globally.

Part 2: Infant Formulas and Artificial Feeding

While "Breast is Best," infant formulas are necessary when breastfeeding is not possible. A comparative table of mammalian milk reveals why cow's milk cannot be given directly to human infants: Cow's milk is too high in protein (3.4% vs 0.9%) and ash/minerals, and too low in lactose (4.8% vs 7.0%) compared to human milk. Furthermore, the protein in cow's milk forms difficult-to-digest "curds" (80% Casein), whereas human milk is primarily easy-to-digest whey protein.

1. Classification of Infant Formulas

Formulas are classified based on their macronutrient modifications:

A. Protein Content

1. Cow’s Milk-Based Formulas: Have variable protein content and variable whey-to-casein ratios to mimic human milk. (Examples: S26, Nan, Bebelac, Similac).
2. Soy Formulas: Use soy protein. Can be an option for infants >6 months. (Examples: Prosobee, Isomil).
3. Casein Hydrolysate Formulas: Proteins are broken down. Used for allergies or malabsorption.
   • Partial Hydrolysate: "Sensitive" or "HA" formulas (e.g., Bebelac HA, Nan HA).
   • Extensively Hydrolyzed: (e.g., Nutramigen, Alimentum, Pregestimil).
4. Amino Acid-Based Formulas: Proteins are completely broken down into elemental amino acids. Used for severe, unresponsive protein allergies. (Examples: Neocate, Elecare).

B. Carbohydrate Content

• Main types used: Lactose, Sucrose, Glucose polymers.
• Clinical Correlation: Patients with Galactosemia must be given formulas that do not contain lactose.

C. Fat Content

• Main types used: Long-chain triglycerides (LCTs) and Medium-chain triglycerides (MCTs).
• Physiological Mechanism: An anatomical diagram of an intestinal villus shows that LCTs require bile/micelles and are absorbed into the lacteal (lymphatic system) as chylomicrons. MCTs are absorbed directly into the capillary network (bloodstream) and sent to the liver.
• Clinical Correlation: MCT formulas (e.g., Portagen 87%, Pregestimil 55%, Alimentum 33%) are beneficial for infants with impaired fat absorption or lymphatic abnormalities.

2. Proper Preparation and Caloric Calculations

• Preparation: Hand washing is mandatory. Always read instructions. Most local market formulas (Nan, Bebelac, Seha) require 1 scoop per 30 mL of water. Exceptions: S26 and Similac require 1 scoop per 60 mL.
• Caloric Content: Regular formula and breast milk contain roughly 67 kcal per 100 mL (or 20 kcal per 30 mL/1 oz).
• Caloric Needs: Infants require at least 100 kcal/kg/day.
• Calculation Formula: Total Volume (mL) / Weight (kg) × Formula Caloric Concentration = kcal/kg/day
  • Example: 1-month-old, 4 kg, taking 90 mL every 3 hours (8 feeds/day = 720 mL total).
  • (720 / 4) × (67 / 100) = 180 × 0.67 = 120 kcal/kg/day (Adequate).

Part 3: Cow’s Milk Protein Allergy (CMPA)

• Definition: An adverse health effect arising from a specific immune response that occurs reproducibly upon exposure to cow's milk protein. It is the leading cause of food allergy in infants and children < 3 years old.
• Epidemiology: Prevalence is 2% - 3% in infants, but drops to < 1% in children 6 years and older.
• Pathophysiology: Can be IgE mediated (immediate/early reaction within minutes to 2 hours) or Non-IgE mediated (delayed/late reaction occurring 48 hours to 1 week later).
• Clinical Manifestations: Symptoms are often non-specific but typically involve the skin, GI tract, and respiratory tract. Involvement of >2 systems increases the probability of CMPA.
  • GI: Frequent regurgitation, colic, diarrhea +/- blood, constipation, failure to thrive.
  • Skin: Urticaria, atopic eczema, angioedema.
  • Respiratory: Runny nose, wheezing, chronic coughing.
  • General: Anaphylaxis (IgE mediated).
• Diagnosis: There is no single diagnostic test; it relies heavily on history and physical exam.
  • Patients with GI manifestations are more likely to have negative specific IgE/Skin Prick Tests (SPT) compared to those with skin manifestations.
  • A negative test does not exclude CMPA. A positive test indicates sensitization only. An oral challenge test is needed to confirm the diagnosis.
• Treatment:
  • Breastfed infants: The mother must start a strict CMP-free diet.
  • Formula-fed infants: Should receive an extensively hydrolyzed protein-based formula. Amino acid-based formulas are reserved for severe/unresponsive situations. Soy protein is an option only beyond 6 months of age.
  • Reevaluation: Assess for tolerance every 6 to 12 months. Tolerance is achieved in >75% by age 3, and >90% by age 6. Avoid overly long dietary eliminations.

Part 4: Failure to Thrive (FTT) and Nutritional Rehabilitation

• Definition: The inability to maintain the expected rate of growth over time. One set of measurements is not sufficient. Growth must be assessed by plotting parameters over subsequent visits.

1. Growth Charts: WHO vs. CDC

• WHO Growth Charts (0-2 years): International standards showing how healthy children should grow. Based on high-quality longitudinal studies of breastfed infants (the physiological norm) across six countries. Uses the 3rd and 97th percentiles as cutoff values.
• CDC Growth Charts (2-19 years): National references showing how US children did grow (cross-sectional studies from the 70s-90s). Uses the 5th and 95th percentiles as cutoff values. (Includes weight, height, head circumference, and BMI).

2. Types of Failure to Thrive (FTT)

Graphical representations of growth curves define three distinct types of FTT based on which parameters drop off the curve:

3. Nutritional Assessment and Rehabilitation

• Assessment: Includes detailed history (intake, losses, parental heights), anthropometrics (Weight:length ratio, BMI, skinfold thickness), physical exam (muscle wasting, edema), and labs (visceral proteins, CBC, electrolytes, zinc).
  • Wasting: Weight:length ratio <3rd percentile (acute malnutrition, seen in Type 1).
  • Stunting: Height <3rd percentile with normal weight:length (chronic malnutrition).
• Rehabilitation Strategy:
  • Use the enteral route using the most physiologic method tolerated: Increased caloric density → Oral supplements → Gastric bolus → Gastric continuous → Jejunal continuous.
  • Parenteral support (TPN) is strictly reserved for when the enteral route is impossible or inadequate.
• Complications of Nutritional Support:
  • Refeeding Syndrome: A severe risk in moderate to severe malnutrition characterized by dangerous shifts in electrolytes, specifically hypokalemia, hypomagnesemia, and hypophosphatemia. Prevent by advancing feedings/TPN very slowly and strictly monitoring/supplementing electrolytes.

Part 5: Breastfeeding Promotion, Policies, and BFHIYear 6

1. Breastfeeding Situation in Jordan (Epidemiology)

• Trends: Exclusive breastfeeding (EBF) rates in Jordan have historically fluctuated but remain low. Data shows a drop from 71% EBF at 6 months in the late 1970s to only 24% in 2023.
• Early Initiation: Early Initiation of Breastfeeding (EiBF) plummeted from 67% in 2018 to 34% in 2023.
• Causes for Cessation: A 2017 survey of working mothers in South Jordan showed that while mothers have good knowledge and attitudes, 30% ceased breastfeeding prematurely due to workplace factors (lack of convenient environments, short maternity leave). Other factors include the perception that formula is easier, social/commercial pressures, and lack of support from health professionals.
• Traditional Practices: Qualitative studies in Jordan show harmful practices persist, such as believing colostrum is "expired" or insufficient, giving anise/water, or giving honey/fenugreek at the first feed instead of breast milk.

2. Islamic Practices Regarding Breastfeeding

• Breastfeeding is viewed in the Qur’an as a God-given right of the child.
• While mothers often aim to breastfeed for two years, it is not mandatory, and complementary feeding is allowed.
• Wet Nursing & Milk Siblings: A recognized practice. Children regularly breastfed (3-5 times) by the same woman become "milk-siblings" and are prohibited from marrying each other.
• The Father's Role: Fathers are commanded to provide moral support, food, and clothing for the nursing mother. If the mother does not breastfeed, the father must find an alternative milk source and pay compensation fairly.
• Ramadan: Breastfeeding mothers with sound medical excuses are exempt from fasting during Ramadan.

3. National Policies and the BMS Code

• Jordanian Labor Law: Provides 90 consecutive days of fully paid maternity leave, up to one year of unpaid leave, and up to one hour per day (paid) for nursing breaks within the first year.
• BMS Code (International & Jordanian Law 2015): The Code of Marketing of Breast-milk Substitutes aims to regulate formula marketing.
  • Key Rules: No advertising/promotion of formula to the public, no free samples to mothers, no gifts to health workers. Labels cannot use pictures of infants or idealize artificial feeding.
  • Health workers must not act as sales personnel and must inform mothers of the financial/health costs of formula.
  • Jordanian Law: Penalties exist under the Public Health Law for violating marketing regulations, and the Ministry of Health must pre-approve any educational materials produced by formula companies.

4. The Baby-Friendly Hospital Initiative (BFHI)

Developed by WHO/UNICEF, the BFHI aims to implement practices that protect and promote breastfeeding in health facilities. Note: In 2024, only 13 hospitals (13.9%) in Jordan were BFHI accredited.

The 10 Steps to Successful Breastfeeding:

1. Hospital Policies: Have written policies routinely communicated to staff and parents.
2. Staff Competency: Ensure all staff have the knowledge and skills to support breastfeeding.
3. Antenatal Care: Discuss the importance and management of breastfeeding with pregnant women (counsel all women at least twice; practical breast preparation is not needed).
4. Care Right After Birth: Facilitate immediate and uninterrupted skin-to-skin contact (regulates newborn temp, populates beneficial bacteria, and is strongly predictive of future exclusive breastfeeding success).
5. Support Mothers with Breastfeeding: Show mothers how to breastfeed and express milk (videos on hand expression and proper storage are utilized).
   • Storage Rules: Room temp (up to 4 hours), Refrigerator (up to 4 days), Freezer (6-12 months). Never refreeze thawed milk.
6. Supplementing: Give infants no food or drink other than breast milk, unless medically indicated.
7. Rooming-in: Allow mothers and infants to remain together 24 hours a day.
8. Responsive Feeding: Encourage breastfeeding on demand (recognize hunger cues, don't limit times).
9. Bottles, Teats, and Pacifiers: Counsel mothers on the use and risks of artificial nipples.
10. Discharge: Coordinate post-discharge support and refer mothers to community breastfeeding resources.

Oncology

General Principles of Pediatric Solid TumorsYear 6

Clinical Presentation

Pediatric solid tumors can present in a variety of ways depending on their location, size, and physiological activity. There is often a latency in presentation, and many are found asymptomatically or incidentally.

Table 1: Mechanisms of Solid Tumor Presentation

Diagnostic Workup

A thorough diagnostic evaluation is critical for staging and treatment planning:

• Detailed History and Physical Exam: This is paramount, with a strong emphasis on obtaining an accurate and complete family history.
• Baseline Laboratories: Standard blood work to assess overall organ function and cytopenias.
• Genetic Evaluation: To identify underlying syndromes (e.g., Li-Fraumeni, Beckwith-Wiedemann).
• Imaging Studies: Modalities include X-ray, Ultrasound (US), CT scan, MRI, PET scans, and MIBG scans.
• Metastasis Evaluation: Includes chest CT and Bone Marrow Examination (BMX).
• Tumor Markers: Assessment for specific mediators or hormones secreted by the tumors.

General Management Flow

The management of solid tumors requires a stepwise, multidisciplinary approach:

1. Symptom Management: Treat pain, address other mechanical effects, manage loss of function, and provide supportive care.
2. Surgical Excision: Often the primary definitive treatment; it helps avoid chemotherapy toxicity in certain selected patients.
3. Chemotherapy: Can be administered as adjuvant (post-surgery) or neo-adjuvant (pre-surgery to shrink the tumor).
4. Radiation Therapy: Utilized for radiosensitive tumors, specific locations, oncologic emergencies, and metastatic disease.
5. Alternative Modalities: Includes laser photocoagulation, differentiation agents, and emerging therapies like CAR-T cell therapy.

Brain Tumors

• Epidemiology: The majority of childhood brain tumors are infratentorial (located in the posterior fossa).
• Common Presenting Symptoms:
  • Nausea, vomiting (especially early morning, without preceding nausea, indicative of increased ICP), and headache.
  • Behavioral changes and sleep cycle disruptions (e.g., becoming less playful, more aggressive).
  • Weight changes and developmental delay.
  • Neurological Signs: Papilledema (detectable on fundoscopy), bulging fontanelles, cranial neuropathies, seizures, wide-based ataxic gait, and loss of coordination.
  • Specific Early Sign: Early preference of one hand before the age of 2 years, or a sudden change in handedness.
• Diagnostic Approach: A brain MRI is the most helpful modality for establishing a diagnosis in a child presenting with worsening ataxia and symptoms of increased ICP.

Survival Statistics

Age and histological subtype play massive roles in the prognosis of pediatric brain tumors.

• Survival by Age: SEER data (1995-2009) indicates that younger patients have significantly higher survival rates. The 5-year survival for patients aged 0-19 is over 70%, whereas it drops precipitously in adult populations, falling below 10% for patients 75 and older.
• Survival by Tumor Type: 5-year survival varies drastically:
  • Pilocytic Astrocytoma: ~100%
  • Medulloblastoma: ~80%
  • Ependymoma: ~70%
  • Glioblastoma Multiforme (GBM): ~20%
  • Diffuse Intrinsic Pontine Glioma (DIPG): < 5% (virtually uniformly fatal).

Medulloblastoma

• Overview: The most common malignant pediatric brain tumor. It is of embryonal origin and most are diagnosed in children under the age of 10 years.
• Clinical Picture: Classically presents with ataxia and signs of increased intracranial pressure.
• Visual Finding Integration: Radiographic diagnosis typically utilizes MRI. A representative axial brain MRI with contrast demonstrates a massive, hyperintense, enhancing lesion occupying the posterior fossa, compressing the brainstem and fourth ventricle, which correlates with the clinical presentation of ataxia and obstructive hydrocephalus.
• Management & Prognosis: Treatment involves surgical excision (a more complete excision correlates with better outcomes), followed by radiation and chemotherapy. While overall cure rates are very good, patients suffer high rates of long-term complications from radiation, including growth issues, neurodevelopmental delays, and endocrinopathies.

Neuroblastoma

• Overview: The third most common childhood malignancy. It is an embryonal malignancy arising from the neural crest tissue of the sympathetic nervous system.
• Presentation: Tumors can arise anywhere along the sympathetic chain.
  • Classic Presentation: An abdominal suprarenal mass.
  • Local Mass Effects: Neck masses, intrathoracic masses, or abdominal masses. Involvement of the stellate ganglion may present with Horner’s syndrome.
  • Metastatic Disease: Metastasis to the bone marrow causes anemia (often presenting with low hemoglobin and platelets). Other metastatic signs include skin lesions, bone pain, proptosis, and periorbital ecchymosis.
  • Visual Finding Integration: A clinical photograph of a young patient highlights prominent bilateral periorbital bruising. These are known as "raccoon eyes," a hallmark sign of neuroblastoma metastasis to the skull base and orbits. If a child presents with sudden ataxia, refusal to walk, and raccoon eyes, the immediate next step in management is an abdominal CT to locate the primary tumor.
  • Paraneoplastic Syndromes: VIP-secreting tumors causing diarrhea; Opsoclonus-Myoclonus Syndrome (random, rapid eye movements, myoclonus in limbs, and ataxia). While opsoclonus-myoclonus indicates a good oncologic prognosis, it carries long-term neurological complications.
• Diagnostic Workup: CT scan (chest/abdomen/pelvis), bone marrow biopsy, spine MRI (if spinal involvement is suspected), and urine/serum testing for catecholamine metabolites (Homovanillic Acid - HVA, and Vanillylmandelic Acid - VMA). Elevated HVA is highly consistent with opsoclonus-myoclonus presentations.
  • Visual Finding Integration: Functional imaging is heavily utilized. A side-by-side comparison of whole-body scans shows an I123-MIBG scan alongside an FDG-PET scan. The MIBG scan is highly specific for neuroendocrine tumors and demonstrates multifocal skeletal uptake, clearly delineating the extent of metastatic spread.
• Prognosis & Treatment:
  • Poor Prognostic Features: Normal diploid DNA in tumor cells, advanced stage, age > 18 months at presentation, poorly differentiated histology, and MYCN oncogene amplification.
  • Exception: Stage 4S in infants (where 'S' stands for skin metastasis) paradoxically carries an excellent prognosis.
  • Treatment: Historically very poor with just surgery, chemo, and radiation. Significant outcome improvements have been achieved by adding autologous stem cell transplants and antibody therapy.

Wilms Tumor (Nephroblastoma)

• Overview: The most common pediatric renal malignancy. Most cases are unilateral, though up to 10% can be bilateral.
• Presentation: The most common presentation is the incidental finding of an otherwise asymptomatic abdominal mass. Occasionally, it may present with abdominal pain, hypertension, anemia, and hematuria.
• Genetics & Associations: 2% of cases are familial. It is associated with the WT1, WT2, and WTX genes. Up to 10% of cases are associated with malformations (aniridia, hemi-hypertrophy, GU malformations), which generally leads to an earlier diagnosis.
  • Children with overgrowth syndromes (e.g., up to 10% of those with Beckwith-Wiedemann syndrome, and some with Perlman syndrome) are at the highest risk for developing Wilms tumor.
  • 5% of patients with isolated hemi-hypertrophy will develop Wilms tumor.
• Workup: Document blood pressure, check for congenital anomalies, obtain a geneticist evaluation, CBC, Urinalysis (UA), electrolytes, liver function tests, and CT/MRI of the chest, abdomen, and pelvis.
• Management & Prognosis: Most have a favorable histology with an excellent prognosis (only ~8% show anaplastic histology). Lower stage disease is managed with surgery alone; higher stages require chemotherapy, and radiation is reserved for situations like lung metastasis.

Bone Sarcomas

Table 2: Comparison of Primary Pediatric Bone Tumors

Retinoblastoma

• Overview: A rare childhood tumor affecting the retina. Most patients present by 5 years of age.
• Genetic Forms:
  1. Hereditary Form (25%): Due to germline mutations in the RB1 gene. Usually bilateral and multifocal. Median age of presentation is 15 months. Note: Most familial retinoblastomas are bilateral.
  2. Non-Hereditary Form (75%): Due to somatic cell mutations in the RB1 gene. Unilateral or unifocal. Median age of presentation is 30 months.
• Presentation:
  • Leukocoria (white pupillary reflex) is the most common presenting feature.
  • Visual Finding Integration: A clinical photograph of a pediatric patient's face demonstrates a stark, bright white reflection in the right pupil (leukocoria), contrasting sharply with the normal dark pupil of the left eye.
  • Other features: Strabismus, nystagmus, glaucoma, periorbital cellulitis, proptosis, and buphthalmos.
• Diagnosis & Workup:
  • Requires examination under anesthesia (EUA) of the retina for direct tumor visualization and evaluation of intraocular pressure.
  • Visual Finding Integration: A gross pathological cross-section of an enucleated eye shows massive, white, calcified, endophytic tumor growths entirely replacing the vitreous chamber and retinal tissue, confirming advanced disease.
  • Ocular ultrasound, orbit and brain MRI.
  • Bone scan and bone marrow studies to evaluate for metastasis. (Most common metastatic sites: bone, bone marrow, liver, and CNS).
• Management & Complications:
  • Treatment is highly multidisciplinary and depends on laterality and eye salvage potential. Modalities include surgical excision, chemotherapy, radiation, and laser photocoagulation. Genetic counseling is mandatory.
  • Second Cancers: Survivors are at a very high risk for second primary cancers post-therapy (not all are radiation-induced). The most common second cancer is Osteosarcoma, followed by soft tissue sarcomas, melanoma, and lung cancer.
  • Trilateral Retinoblastoma: Defined as bilateral retinoblastoma combined with a midline pineoblastoma; carries a very poor outcome.

Hepatoblastoma

• Overview: The most common liver malignancy in children. It typically affects infants and young children (median age at diagnosis is 19 months), with the vast majority of patients being under 15 years old.
• Risk Factors: Prematurity and low birth weight. About 5% of patients have Familial Adenomatous Polyposis (FAP) syndrome, underscoring the critical need for an accurate family history.
• Presentation: Painless abdominal distention/mass (pain is present only in advanced disease), weight loss, and loss of appetite.
• Diagnostic Workup:
  • Abdominal ultrasound, CT or MRI imaging, and tumor biopsy.
  • Alpha-Fetoprotein (AFP) Levels: Most cases feature highly elevated AFP. Normal AFP levels do not rule out the disease but are associated with a poorer prognosis. Elevated levels are used as a marker to assess treatment response.
• Management: Treatment relies on a combination of surgical resection and chemotherapy. Patients with unresectable tumors may require a liver transplant to achieve a cure.
• Metastasis: If spread occurs, it is usually to the lungs, though brain and peritoneal spread are also possible.

(Note: The source material concludes with a decorative photograph of a hollowed log filled with autumn leaves, signifying the end of the presentation.)

Respiratory

1. Pediatric Respiratory History and Clinical Evaluation

A meticulous history and physical examination (H&P) are foundational for differentiating pediatric respiratory conditions. Information is typically obtained from parents/caretakers, though older children should be asked about their symptoms directly and objectively.

A. Comprehensive History Taking Elements

• Chief Complaint: Must be recorded in the informant's or patient's own words (e.g., chronological description of the problem).
• History of Present Illness (HPI):
  • Onset & Progression: Sudden vs. gradual. Trace daily events, frequency, timing (e.g., diurnal variation—worse at night/early morning), and duration.
  • Cough Characteristics: Dry vs. wet, paroxysmal, barking, or brassy. Assess severity by determining if it disturbs sleep, interferes with physical activity/feeds, or causes post-tussive vomiting.
  • Associated Symptoms: Dyspnea, wheezing (whistling sound), chest tightness, fever, apnea, cyanosis, nasal congestion/discharge, and snoring.
  • Relieving & Aggravating Factors: Aggravation by exercise, crying, laughter, allergens (smoke, perfumes, mold, pets). Relief with specific interventions (e.g., nebulizers, "blue puffer" / beta-agonists).
  • Medications: Document drug names, doses, frequency, compliance, and delivery technique (e.g., using an inhaler directly vs. with a spacer).
• Past Medical & Surgical History: Previous similar episodes, hospitalizations, PICU/NICU admissions, surgeries (e.g., tonsillectomy at age 5 for recurrent infections), frequency of ER visits, and recent check-ups.
• Birth & Neonatal History: Gestational age, delivery type (vaginal vs. cesarean), birth weight, APGAR scores, maternal health (GBS, Chlamydia, Hepatitis), and neonatal jaundice or respiratory support.
• Feeding & Nutrition History: Breast vs. bottle-fed (relevant <1 year), formula type, amount and interval (e.g., 120 ml every 3 hours), onset of solid foods, and vitamin D supplementation (e.g., 400 IU/day). Note choking, vomiting, or failure to thrive.
• Growth & Development: Plot on growth charts (head circumference, weight, length). Note major milestones to screen for delays.
• Immunization History: Confirm routine vaccinations according to local Ministry of Health guidelines, specifically looking for H. influenzae type b (Hib), pneumococcal conjugated vaccine, and annual influenza vaccines.
• Family & Social History: Sick contacts (parents, siblings, daycare), family history of atopy, asthma, or cystic fibrosis (draw a pedigree), parental smoking, home environment (stairs, pets, gardens, mold, altitude/floor level), and socioeconomic factors.

B. Physical Examination

• General Appearance: Assess level of consciousness (LOC). Agitation/irritability indicates early hypoxemia, while drowsiness/lethargy indicates late-stage CO₂ narcosis and severe distress. Observe for cyanosis or pallor.
• Vital Signs & Oximetry:
  • SpO₂ must be measured (Normal >93% on room air).
  • World Health Organization (WHO) Tachypnea Definitions:
    • 0–2 months: >60 breaths/min
    • 2–12 months: >50 breaths/min
    • 1–5 years: >40 breaths/min
    • >5 years: >20 breaths/min
  • Assess heart rate (tachycardia), temperature, and blood pressure (check for pulsus paradoxus).
• Signs of Respiratory Distress: Flaring of alae nasi (nostrils), grunting, head bobbing (in infants), apnea, and retractions (suprasternal, intercostal, and subcostal).
• Chest Examination:
  • Inspection: Increased anteroposterior (AP) diameter (indicates chronic hyperinflation), pectus excavatum (caused by chronic airway obstruction and exaggerated intrathoracic pressure swings), or scoliosis.
  • Palpation: Supratracheal lymphadenopathy, tracheal deviation, and tactile vocal fremitus (increased in consolidation).
  • Percussion: Hyperresonance (air trapping) vs. dullness (consolidation/effusion). Determine liver span; hyperinflated lungs can push the liver downward (palpable below the costal margin) without true hepatomegaly.
  • Auscultation: Note prolonged inspiratory phase (laryngeal/upper obstruction) or prolonged expiratory phase (tracheal/lower obstruction). Differentiate central/large airway wheeze (constant acoustic character) from focal wheeze (structural abnormality). Note crackles (early inspiratory in asthma vs. late inspiratory in interstitial lung disease/CHF) or bronchial breathing.
• Extrapulmonary Examination:
  • ENT: Nasal polyps (rare in young children with asthma; highly suspicious for Cystic Fibrosis or ciliary dysfunction). "Allergic shiners" (dark halos around eyes) and "Allergic salute" (sniffing/crease on nose) suggest allergic rhinitis. Examine for hyperemic throat and post-nasal drip (PND).
  • Skin/Extremities: Digital clubbing (older children with chronic suppurative disease/CF) and eczema on extensor surfaces.
  • Cardiac: Murmurs, gallops, signs of heart failure (e.g., left-sided CHF causing pulmonary edema/cardiac asthma; right-sided cor pulmonale from chronic lung disease).

2. Approach to Stridor & Upper Airway Obstruction

Definition: Stridor is a continuous, high-pitched musical sound heard predominantly on inspiration, caused by the oscillation of opposing airway walls narrowed almost to closure outside the chest cavity.

A. Anatomical Classification of Stridor

• Visual Integration: Anatomical diagrams of the larynx map specific sounds to structures:
  • Inspiratory Stridor: Suggests airway obstruction above the glottis (supraglottic/epiglottic).
  • Expiratory Stridor: Indicative of obstruction in the lower trachea.
  • Biphasic Stridor: Suggests a glottic or subglottic lesion.

B. Etiology of Stridor in Infants and Children

C. Clinical Evaluation Tables for Stridor

Historical Data and Possible Etiology:

Associated Symptoms and Signs:

D. Specific Infectious Upper Airway Obstructions

1. Laryngotracheobronchitis (Viral Croup)

• Epidemiology: Most common cause of acute stridor. Age: 5 months to 5 years (peak in the 2nd year of life). Male-to-female ratio is 3:2.4. Recurrence is frequent between 3-6 years, strong family history.
• Etiology: Parainfluenza virus types 1, 2, 3 (75%). Also Influenza A/B (severe), Adenovirus, RSV, Measles, and rarely Mycoplasma pneumoniae.
• Clinical Presentation: Prodrome of URTI (rhinorrhea, mild cough, low-grade fever) for 1-3 days. Progresses to a barking cough, hoarseness, and inspiratory stridor. Symptoms are worse at night, exacerbated by agitation/crying, and resolve within a week.
• Diagnosis: Clinical. Radiography is only considered after airway stabilization for atypical presentations to differentiate from epiglottitis.
  • Visual Integration: An AP neck radiograph demonstrates the "Steeple sign", characterized by a smooth, symmetric tapering of the subglottic tracheal air column resembling a church steeple, caused by subglottic edema.
• Treatment: Airway management is paramount.
  • Cool mist (moistens secretions, soothes mucosa).
  • Nebulized epinephrine (causes arteriole constriction and decreases edema). Dose: Racemic solution 1:1, or L-epinephrine 5cc of 1:1,000.
  • Glucocorticoids: Dexamethasone, single dose 0.6 mg/kg IM or orally.
  • Admit if: Progressive/severe resting stridor, respiratory distress, hypoxia, cyanosis, altered mental status, or need for reliable observation.

2. Acute Epiglottitis

• Epidemiology: Dramatic, potentially lethal medical emergency. Previously peaked at 2-4 years, but H. influenzae type b (Hib) vaccine reduced incidence by 90%. Now seen as early as 1 year and as late as 7 years.
• Etiology: H. influenzae type b (historical), S. pyogenes, S. pneumoniae, S. aureus.
• Clinical Presentation: Acute fulminating course (hours). High-grade fever, toxicity, dyspnea, sore throat, severe dysphagia, and drooling. Rapid progression to airway obstruction.
  • Posture: Patient adopts a tripod position (sitting upright, leaning forward, chin up, mouth open, bracing on arms).
  • Progression: Air hunger → restlessness → cyanosis → coma. Stridor is a late sign of near-complete obstruction.
• Diagnosis:
  • Visual Integration (Laryngoscopy): Reveals a cherry-red, swollen epiglottis. Crucial: This must only be performed in the OR or ICU by a physician skilled in intubation, as manipulating the airway can cause fatal spasm. Avoid anxiety-provoking actions (phlebotomy, forcing supine position, IV lines) until the airway is secure.
  • Visual Integration (Radiography): Lateral neck radiograph shows the "Thumb sign", where the enlarged, edematous epiglottis appears as a thick, thumb-like radiopacity protruding into the airway.
• Treatment:
  • Establish Airway: Nasotracheal intubation (lasts 2-3 days) or tracheostomy, regardless of the degree of respiratory distress. 6% of patients die without an artificial airway vs. 1% with one.
  • Medical: IV Ceftriaxone, Cefotaxime, or Ampicillin-sulbactam for 7-10 days. Blood and epiglottic surface cultures.
  • Prophylaxis: Rifampin for contacts if a child <2 years or an immunocompromised individual is present.

3. Bacterial Tracheitis

• Etiology: S. aureus (most common), H. influenzae, M. catarrhalis.
• Presentation: Age <3 years. Follows a URTI, rapidly progressing to high fever, toxicity, and distress.
• Treatment: Antibiotics and supportive care.

E. Specific Structural Causes of Chronic Stridor

• Laryngomalacia: Most common cause of chronic stridor (<2 years). M:F ratio is 2:1. Due to delayed maturation/intrinsic defect of laryngeal supporting structures. Flaccid epiglottis, arytenoids, and aryepiglottic folds prolapse during inspiration. Stridor worsens in the supine position, with crying, or during URTIs, and lessens in the prone position.
• Tracheomalacia: Inadequate cartilaginous/myoelastic support causing tracheal collapse during expiration. Appears insidiously after the first weeks of life.
• Vocal Cord Paralysis:
  • Unilateral: More common on the left (longer recurrent laryngeal nerve). Causes: birth trauma, thoracic surgery, mediastinal masses. Cry is weak/feeble; usually no respiratory distress.
  • Bilateral: Associated with CNS problems (perinatal asphyxia, hemorrhage, hydrocephalus, Arnold-Chiari) or direct intubation trauma. Voice is good quality, but marked respiratory distress and biphasic stridor are present.

3. Upper Respiratory Tract Infections (URTIs) & Pharyngitis

A. The Common Cold (Rhinitis/Rhinosinusitis)

• Definition: Viral illness with prominent rhinorrhea and nasal obstruction; systemic signs (fever, myalgia) are absent or mild.
• Epidemiology: Children average 6-7 colds/year (10-15% have ≥ 12/year). Decreases to 2-3/year in adults. Daycare increases incidence by 50% in the first 3 years.
• Etiology & Pathogenesis:
  • Rhinoviruses (RV): Frequent. Peaks early fall (Aug-Oct) and late spring (Apr-May). Direct contact is efficient. No histologic damage. Large number of serotypes prevents lasting immunity.
  • Coronaviruses: Occasional.
  • RSV & Parainfluenza: Occasional. Parainfluenza peaks in late fall; RSV peaks Dec-April. Immunity is not protective but moderates subsequent illness severity.
  • Influenza Viruses: Uncommon cause of simple cold. Spreads via small-particle aerosols. Destroys nasal epithelial lining. Changes antigens to evade immunity.
  • Adenoviruses: Uncommon. Destroys epithelial lining.
• Clinical Manifestations: Onset 1-3 days post-infection. Sore/scratchy throat, followed by nasal obstruction and rhinorrhea. Cough in 30% of cases. Fever is infrequent unless caused by Influenza, RSV, or Adenovirus.
• Physical Findings: Limited to the upper respiratory system. Erythematous, swollen turbinates. Note: A change in nasal secretion color/consistency does not indicate bacterial superinfection or sinusitis.
• Diagnosis: Clinical. Differentiate from Allergic Rhinitis (itching, sneezing), Foreign Body (unilateral, foul, bloody), Sinusitis (>10-14 days), Streptococcal nasopharyngitis (excoriated nares), Pertussis, and Congenital Syphilis.
  • Labs: Nasal smear for eosinophils (allergic rhinitis). PMN cells predominate in a normal cold. Viral cultures/serology only if antiviral therapy is planned. Bacterial cultures only if Strep, Pertussis, or Diphtheria suspected.
• Treatment: Symptomatic. Antipyretics (Acetaminophen/Ibuprofen; strictly avoid Aspirin due to Reye syndrome risk with influenza).
  • Decongestants: Topical oxymetazoline or phenylephrine (not approved <2 years). Side effects include bradycardia, hypotension, and Rhinitis Medicamentosa (rebound effect with prolonged use). Oral agents cause CNS stimulation and hypertension.
  • Rhinorrhea: 1st generation antihistamines reduce secretions by 25-30%.
  • Cough: Expectorants and dextromethorphan/codeine show no benefit. Antihistamines help if cough is due to post-nasal drip.
• Prevention: Handwashing. Chemoprophylaxis generally unavailable. Influenza vaccine protects against a small percentage of colds.

B. Acute Sinusitis

• Pathogenesis: Ethmoid and maxillary sinuses are present at birth (maxillary pneumatized by 4 yrs). Sphenoids pneumatize by 5 yrs, frontals by 7-8 yrs. Viral illness causes inflammation/edema blocking drainage. Nose blowing forces fluid and bacteria into the normally sterile sinus cavities.
• Epidemiology: Complicates 0.5-2% of viral URTIs.
• Etiology: S. pneumoniae (30%, 25% beta-lactamase positive), non-typable H. influenzae (20%, 50% beta-lactamase positive), M. catarrhalis (20%, 100% beta-lactamase positive). Chronic infections involve anaerobes and S. aureus.
• Diagnosis: Based solely on history: Persistent URTI (cough/nasal discharge) for >10-15 days without improvement, OR severe symptoms (Temp >39°C + purulent discharge for 3-4 days). Plain radiographs show thickening and air-fluid levels.
• Complications:
  • Orbital: Periorbital/orbital cellulitis (acute bacterial ethmoiditis).
  • Intracranial: Meningitis, cavernous sinus thrombosis, subdural empyema, epidural/brain abscess. (Requires immediate CT of brain/orbit).
  • Bone: Osteomyelitis of the frontal bone (Pott Puffy Tumor) and mucoceles.
• Treatment: Amoxicillin (45 mg/kg/day). Alternatives: Cefuroxime axetil, Cefpodoxime, Clarithromycin, Azithromycin. Treat for 7 days after resolution of symptoms. Decongestants/intranasal steroids are not recommended.

C. Acute Pharyngitis and Tonsillitis

• Etiology: Viruses (most common), Group A Beta-Hemolytic Streptococcus (GABHS), Group C strep, Arcanobacterium hemolyticum, Mycoplasma pneumoniae.
• Epidemiology: GABHS is uncommon <2-3 years. Peaks in childhood, declines in adults. Occurs winter/spring.
• Viral Pharyngitis Variations:
  • Herpangina (Coxsackievirus): Visualized as small grayish vesicles and punched-out ulcers on the posterior pharynx, soft palate, and uvula.
  • Infectious Mononucleosis (EBV): Visualized as prominent tonsillar enlargement covered in thick white/grey exudate, with cervical lymphadenitis, hepatosplenomegaly, and fatigue.
  • Primary Herpetic Gingivostomatitis (HSV): High fever in young children, visualized as severe blistering and ulceration of the lips, gums, and anterior oral mucosa.
  • Adenovirus: Often concurrent with conjunctivitis.
• GABHS Pharyngitis:
  • Pathogenesis: M-protein resists phagocytosis. SPE-A, B, C toxins induce rash.
  • Clinical: Rapid onset, sore throat, fever, headache, prominent GI symptoms. O/E: Red pharynx, enlarged tonsils with yellow/blood-tinged exudate, petechiae ("doughnut" lesions) on soft palate, swollen red uvula, tender anterior cervical lymphadenopathy.
  • Scarlet fever: Circumoral pallor, strawberry tongue, fine red "sandpaper" papular rash.
• Diagnosis: Throat culture (imperfect) or Rapid Antigen Detection Test (highly specific, less sensitive).
• Treatment (GABHS): Primary aim is to prevent Acute Rheumatic Fever (ARF) (treatment must start within 9 days of illness).
  • Penicillin V (250mg/dose bid/tid), Amoxicillin (250mg tid), or a single IM injection of Benzathine Penicillin G. Erythromycin (40 mg/kg/day) or Azithromycin for allergy.
  • Recurrent GABHS: Relapse with identical strain (use IM penicillin for compliance), resistance (use non-penicillin ABX), or new strain. Tonsillectomy indicated if >7 episodes in the previous year, or >5 in each of the preceding two years.

D. Deep Neck Infections & Abscesses

• Retropharyngeal Abscess: Occurs in boys > girls, usually <3-4 years (retropharyngeal lymph nodes involute after age 5). Presents with fever, irritability, decreased oral intake, drooling, neck stiffness/torticollis, refusal to move neck, stridor. O/E: bulging of posterior pharyngeal wall (<50%), cervical LAP.
• Lateral Pharyngeal Abscess: Prominent bulge on the lateral wall of the pharynx, medially displaced tonsil.
• Peritonsillar Cellulitis/Abscess: Relatively common in adolescents post-tonsillitis. Direct bacterial invasion through tonsil capsule. Presents with severe sore throat, fever, trismus, dysphagia, and an asymmetrical bulge of the tonsil with uvula displacement. Polymicrobial (GABHS + Anaerobes). Treatment: IV antibiotics, surgical needle aspiration (90% success), incision & drainage (5%), or curative tonsillectomy.
• Lemierre Disease: Uncommon complication of oropharyngeal infection. Septic thrombophlebitis of the internal jugular vein (Anaerobe driven) causing metastatic abscesses in the lungs.

E. Tonsils and Adenoids

• Waldeyer Ring: Palatine tonsils, pharyngeal tonsils (adenoids), lingual tonsil, and scattered lymphoid tissue. Immunologically active 4-10 years.
• Chronic Infection: Polymicrobial (aerobic streptococci, H. influenzae, anaerobic Peptostreptococcus, Prevotella, Fusobacterium). High incidence of beta-lactamase producers. Tonsillar crypts accumulate squamous cells, lymphocytes, bacteria, and debris, causing halitosis and a foul-taste sensation. Treatment: Clindamycin or Amoxicillin-clavulanate.
• Airway Obstruction: Enlarged tonsils/adenoids cause chronic mouth breathing, hyponasal speech, poor school performance, snoring, frank apneas, night terrors, and enuresis. Treated with Adenotonsillectomy.

4. Approach to Wheezing in Children

Definition: A wheeze is a continuous musical sound produced by the oscillation of opposing airway walls narrowed almost to the point of closure. It requires sufficient airflow to generate sound and signifies lower airway narrowing/compression.

A. Classification of Wheezing

1. Acute Wheezing (Hours to Days)

• Asthma: Most frequent cause of recurrent wheezing. Characterized by evidence of atopy, intermittent episodes triggered by specific events (URTI, weather, exercise), family history, and good response to bronchodilators.
• Infections:
  • Bronchiolitis: Most common cause of acute wheeze in infants <2 years. Caused primarily by RSV, Rhinovirus, Parainfluenza, and Metapneumovirus. Prodrome of URTI followed by tachypnea, increased work of breathing, and polyphonic wheezes.
  • Atypical Pneumonia: Mycoplasma pneumoniae (older children).
  • Bacterial Tracheitis: Distinguished by high fever and toxic appearance.
• Foreign Body Aspiration (FBA): Sudden onset. Must be suspected even without a clear choking history. In children, objects can lodge in any bronchus without predilection for the right side. Presents with unilateral wheeze or unequal breath sounds. Esophageal foreign bodies can also cause wheezing via compression, associated with feeding difficulties.

2. Chronic or Recurrent Wheezing

• Structural Abnormalities (Thoracic/Tracheobronchial): Congenital tracheomalacia/bronchomalacia, vascular rings/slings, tracheoesophageal fistulas, mediastinal masses, and cardiovascular disease. Typically present in infancy.
• Non-structural / Functional Causes: Asthma, aspiration syndromes, bronchopulmonary dysplasia (BPD), Cystic Fibrosis (CF), primary ciliary dyskinesia, bronchiolitis obliterans, and paradoxical vocal cord dysfunction (presents in later childhood/adolescence).

B. Diagnostic Evaluation of the Wheezy Child

A diagnostic evaluation is driven by clinical stability. If a child presents in distress, stabilize first (O2, SABA) before investigating. If stable, a therapeutic trial of asthma medication is often diagnostic.

• Radiography (CXR - AP and Lateral): Not needed for every exacerbation. Indicated for new-onset wheezing of unknown etiology, lack of response to therapy, or severe distress.
  • Generalized Hyperinflation: Suggests diffuse air trapping (Asthma, CF, ciliary dyskinesia, aspiration, viral bronchiolitis). Visual Integration: Evidenced by flattening of the diaphragm (domes parallel), narrow mediastinum, increased lucency of lung fields, and >6 anterior/>8 posterior ribs visible.
  • Localized Findings: Suggest structural abnormalities or FBA.
• Pulmonary Function Testing (Spirometry): Used in cooperative children >7 years.
  • Asthma Confirmation: Obstructive pattern (FEV₁ < 80% predicted, FVC normal, FEV₁/FVC < 80%) with bronchodilator reversibility (>12% improvement in FEV₁). Normal spirometry between attacks does not exclude asthma.
  • Visual Integration (Flow-Volume Loop): A loop showing a truncated/flattened inspiratory and expiratory curve with low FEV₁, low FEV₁/FVC, and no response to ventolin indicates a fixed intrathoracic obstruction, not asthma.
• Allergy Testing:
  • Skin Prick Test (SPT): Identifies inhaled allergen sensitization. Visual Integration: Drops of allergens are placed on the forearm and pricked. A positive result (wheal >3-4 mm) confirms atopy. Antihistamines must be stopped 5 days prior.
  • Total IgE: Used if considering anti-IgE therapy or suspecting Allergic Bronchopulmonary Aspergillosis (ABPA).
• Other Labs: Vitamin D (deficiency linked to poor immune modulation), CBC (eosinophilia in atopy, leukocytosis in infection), Scintigraphy (contrast study for chronic aspiration).

C. Asthma Management Strategy

• Acute (Rescue) Settings: 100% O₂ for hypoxemia, rapid-acting nebulized/inhaled beta-2 agonists (SABA), short-course systemic steroids, and nebulized Ipratropium Bromide.
• Chronic (Control) Settings: Step-up approach based on GINA guidelines.
  • Inhaled Corticosteroids (ICS) are the first choice in children.
  • Leukotriene receptor antagonists (LTRA), LABA/ICS combination, Cromolyn, Methylxanthines (Theophylline).
• Delivery Methods: Metered Dose Inhalers (MDI) with a spacer, Dry Powder Inhalers (DPI), or Nebulizer machines.

5. Pneumonia in Children

Pneumonia is an acute infection of the pulmonary parenchyma. It accounts for 14% of all deaths in children under 5 years old (740,180 deaths in 2019). Preventable via immunization, adequate nutrition, and mitigating environmental factors (indoor pollution, parental smoking, crowding).

A. Classifications of Pneumonia

• By Anatomy:
  • Lobar/Lobular Pneumonia: Affects one or more lobes. Bronchi are not primarily affected and remain air-filled (Air Bronchograms). Generally no volume loss.
  • Bronchopneumonia: Primarily affects bronchi and adjacent alveoli causing multifocal, patchy consolidation, usually in dependent (basal) zones. Volume loss may occur as bronchi fill with exudate.
  • Interstitial Pneumonia: Patchy/diffuse inflammation of the interstitium with lymphocyte and macrophage infiltration.
  • Congenital Pneumonia: Presents within the first 24 hours after birth.
• By Etiology (Age-Dependent):
  • 1st 2 months: Klebsiella, E. coli, and Staphylococci.
  • 3 months to 3 years: S. pneumoniae, H. influenzae, and Staphylococci. (Viral causes are also highly prevalent).
  • Over 3 years: S. pneumoniae and Staphylococci. Atypical organisms (Chlamydia species and Mycoplasma).
  • Immunocompromised: Pneumocystis carinii.

B. Clinical Features & Radiographic Diagnosis

• Clinical Presentation: Can be insidious (starting with a URTI) or acute (high fever, dyspnea, respiratory distress). Can present with acute abdominal pain referred from the pleura.
• Chest Radiography (CXR): Confirms diagnosis and indicates complications.
  • Lobar Pneumonia: Visualized as dense, confluent, homogenous consolidation confined to a lobe. Pathogens: S. pneumoniae, S. aureus, H. influenzae.
  • Round Pneumonia: Visualized as a distinct, spherical, coin-like opacity mimicking a mass. Pathogens: S. pneumoniae, Klebsiella, Atypical Measles.
  • Bronchopneumonia: Visualized as multifocal, patchy opacities scattered throughout the lung fields.
  • Viral Pneumonia: Visualized as hyperinflation with bilateral interstitial infiltrates and peribronchial cuffing.
  • Staphylococcal Pneumonia: Frequently causes pneumatoceles.
  • Mycoplasma: Ages 5-20 yrs. Gradual onset of headache, malaise, sore throat. Visualized as diffuse interstitial infiltrates.
• Laboratory Diagnostics:
  • Peripheral WBC: Viral (normal or elevated, but <20,000 with lymphocytosis). Bacterial (elevated 15,000–40,000 with neutrophilia).
  • Blood Culture: Not routine for fully immunized, non-toxic children. Indicated if failing therapy or progressive deterioration.
  • Specific Testing: Nasal swab/PCR for viruses (RSV, Influenza, Adenovirus). Mycoplasma IgM titers.

C. Complications of Pneumonia

• Visual Integration (Complications):
  • Pleural Effusion: Visualized on CXR as a dense opacity at the lung base with a meniscus obliterating the costophrenic angle.
  • Lung Abscess: Visualized on CXR/CT as a thick-walled cavity containing a distinct horizontal air-fluid level.
  • Pneumatocele: Visualized on CXR as thin-walled, air-filled cystic lucencies within the lung parenchyma.

D. IDSA Treatment Guidelines

• Hospitalization Criteria: Children/infants with moderate to severe CAP (respiratory distress, sustained SpO₂ < 90%). Infants <3-6 months with suspected bacterial CAP. Suspected MRSA. Failure of outpatient therapy or inability to observe at home.
• Inpatient Management: Hydration, oxygenation, antipyretics.
  • Presumed Bacterial: IV Ampicillin or Penicillin G. Alternatives: Ceftriaxone or Cefotaxime. Add Vancomycin or Clindamycin for suspected CA-MRSA.
  • Presumed Atypical: Azithromycin (added to beta-lactam if diagnosis is in doubt). Alternatives: Clarithromycin, Erythromycin.
• Outpatient Management:
  • Presumed Bacterial: Oral Amoxicillin (90 mg/kg/day) or Amoxicillin-clavulanate.
  • Presumed Atypical: Azithromycin, Clarithromycin, or Erythromycin.

6. Cystic Fibrosis (CF)Year 6

Definition: An autosomal recessive, monogenic, multisystem genetic disorder most common in the Caucasian population (but occurs in all ethnicities). It is characterized by chronic, progressive obstructive lung disease and nutrient malabsorption due to exocrine pancreatic insufficiency.

A. Genetics and Mutation Classes

• Mutation in the CFTR gene (Cystic Fibrosis Transmembrane Conductance Regulator) on the long arm of Chromosome 7 (7q31.2). The most common mutation is delta F508.

B. Pathophysiology

• Mechanism Flow: CFTR Gene Defect → Defective ion (chloride) transport → Airway surface liquid depletion → Defective mucociliary clearance → Mucus obstruction → Chronic Infection & Inflammation.
• Visual Integration: At the cellular level, the normal CFTR channel moves chloride ions to the outside of the cell. In the mutant CFTR (e.g., F508del), ions do not move, causing sticky mucus to build up outside the cell.
• Gastrointestinal: The absence of CFTR limits the chloride-bicarbonate exchanger in the pancreas, reducing bicarbonate secretion. This leads to retention of enzymes and destruction of pancreatic tissues. In the intestines, decreased water secretion leads to desiccated contents and obstruction. In the biliary tree, retention causes focal biliary cirrhosis and cholelithiasis.

C. Clinical Manifestations

• Respiratory Tract:
  • Chronic sinusitis, nasal obstruction, and nasal polyps in 25% (often requires surgery).
  • Chronic, persistent cough producing viscous, green, purulent sputum.
  • Infection Sequence: Initially infected with H. influenzae and S. aureus, subsequently colonized by Pseudomonas aeruginosa. Occasionally Burkholderia gladioli, Proteus, E. coli, Klebsiella.
  • Lung Function: Small airway disease is the first abnormality, progressing to irreversible drops in FEV₁.
  • Visual Integration (CF Lungs): CXR shows hyperinflation, mucus impaction, bronchial cuffing, and cystic bronchiectasis. Gross pathology reveals lungs destroyed by massive, thick-walled, purulent cavities and fibrotic remodeling.
• Gastrointestinal Tract:
  • Meconium ileus: Abdominal distention, emesis, and failure to pass stool in neonates.
  • DIOS (Distal Intestinal Obstruction Syndrome): RLQ pain, palpable mass, emesis (can mimic appendicitis).
  • Exocrine Pancreatic Insufficiency (>90%): Protein and fat malabsorption leading to frequent, bulky, foul-smelling stools and deficiency in fat-soluble vitamins (A, K, E, D).
  • Increased incidence of GI malignancy.
• Genitourinary Tract:
  • Late-onset puberty (due to chronic lung disease and malnutrition).
  • >95% of males have azoospermia due to obliteration of the vas deferens.
  • 20% of females are infertile.

D. Diagnosis

• Newborn Screening (NBS): Tests for elevated pancreatic-derived enzyme Immunoreactive Trypsinogen (IRT).
• Sweat Chloride Testing: The most useful diagnostic test.
  • If NBS is positive, perform sweat test when infant weighs >2 kg and is at least 36 weeks corrected gestational age. Ideally performed by the end of the neonatal period (4 weeks).
  • ≥60 mmol/L is positive for CF.
  • In children ≤6 months: <30 mmol/L is negative. 30-59 mmol/L is an intermediate value (requires extended CFTR gene analysis).
• Diagnostic Criteria:
  • One of the following: Typical clinical features, History of CF in a sibling, OR Positive newborn screening test.
  • PLUS evidence of CFTR dysfunction: Two elevated sweat chloride tests on separate days, identification of 2 CF mutations, or abnormal nasal potential difference measurement.
• Other Tests: The 3-day fat collection is standard for diagnosing pancreatic insufficiency.

E. Management (High Treatment Burden)

• Lung Management: (>90% of CF patients die from lung infection complications).
  • Clearance: Long-term DNAse treatment, inhaled beta-agonists, and chest physiotherapy.
  • Antibiotics: Early, long-course, high-dose. S. aureus treated with flucloxacillin. Pseudomonas treated with two drugs of different mechanisms to prevent resistance (e.g., Cephalosporin/Ceftazidime + Aminoglycoside/Amikacin, Gentamicin). Aerosolized antibiotics are heavily utilized.
  • ABPA (Allergic Bronchopulmonary Aspergillosis): Treated with oral glucocorticoids.
  • End-Stage: Vigorous medical management, oxygen, NIV, and ultimately lung transplantation.
• Gastrointestinal Management:
  • Pancreatic enzyme replacement (Creon) and fat-soluble vitamin (A, D, E, K) supplementation.
  • Insulin for CF-Related Diabetes (CFRD).
  • Intestinal obstruction: Osmotically active agents or distal-hypertonic radiocontrast enemas.
  • End-stage liver disease: Liver transplantation (2-year survival >50%).